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                                                     SUMMARY 
 
This thesis aimed to comprehensively evaluate the pharmacogenetics of the 
regulatory nuclear receptor Pregnane-X Receptor (PXR), influx (SLC22A16) and 
efflux drug transporters (ABCB1, ABCG2, ABCC5, ABCB5 and RLIP76) and drug 
metabolizing enzymes (CBR1, CBR3) across the biochemical pathway of 
doxorubicin in Asian breast cancer patients receiving doxorubicin based adjuvant 
chemotherapy.  The moderately linked ABCB1 1236CC-2677GG-3435CC 
genotypes were associated with significantly increased exposure levels, peak 
plasma concentrations and reduced clearance of doxorubicin in patients who were 
homozygous for the variant alleles at the three ABCB1 loci. Breast cancer patients 
homozygous for the ABCC5 g.-1679T allele had significantly higher exposure 
levels of doxorubicin when compared to the patients who were heterozygous for 
the polymorphism. Three novel ABCB5 exonic polymorphisms [c.2T>C (exon 1), 
c.343A>G (exon 2) and c.1573G>A (exon 12)] were identified among the healthy 
Asian ethnic groups in the present study but showed no influence on doxorubicin 
disposition in the Asian breast cancer patients. No significant influences of the 
ABCG2 c.421C>A polymorphism on doxorubicin disposition was observed. 
Screening the coding regions of the gene encoding Ral-Binding Protein 1 
(RLIP76) among the three distinct Asian ethnic groups failed to identify any 
polymorphic variations.  
 
Four novel exonic polymorphisms were identified by direct sequencing of the 
coding regions of the SLC22A16 gene [c.146A>G (exon 2), c.312T>C (exon 2), 
c.755T>C (exon 4) and c.1226T>C (exon 5)]. Breast cancer patients harboring the 
SLC22A16 c.146GG genotype showed a trend towards higher exposure levels to 
 X
doxorubicin and doxorubicinol compared to patients with either the reference 
genotype or heterozygotes. With regards to doxorubicin metabolizing enzymes, 
screening the exon and exon-intron boundaries of carbonyl reductase 1 (CBR1) 
gene identified five polymorphisms (-48G>A, c.219G>C, c.627C>T, c.693G>A and 
+967G>A) which exhibited significant inter-ethnic variations. The CBR1 D2 
diplotypes were characterized by the presence of at least one variant allele at the 
c.627C>T and +967G>A loci. Patients in the CBR1 D1 diplotype group had 
significantly higher clearance and significantly lower exposure levels of doxorubicin 
compared to patients belonging to the CBR1 D2 diplotype group. Five carbonyl 
reductase 3 (CBR3) polymorphisms (c.11G>A, c.255T>C and c.279C>T, 
c.606G>A and c.730G>A) were identified in Asian ethnic groups but did not reveal 
any influence on doxorubicin disposition in breast cancer patients, possibly due to 
its minimal tissue expression. Significant differences in the genotype and allele 
frequencies of PXR polymorphisms and their linkage patterns among the Asian 
ethnic groups were observed in the present study.  Haplotype analysis revealed 
that the PXR*1B haplotypes occurred at a higher frequency in Chinese (28.7%)  
and Malays (35%)  compared to Indians (19.4%) and was found to be associated 
with significantly decreased hepatic mRNA expression of both PXR and also its 
downstream target gene, ABCB1. The PXR*1B haplotype was found to be 
associated with significantly reduced clearance of doxorubicin in Asian breast 
cancer patients suggesting that genetic polymorphisms and specific haplotype 
clusters in the PXR nuclear receptor could have significant contributory roles in 
affecting interethnic variations in doxorubicin disposition. 
 
 XI
In conclusion, the findings of these studies showed that functional polymorphisms 
in candidate genes across the doxorubicin biochemical pathway (PXR, ABCB1, 
ABCC5, SLC22A16 and CBR1) may significantly contribute to the heterogeneity in 
doxorubicin disposition among Asian breast cancer patients. It is conceivable that 
the observed polygenic influence on doxorubicin pharmacogenetics may also 
influence efficacy of doxorubicin in patients receiving adjuvant chemotherapy. 
Development and independent validation of multi-compartmental pharmacokinetic-
pharmacodynamic models that succinctly incorporate both genetic and non-genetic 
factors will be invaluable in definitively establishing the clinical utility of findings in 
the present study on doxorubicin pharmacogenetics.  
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CHAPTER 1: INTRODUCTION 
 
1.1 BREAST CANCER CHEMOTHERAPY 
 
1.1.1 Incidence and Trends 
 
Breast cancer accounts for one third of all cancers in women and is the most 
prevalent cancer diagnosed among women around the world, occurring with a 
lifetime risk of one in eight.(1,2)The incidence of breast cancer is continuously 
increasing, with more than 1,000,000 cases diagnosed each year 
worldwide.(3,4) Detection of disease at an earlier stage and appropriate 
administration of systemic therapy in conjunction with conservative surgery 
and radiation has improved survival and decreased the morbidity and 
mortality of breast cancer patients.5 Although the number of effective 
treatments for breast cancer is on the rise, the benefit from specific treatments 
to individual patients and the adverse effects experienced vary considerably 
depending on tumor, treatment and host characteristics. Following the 
increasingly integrated study of the genetic, molecular, biochemical and 
cellular basis of breast cancer and its treatment, the field of breast cancer 
research is now intensely involved in elucidating the molecular basis of 
variations in clinical response and mechanisms of resistance to treatment.  
 
1.1.2 Neo-adjuvant and Adjuvant Chemotherapy 
 
Chemotherapy involving the use of cytotoxic agents is an important strategy in 
the management of patients with malignant tumors, complimented by 
 2
radiotherapy and surgery.(6) Neoadjuvant or induction chemotherapy refers to 
the administration of anticancer agents prior to local therapy and is aimed at 
decreasing tumor size, rendering them more amenable to surgery.(7,8) The 
main clinical indication for neoadjuvant treatment in breast cancer is the 
downstaging of tumors, allowing either mastectomy in cases initially thought 
to be inoperable, or allowing breast-conserving surgery in cases initially 
thought suitable for mastectomy as the only surgical option.(9) The clinical 
response rate to neoadjuvant chemotherapy varies between 30 to 90%(10,11,12) 
and the five year overall survival rate is reported to range between 40 and 
80%.(10,13,14) A pathological complete response (pCR) to neoadjuvant 
chemotherapy is a clear-cut predictor of survival, occurring in 3 to 6% of 
patients.(15) Several trials of neoadjuvant chemotherapy have shown an 
increase in the rate of breast conservation, and preoperative systemic 
treatment is now an established component in the management of large, 
potentially operable and locally advanced breast cancers.(16,17)  
 
Adjuvant chemotherapy involves drug administration after removal of the 
primary tumor when there is no evidence of residual disease, and is based on 
studies showing an inverse relationship between chemotherapeutic response 
and the number of tumor cells.(18,19) The benefits of adjuvant chemotherapy as 
a successful addition to locoregional treatment seem to be greater in younger 
women.(20) Below the age of 50, the absolute gain at 10 years is 4.5% and 
11.3% in node negative and node positive patients, respectively, whereas in 
women aged 50 to 69, a smaller though still significant gain (3.2% and 3% 
respectively) is observed.(21,22) Women in the 50-69 age group have been 
reported to achieve a 20% proportional reduction in the risk of recurrence and 
 3
an 11% proportional reduction in the risk of death following adjuvant 
chemotherapy22 while demonstration of a modest but sustained and 
significant impact on survival gain has also been shown in women aged < 70 
years with moderate to high risk breast cancer.23 These benefits of adjuvant 
chemotherapy have been observed to be independent of the estrogen 
receptor (ER) status of the primary tumors and of the use of adjuvant 
tamoxifen.24 
 
1.1.3 Breast Cancer Chemotherapy Regimens 
 
The Early Breast Cancer Trialist’s Collaborative Group (EBCTCG) study 
summarized the results of all randomized adjuvant chemotherapy trials that 
began before 1990, concluding that combination chemotherapy in breast 
cancer improved long term relapse free and overall survival rates in women 
up to 70 years of age irrespective of nodal status or estrogen receptor (ER) 
status.22 Combination chemotherapy that uses two or more drugs appeared to 
be superior to single agents; with four to six cycles of treatment (3-6 months) 
considered optimal.(25) The current combination chemotherapy regimens used 
in the treatment of breast cancer are summarized in Table 1.1. The higher cell 
killing achieved due to non-overlapping toxicity of the component drugs and 
the tumor cell heterogeneity that vary in terms of drug sensitivity and 









Regimen Agents and doses used Overall duration 
AC A: Doxorubicin 60 mg/m2 IV d1, and 12 week: 
 C: Cyclophosphamide 600 mg/m2 IV d1 Every 21 d x 4 cycles 
CAF C: Cyclophosphamide 100 mg/m2 po d1–14, 
d
24 week: 
 A: Doxorubicin, 30 mg/m2 IV d1, d8, and Every 28 d x 6 cycles 
 F: Fluorouracil, 500 mg/m2 IV d1, d8  
CMF C: Cyclophosphamide 100 mg/m2 po d 1–14, 
d
24 week: 
 M: Methotrexate, 40 mg/m2 IV d1, d 8, and Every 28 d x 6 cycles 
 F: Fluorouracil, 500 mg/m2 IV d1, d 8  
AC > T A: Doxorubicin 60mg/m2 IV d1, and 24 week: 
 C: Cyclophosphamide 600 mg/m2 IV d1 Every 21 d x 4 cycles; 
 Followed by: Every 21 d x 4 cycles 
 T: Paclitaxel 175 mg/m2 IV over 3h or  
 Docetaxel 100 mg/m2 IV over 1h  
Dose dense  
AC < T A: Doxorubicin 60mg/m
2 IV d1, and 16 week: 
 C: Cyclophosphamide 600 mg/m2 IV d1 Every 14 d x 4 cycles 
 Followed by: Every 14 d x 4 cycles 
 T: Paclitaxel 175 mg/m2 IV over 3h or  
 Docetaxel 100 mg/m2 IV over 1h  
CEF C: Cyclophosphamide 500 mg/m2 IV d1, and 12 week: 
 E: Epirubicin 100 mg/m2 IV d1, and Every 21 d x 6 cycles 
 F: Flourouracil 500 mg/m2 IV d1  
MF M: Methotrexate 100 mg/m2 IV d1, d8, and 24 week: 
 F: Flourouracil 600 mg/m2 IV d1, d 8 Every 28 d x 6 cycles 
TAC T: Docetaxel 75 mg/m2 IV d1, and 24 week: 
 A: Doxorubicin 50 mg/m2 IV d1, and  
 C: Cyclophosphamide 500 mg/m2 IV, d1 Every 21 d x 6 cycles 
 
Adapted from: Rock and DeMichele et al.(26) 
 
 
The combination of alkylating agent cyclophosphamide with two 
antimetabolites, methotrexate and fluorouracil (CMF), was established as the 
gold standard for adjuvant therapy of breast cancer in the mid 1970s.(27,28) 
Studies showed that there was a significant reduction in recurrence rates in 
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patients on anthracycline regimens (P = 0.006), and a modest but significant 
improvement in 5-year survival (72% with anthracycline v 69% with CMF 
regimen; P = 0.02).(29,30) Later, the addition of taxanes (paclitaxel or 
docetaxel) to anthracycline-containing regimens were reported to give 
additional survival benefit with an absolute gain of 2-7% in randomized 
trials.(31) Paclitaxel is usually administered for four cycles after doxorubicin 
and cyclophosphamide (every 3 weeks) or as a 'dose-dense' regimen (every 2 
weeks) with growth factor (G-CSF) support in between cycles.(32,33) Docetaxel 
is given as part of the TAC12 regimen (taxotere, adriamycin, and 
cyclophosphamide) every 3 weeks with growth factor support or three 3-
weekly cycles following three cycles of FEC (5-fluorouracil, epirubicin, and 
cyclophosphamide).(34) The five-year disease free survival (DFS) rates were 
73.2% and 78.4%  (FEC and FEC-D regimens, respectively) whereas five-
year overall survival rates were 86.7% and 90.7% (FEC and FEC-D regimens, 
respectively), demonstrating a 27% reduction in the relative risk of death.(34)  
 
Human epidermal growth factor receptor-2 (Her2-neu) overexpression is seen 
in 20-30% of breast cancers and tend to occur in poorly differentiated (grade-
3), ER-negative and node-positive tumors.(35) The overexpression of Her2-neu 
correlates with poor prognosis, shorter overall survival, and altered response 
to hormonal therapy and chemotherapy.(36,37) Trastuzumab is a humanised 
monoclonal antibody directed against the external domain of the Her2-neu 
receptor and has clinical activity as a single agent in patients whose cancers 
overexpress Her2-neu.(38) Large-scale randomized studies have been 
conducted to evaluate the use of trastuzumab in the adjuvant setting.(39) 
Following trials that showed dramatic improvement of response rates when 
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trastuzumab was combined with chemotherapy in Her2-neu oncogene 
amplified metastatic breast cancer, it is now recommended that one year of 
adjuvant trastuzumab should be considered for high-risk Her2-neu amplified 
or over-expressed breast cancer after considering the potential cardiac risk of 
the drug (seen in 0.6% of patients taking trastuzumab compared to 0.1% in 
the control arm), especially when used concurrently with other cardiotoxic 
antineoplastic agents such as anthracyclines.(39,40) 
 
A general guideline for adjuvant chemotherapy in breast cancer patients is 
outlined in Figure 1.1.  The most appropriate chemotherapy regimen and 
treatment schedule depends on the estimated risk of relapse of the breast 
cancer and is done by evaluating the clinical prognostic factors including the 
number of metastatic axillary nodes, estrogen receptor (ER) status, grading of 
tumor and the age of the patient. In many studies, breast cancer at a young 
age (35-40 years) has been reported to have a more aggressive biological 
behavior (higher grade, higher proliferative index, more vascular invasion) and 
to be associated with poor prognostic factors than in older women,(41) whereas 
the choice of chemotherapy regimens may vary among older patients due to 
the higher chances of comorbidities and increased toxicity.(42) Despite recent 
advancements in the field, the optimal timing, duration, intensity, and 
















Fig 1.1 Guidelines for systemic adjuvant therapy in breast cancer. 
Adapted from: Kontoyannis et al.(43) 
 
1.1.4 Anthracycline Based Chemotherapy 
 
Both neoadjuvant and adjuvant combination chemotherapy regimens for 
breast cancer now have anthracyclines as the central component, 
representing the treatment of choice in both high risk node-negative and 
node-positive patients.(6,44,45) In anthracycline based regimens, an 
anthracycline is incorporated into a cyclophosphamide-methotrexate-5-
fluorouracil (CMF) regimen by administering it instead of methotrexate in CMF 
or by adding it either before or after the administration of CMF.(46,47) The Early 
Breast Cancer Trialist’s Collaborative Group (EBCTCG) study that performed 
an extended 15-year follow-up meta-analysis showed that anthracycline 
containing regimens were significantly more effective at preventing recurrence 
(hazard ratio, 0.89; P = 0.001) and increasing survival (risk of breast cancer 
death rate ratio, 0.84; P < 0.00001), and had substantial advantages in terms 
 8
of tolerability when compared to CMF regimen in the treatment of breast 
cancer.(29,48) Three randomized trials (NCIC MA547, intergroup 0102/SWOG 
88949 and NEAT/SCTBG Br960150) also clearly demonstrated the superiority 
of therapy with anthracycline-based regimens over CMF.  The trends toward 
superiority of anthracycline-based chemotherapy regimens over CMF regimen 
extend to the major subsets of early breast cancer patients: premenopausal 
and postmenopausal patients, ER-poor and ER-positive patients, and both 
node-negative and node-positive patients.(44) Two randomized studies, 
National Surgical Adjuvant Breast and Bowel Project (NSABP-15 and 
NSABP-23) found that four cycles of doxorubicin/cyclophosphamide (AC) 
were equivalent to six cycles of conventional CMF with respect to event-free 
survival, relapse-free survival, and overall survival in breast cancer patients 
regardless of nodal status, age, or estrogen-receptor status.(44) Since AC 
regimen also offered the advantages of a shorter treatment course with fewer 
side effects,30 it has been readily adopted as a standard adjuvant regimen in 
breast cancer chemotherapy.(30,51)  
 
Although the use of anthracyclines results in a definite survival gain in the 
adjuvant setting, the margin of benefit may vary in some populations.(49,52) 
Clinical trials have shown that the treatment with cyclophosphamide–
epirubicin–fluorouracil (CEF) is associated with longer relapse-free survival 
and overall survival than treatment with cyclophosphamide-methotrexate-5-
fluorouracil (CMF) alone in women whose tumors showed Her2-neu 
amplification or Her2-neu overexpression.(53) However, clinical benefits of 
anthracycline-based chemotherapy are also likely in Her2-neu negative breast 
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cancer; hazard ratios associated with treatment with anthracycline based 
chemotherapy, as compared with CMF range from 0.79 to 1.22 for disease-
free survival or relapse-free survival and from 0.82 to 1.64 for overall 
survival.(54)  Similar to Her2-neu, overexpression/amplification of 
topoisomerase II-α (TIIα) is also considered as a good predictor of response 
to anthracyclines in breast cancer.(55,56) However, the gene encoding 
Topoisomerase IIα is located on chromosome 17q12 in close proximity to the 
gene encoding Her2-neu, and the two genes are frequently, but not 
univocally, coamplified,(57) leading to suggesions that Topoisomerase IIα 
amplification may sensitize tumours to treatment with anthracyclines in early 
breast cancer.(58,59,60) 
 
Since its discovery, several hundred structural analogues of doxorubicin have 
been synthesized, but few have found clinical applications.(61,67) Epirubicin 
differs from doxorubicin in an axial-to-equatorial epimerization of the hydroxyl 
group at C-4' in daunosamine, rendering it a much better substrate for 
glucuronidation, consequently facilitating excretion in bile and urine.(62) 
Improved glucuronidation and body clearance alter the dose-related 
antiproliferative activity of epirubicin, with a dose of 1 mg of epirubicin 
considered equimyelotoxic to 1.5 mg of doxorubicin.(63) The clear dose-effect 
relationship of epirubicin allows for dose escalation and several regimens that 
have shown a clear therapeutic advantage over CMF contain epirubicin rather 
than doxorubicin, with a considerably lower degree of myelosuppression and 
cardiotoxicity than doxorubicin in randomized clinical trials.(47,51,64,65) The use 
of cyclophosphamide–epirubicin–fluorouracil (CEF) regimen has been 
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reported to be superior to the CMF regimen,(66) with a 16% relative reduction 
in deaths from breast cancer that  corresponded to a 4% gain in the absolute 
survival rate at 10 years.(29)   
 
Considerable efforts are being devoted in recent years to the development of 
better anthracyclines, focused on development of better tumor targeting 
formulations and newer analogs.(67) Newly designed nuclear-targeted analogs 
(anthracyclines with morpholinyl or alkyl substituents at amino group C-3 and 
disaccharide anthracyclines where the amino group is displaced to the second 
sugar) utilize the impact of critical moieties, whereas non-nuclear targeted 
congeners obtained by combining modifications at C-14 with modifications of 
amino sugar potentiate apoptotic pathways.(68) Development of carriers that 
assist preferential distribution of anthracyclines (liposomal formulations),(68,69) 
or conjugation of anthracyclines to a carrier that specifically recognizes tumor 
cells [extracellularly tumor activated prodrugs (ETAPs)](70) and polymer bound 
doxorubicin(71) are being pursued. These carriers that include anthracycline 
conjugates to specific proteins appear to be promising strategies in 








Doxorubicin, produced by a variant of Streptomyeces peucetius (var.caesius), 
is a nucleolar non-selective class I anthracycline that inhibits both DNA and 
nucleolar RNA synthesis at approximately equivalent concentrations.(72) It has 
a wide spectrum of antitumor activity, and is widely used in the treatment of 
lymphomas, leukemias, breast, lung, ovarian, gastric and thyroid 
malignancies.(73) Apart from its established role in chemotherapy, doxorubicin 
is also widely used in studies investigating molecular mechanisms of 
topoisomerase activity,(74) evaluation of cellular models of drug resistance,(75) 
and to probe metabolic pathways in free radical biochemistry.(76)   
 
1.2.2 Chemistry  
 
Doxorubicin has a planar polyaromatic ring system bearing a quinone moiety 
that is linked by an O-glycosidic bond to an amino sugar (Figure 1.2).(77)  
Being a class I anthracycline, doxorubicin is characterized by the presence of 
a diphenol function on ring B on the aglycone, and an acetylated side chain 
on ring A. Doxorubicin is intensely orange red and is sensitive to light, 
absorbing light both in the UV range (254 nm) and in the visible range (around 
480 nm).(78) Doxorubicin has a molecular weight of 580 kDa, and is currently 
used as the hydrochloric form that is readily soluble in water and in polar 
organic solvents. Being a weak alkaloid, doxorubicin becomes a more polar, 
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charged molecule at low pH, thereby contributing to its selective retention in 















1.2.3 Mechanism of Action 
 
Major mechanisms of doxorubicin cytotoxicity include DNA intercalation and 
initiation of DNA damage via inhibition of topoisomerases.(81,82) 
Topoisomerases modify the topology of DNA without altering deoxynucleotide 
structure and sequence and can cause transient single-strand (topoisomerase 
I) or doublestrand (topoisomerase II) DNA breaks that are resealed after 
changing the twisting status of the double helix.(83) Doxorubicin stabilizes 
reaction intermediates where DNA strands are cut and covalently linked to 
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leading to cytotoxic DNA damage and activation of apoptotic pathways.(84,85) 
The mechanisms by which doxorubicin stabilizes topoisomerase IIα cleavable 
complexes may be independent of DNA intercalation.  Doxorubicin also 
inhibits important cellular enzymes including toposiomerase I, DNA and RNA 
polymerases, and DNA helicases at varying degrees to induce cell damage. 
The inhibition of DNA helicases may also have direct inhibitory effects on 
topoisomerase IIα independent of cleavable complex stabilization.(86)  
 
The binding of doxorubicin to various components of cell membranes leads to 
altered membrane fluidity. The changes in permeability to various ions and its 
ability to chelate various metals including copper, zinc and iron, contributes to 
the cytotoxicity of doxorubicin.(87) Generation of reactive oxygen species 
through quinone redox cycling and subsequent lipid peroxidation and DNA 
damage has also been implicated doxorubicin induced toxicity.(88) These 
effects are particularly pronounced in organ systems that are deficient in 
repair mechanisms induced by free radical injury, as in the myocardium, 
resulting in dose related doxorubicin cardiotoxicity. The exact contribution of 
the above mechanisms in the antitumor activity and adverse effects of 
doxorubicin are not known and it is reasonable to assume that all the 





1.2.4.1 Administration and Distribution 
 
Doxorubicin is administered intravenously at doses of 35-70 mgm-2, typically 
as a bolus (3 to 10 minutes) or short-term (up to 1 hour) infusions  to avoid 
problems associated with extravasation.(77,80) The dosage is repeated every 
three weeks to facilitate recovery from bone marrow suppression.  
Doxorubicin is approximately 50 to 80% bound to plasma proteins, and has a 
volume of distribution (Vd) ranging from 500 to 800 Lm-2.(77,89) The blood levels 
of doxorubicin fall rapidly as the drug distributes to tissues and the high tissue 
penetration and retention in nucleated cells has been attributed to its 
lipophilicity and DNA binding capacity.(90) Doxorubicin has been shown to 
enter cells via passive diffusion, and intracellular accumulation result in 
concentrations that are 10- to 500-fold greater than extracellular 
levels.(77,91,92,93) Intracellularly, nuclear concentrations of doxorubicin are 50-
fold higher than in the cytoplasm (reaching 340 uM at saturation)(94) 
representing one molecule intercalated every 5 base pairs of DNA,(94,95) 
whereas free doxorubicin is very low (0.2% of the total intracellular drug) and 
heterogeneously distributed due to sequestration in organelles such as 
lysosomes, mitochondria and Golgi apparatus.(92) 
 
The highest accumulation of doxorubicin among tissues is seen in the liver,(96) 
while white blood cells and the bone marrow concentrates doxorubicin at 200 
to 500 fold higher levels than in the plasma.(97) Doxorubicin does not cross the 
blood brain barrier but transplacental transfer of doxorubicin has been 
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observed, and traces of doxorubicin have been detected in human milk.(98) 
Salivary concentrations of doxorubicin reach 25% of plasma levels in 75 
minutes after administration, and can exceed plasma concentrations after 2 
hours.(99) Significant concentrations of doxorubicin have also been detected in 
ascitic and pleural fluids of cancer patients following intravenous 




The biotransformation of doxorubicin occurs primarily in the liver, by the 
stereo-specific reduction of the ketone on the C-13 yielding doxorubicinol, a 
13-dihydroderivative with a hydroxyl moiety (Figure 1.3). This is carried out by 
the ubiquitious cytoplasmic carbonyl reductase and aldo-keto reductase 
metabolizing enzymes.(101) Subsequent metabolism of both doxorubicin and 
doxorubicinol involves reductive and hydrolytic glycosidic cleavage, O-
demethylation, O-sulfation, and O-glucuronidation.(102) The acid-catalysed 
hydrolysis of the glycosidic bond eliminates the sugar component to derive 
doxorubicinone from doxorubicin and doxorubicinolone from 
doxorubicinol.(103,104) The reductive removal of the C7-linked daunosamine 
sugar group via a semi-quinone intermediate and subsequent protonation of 
the C7-aglycone radical produces 7-deoxydoxorubicinone from doxorubicin 
and 7-deoxydoxorubicinolone from doxorubicinol.(105) These insoluble 7-
deoxyaglycones after demethylation require conjugation with glucuronic or 
sulphonic acid for excretion.(102) Doxorubicin aglycones have been detected in 
the biological fluid of only some patients undergoing treatment, and occur only 
transiently and at very low concentrations compared with doxorubicin and 
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doxorubicinol.(106) Doxorubicin hydroquinone production by the two-electron 
reduction of the quinone moiety by NAD(P)H-quinone oxidoreductase has 






















Fig 1.3 The metabolic pathway of doxorubicin. 
Carbonyl reduction  














































Doxorubicin clearance is predominantly mediated by the hepatobiliary 
pathway, with more than 50% of the drug excreted in bile within 7 days after 
treatment.(108) About 10 to 20% and 40 to 50% of the dose is excreted in 
faeces within 24 and 150 hours, respectively. Renal clearance of doxorubicin 
is low, and about 12% of total dose is recovered in the urine during 6 days 
after treatment.(109) Intravenous infusion of doxorubicin is followed by a 
triphasic plasma clearance characterized by three successive half lives (t½α: 3 
to 5 minutes, t½β: 1 to 2 hours, t½γ: 24 to 36 hours).(108)  A fourth half life (t½δ of 
110 hours), representing up to 30% of the total area under the plasma 
concentration-time curve (AUC0-∞) has also been reported.(110) The initial short 
distributive half-life suggests rapid tissue uptake of doxorubicin, while its 
successive terminal half lives reflects slow elimination from tissues. The 
plasma concentration of doxorubicinol rapidly increases and then decreases 
parallel to that of doxorubicin, following bolus injection of the parent drug.(111)  
During instances of prolonged infusion of doxorubicin, the concentration of 
doxorubicinol might exceed that of doxorubicin, and the ratio of the AUC0-∞ of 
doxorubicinol to the AUC0-∞ of doxorubicin may exceed 1.(112) Doxorubicinol 
contributes to 23% of biliary excretion whereas the remainder consists of 
other metabolites.(113) A rebound of plasma concentrations of doxorubicinol 
has been observed 4-8 hours after doxorubicin administration suggesting the 
existence of an entero-hepatic recirculation.(114) 
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Alterations in doxorubicin pharmacokinetics in relation to hepatic and renal 
dysfunction have been investigated.(109) Most studies concluded that patients 
with liver damage have reduced doxorubicin clearance and greater incidence 
of toxicity, while few studies reported no alterations in doxorubicin 
pharmacokinetics in patients with hepatocellular carcinoma, cirrhosis(96) or 
other moderate liver involvements.(115) Significant reduction in clearance of 
doxorubicin and increase in clearance of doxorubicinol has been observed in 
patients on hemodialysis.(109) Reports of reduced doxorubicin clearance with 
age(116) and differences in doxorubicin clearance associated with gender have 




The pharmacodynamics of doxorubicin results from its cytotoxic and 
antiproliferative effects, attributed to its action on multiple molecular targets 
including key cellular enzymes such as topoisomerases I and II.(119) 
Topoisomerase II mediated DNA damage by doxorubicin is followed by G1 
and G2 growth arrest and induction of apoptosis, and has been proposed to 
correlate with tumor response and patient’s outcome.(120) Doxorubicin also 
inhibits topoisomerase I and doxorubicin induced cytotoxicity is greatly 
dependent on cellular topoisomerase I content.(121)   Other pharmacodynamic 
effects of doxorubicin at the cellular level include intercalation of doxorubicin 
into DNA leading to the inhibition of the synthesis of macromolecules, 
generation of free radicals that results in DNA damage or lipid peroxidation, 
DNA binding and alkylation, DNA cross-linking, interference with DNA 
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unwinding or DNA strand separation, helicase activity and direct membrane 
effects.(88,122)  
 
Due to its mechanism of action and toxicity, clinical or biochemical 
pharmacodynamic endpoints rather than molecular alterations are often used 
as surrogates to monitor efficacy of doxorubicin based chemotherapy. 
Relationship between the pharmacokinetics of doxorubicin, cytotoxicity and 
clinical outcomes have been established in several studies.(123,124) Increase in 
peak plasma concentrations (Cmax) of doxorubicin has been correlated to 
increased incidence of cardiotoxicity(125) and post-infusion plasma steady 
state levels (Css) of doxorubicin have also been associated with the relative 
nadir of white blood cell count that follows doxorubicin administration.(126) 
Piscitelli et al(125) correlated plasma doxorubicin exposure levels (AUC) with 
surviving fraction of white blood cells, showing that 10% cell survival is 
obtained for an AUC of approximately 3000 ng.ml-1.h. Robert et al(127) showed 
a correlation between the Cmax and the short-term response to the drug 
(evaluated as the reduction of tumor mass at 3 weeks) in patients with locally 
advanced breast cancer treated primarily with doxorubicin while Preisler et 
al(128) showed that the doxorubicin plasma concentration obtained 3 hours 
after administration correlated significantly to the outcome of remission 
induction therapy in acute nonlymphocytic leukemia patients. The high plasma 
levels of doxorubicin in these studies may have led to improved tumor cell 
drug uptake up to a detrimental level, explaining these observations. Taken 
together, the variability in both biochemical and clinical pharmacodynamic 
outcomes following doxorubicin administration could be attributed to factors 
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such as tumor heterogeneity, preexisting physiological conditions as well as 
variations related to dosing schedules of doxorubicin and its associated 
pharmacokinetics. 
 
Similar to other chemotherapeutic agents, several factors may be considered 
important determinants of pharmacodynamic variations in response to 
doxorubicin administration (Figure 1.4).  These include factors responsible for 
altering drug effects such as genetics, age, prior chemotherapy or radiation 
therapy, poor performance status, comorbid disease states, and 
comedications.(129) The phenomenon of pharmacodynamic tolerance that 
relates to doxorubicin induced changes in receptor density or efficiency of 
receptor coupling to signal transduction pathways is also important and needs 
















Fig 1.4 Potential determinants of doxorubicin pharmacodynamic effects. 
Adapted from: Weser K et al.(130) (Goodman and Gillman, 11th ed) 
 
The clinical supervision of the patient on doxorubicin therapy involves 
continuous monitoring for the pharmacodynamic parameters of febrile 
neutropenia such as absolute neutrophil count (ANC) and platelet counts,(131) 
biochemical parameters such as liver function tests, clinical biomarkers such 
as the development of alopecia and mucositis, and clinical outcomes such as 
myelosuppression, febrile neutropenia or cardiomyopathy.(132)  Doxorubicin 
treatment is followed by a unique dose related dilated cardiomyopathy that 
occurs late during the course of disease, eventually leading to congestive 
cardiac failure and is characterized by loss of myofibrils, dilation of the 
sarcoplasmic reticulum, cytoplasmic vacuolation and swelling of the 
mitochondria.(122) Although pharmacokinetic studies have not established 
predictive indicators for cardiotoxicity, several studies have suggested that 
exposure levels to doxorubicin and its metabolites, particularly the free 
radicals, may be associated with cardiomyopathy.(133)   
 
Identification and measurement of pharmacodynamic end points are used to 
interpret pharmacologic events by quantitating the relationship between 
plasma or target organ drug concentrations with pharmacologic response.(134) 
With regards to doxorubicin, reports indicate a relationship between cellular 
doxorubicin levels and cytotoxicity.(123,124) The principle that clinical outcomes 
of chemotherapy are more of a direct consequence of the drug concentration 
than its administered dose highlights the importance of understanding 
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variations in pharmacokinetics of doxorubicin in relation to variations in its 
pharmacodynamic effects. 
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Pharmacogenetics is defined as the study of genetic variants that may 
influence the absorption, distribution, metabolism and elimination of a drug 
and as a consequence, its efficacy and toxicity.(135) Genetic factors are 
suggested to account for 20-95% of the inherited variability in therapeutic 
efficacy and toxicity of drugs in individual patients.(136,137)  Pharmacogenetic 
studies in breast cancer may provide critical insights regarding variability in 
response and/or toxicity to doxorubicin based adjuvant and neo-adjuvant 
chemotherapy regimens and mechanisms of resistance to treatment. 
 
The factors influencing the disposition of doxorubicin and mechanisms 
determining efficacy of treatment during breast cancer chemotherapy are 
complex and are influenced by the concerted action of various influx and 
efflux transporters that are responsible for its translocation across cellular 
membranes as well as the drug metabolizing enzymes which are responsible 
for its biotransformation (Figure1.5). In-vitro and in-vivo studies have 
demonstrated these genetic candidates to play significant roles, acting as 
determinants of intracellular doxorubicin and doxorubicinol concentration 
levels, and hence, its pharmacokinetics and pharmacodynamics following 























Fig 1.5 Major pharmacogenetic candidates across the doxorubicin 
biochemical   pathway. 
 
 
The multiple molecular targets of doxorubicin and varied mechanisms of 
cytotoxicity that determines its pharmacodynamic effects introduces further 
complexity in understanding the pharmacokinetic-pharmacodynamic variability 
of doxorubicin. In addition, several of the key drug transporters and 
metabolizing enzymes are now known to be under transcriptional control by 
regulatory genes such as the orphan nuclear receptors encoding genes. 
Understanding the influence of functional polymorphic variants in the orphan 
nuclear receptor genes and their impact on expression of downstream target 
proteins involved in the disposition of doxorubicin may be important in further 
understanding the pharmacokinetic-pharmacodynamic variability of 
doxorubicin.  
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1.3.2 Pharmacogenetics of Nuclear Receptors, Drug Transporters and 
Metabolizing Enzymes 
 
1.3.2.1 Regulatory Nuclear Receptors 
 
Nuclear receptors comprise a family of ligand-activated transcription factors 
that include the steroid, retinoid and thyroid hormone receptors acting as 
sensors for endogenous and exogenous compounds. They are involved in 
transferring of stimuli into cellular responses and regulating the expression of 
their target genes.(143,144) Recent classification scheme for nuclear receptors is 
based on sequence homology in which both the constitutive androstane 
receptor (CAR) and pregnane X receptor (PXR) belong to the NR1I family 
(NR1I3 and NR1I2, respectively),(145,146) which also includes the Vitamin D 
receptor (VDR) and benzoate X receptors (BXRs). Both PXR and CAR have 
been widely studied and are well known for their diversity, but not specificity, 
in their interaction with drugs.(147,148,149) Typically, there are two transcriptional 
activation domains in a nuclear receptor: the activation function 1 (AF-1), 
which resides in the N-terminal domain, and the AF-2, which is present in the 
C-terminal portion of the ligand binding domain (LBD).(150,151)  Unliganded 
nuclear receptors typically reside in the cytoplasm, bound to transcriptional 
co-repressors that recruit specific histone deacetylase-containing 
complexes.(152) The ligands for the nuclear receptors are small and lipophilic in 
nature, which either permits them to diffuse readily into cells or are subjected 
to uptake by specific transport mechanisms. The binding of a ligand to the 
LBD results in a conformational change in the AF-2 that disrupts interactions 
with transcriptional co-repressor proteins such as nuclear receptor co-
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repressor (N-CoR) and silencing mediator of retinoic acid and thyroid 
hormone receptor (SMRT) and permits interactions with transcriptional 
coactivator proteins such as the steroid receptor co-activator-1(SRC-1) family 
members.(153) Once in the nucleus, the ligand-receptor complex recruits co-
activators and form homodimers or, in many cases, heterodimerize with the 
retinoid X receptor (RXR). These heterodimer complexes stimulate the 
expression of target genes by binding to short DNA sequence motifs, termed 
response elements, located in the regulatory regions of target genes. In 
addition, DNA binding of these nuclear receptors to their cognate nuclear 
receptor binding elements (NREs) triggers a complex cross-talk between 
other nuclear receptors, co-activators and corepressors, histone modification 
enzyme complexes, subsequently activating transcriptional response. 
 
1.3.2.1.1 Pregnane X Receptor (PXR) 
 
The discovery of the orphan nuclear receptor Pregnane X Receptor (PXR; 
NR1I2), also referred to as Steroid and Xenobiotic Receptor (SXR) provided 
insights into the molecular basis of how specific drugs could induce pathways 
of clearance and enhance rate of elimination of drugs.(154) A wide variety of 
structurally divergent endogenous compounds and therapeutic agents have 
been identified as ligands of PXR, including steroid hormones and anti-
inflammatory, antifungal, antihypertensive, antiviral and antineoplastic 
agents.(154,155) Since its discovery, substantial research on PXR and its 
function established its role as a master transcriptional regulator of drug 
metabolizing enzymes that are responsible for catalyzing the oxido-reductive 
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reactions of a broad range of substrates and facilitating their clearance.(156) 
The activation of PXR is initiated in the cytoplasm, where following exposure 
to ligands, heterodimers consisting of PXR and the retinoic acid receptor 
(RXR; NR2B) binds to nuclear receptor response elements in the target genes 
and induce their transcription. PXR regulates the expression of drug 
transporters such as adenosine triphosphate (ATP) binding cassette (ABC) 
superfamily of transporters,(157) organic anion transporter protein 2 
(SLC21A6)(158) and multidrug resistance proteins (MRP1 and MRP2)(157,159) as 
well as cytochrome P450 drug metabolizing enzymes(160,161), highlighting its 
role in influencing drug disposition. 
 
The PXR gene maps to chromosome 3 (3q12-q13.3), spans approximately 40 
kb, encodes the human PXR (hPXR) mRNA consisting of nine exons 
containing 434 amino acids and has a molecular weight of 49.7 kDa. Ten 
alternatively spliced forms of hPXR have been identified to date.(154,162) 
hPXR.1 contains an activation function 1 region (AF-1) (amino acid residues 
1-40), a DNA binding domain (DBD) (amino acid residues 41–140) and a 
ligand binding domain (LBD) (amino acid residues 141–434). The hPXR.2 
cDNA encodes a 390 amino acid protein that lacks a 41 amino acid region in 
the putative LBD of hPXR.1. Tissue specific examination has showed that 
human PXR mRNA is predominantly expressed in liver and small intestine, 
and to a lesser extent, in kidneys, lungs and breast.(163) 
 
Efforts to identify PXR targets by in silico screening showed that 
approximately 281 genes involved in drug metabolism and 97 genes involved 
in drug transporters have putative PXR/RXR binding sites.(164) Among its 
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various target genes, PXR has been well documented to influence the 
expression of ATP–binding cassette family B1 (ABCB1) and the cytochrome 
P-450 3A (CYP3A) genes. PXR binds to CYP3A4 together with RXR as a 
heterodimer to two ER6 (everted repeats of AG(G/T)TCA) in the CYP3A4 5’- 
upstream region and to DR-4 type response elements in the ABCB1 gene. 
ABCB1 expression is also known to be coordinated with expression of 
CYP3A4, with both gene products being induced by the same spectrum of 
drugs.(165) P-glycoprotein and CYP3A4 are colocalized in liver and intestine, 
serving as a coordinated system for the absorption, metabolism and 
disposition of many drugs. Studies by Snyold et al(157) demonstrated that PXR 
can regulate the expression of efflux (ABCB1) and metabolic pathways 
(CYP3A4) of anticancer drugs such as paclitaxel, indicating a novel strategy 
to control drug clearance and suggesting a broad role for PXR in the 
coordinated induction of multiple detoxification pathways. Functional 
polymorphisms in PXR gene may help explain variation in the response of 
many metabolizing enzymes and transporters to drugs that are PXR ligands, 
including mechanisms that induce ABC transporters. In view of the role of 
PXR as a master regulator of drug clearance, PXR polymorphisms are hence 
likely to have widespread effects on drug pharmacokinetics. Information on 
PXR genotypic variability in different populations and ethnic groups would 
therefore enhance understanding of the mechanistic basis of interindividual 




1.3.2.2 Doxorubicin Efflux Transporters 
 
Membrane transporters responsible for drug efflux are integral proteins that 
assist in the movement of substances across biological membranes by 
facilitated diffusion or active transport.(166) The adenosine triphosphate binding 
cassette (ABC) transporters are primary active transporters involved in the 
influx and efflux of a variety of substrates ranging from ions, sugars, amino 
acids, vitamins, lipids, antibiotics and drugs to large molecules such as 
oligosaccharides, oligopeptides and high molecular weight proteins,(167) using 
ATP hydrolysis for substrate translocation.  The ABC efflux pumps are found 
in cytoplasmic and organellar membranes in higher organisms and include the 
endoplasmic reticulum, inner mitochondrial membrane, peroxisomal and 
vacuolar membranes.(168) ABC transporters are expressed constitutively in 
normal cells in the digestive system including the small intestine, large 
intestine, liver, and pancreas; epithelial cells in the kidneys, adrenals, brain, 
and testes; and endothelial cells.(169,170)  
 
There are at least 49 members in the ABC transporter family that is divided 
into 7 subfamilies (ABCA to ABCG) based on sequence homology.(171) 
Structurally, ABC transporters are composed of four domains; 2 hydrophobic 
transmembrane domains (TMDs) and two water soluble nucleotide binding 
domains (NBDs) that are bound to the cytosolic face of TMDs (Figure 1.6).  In 
eukaryotes the domains are generally fused into a single polypeptide chain 
while the NBDs contain the ATP-binding cassettes.(172) The ATP-binding site 
in the NBD monomer is formed by 2 conserving sequences, the Walker A (P-
loop) and Walker B motifs that are both intimately involved in and required for 
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the ATP hydrolysis reactions.(173) Inactivation of the ATP hydrolysis reaction 
by mutations in these sequences has been shown to lead to loss of ATP-









Fig 1.6 Structure of ABC transporters showing the transmembrane domains 
(TMD) and nucleotide binding domains (NBD). Adapted from Zhang et al.(175) 
 
With regards to the mechanism of action of ABC efflux transporters, cycling 
between high and low affinity states for ligand on the different sides of the 
membrane has been described.(176) In the first step, ligand binds to the TMDs 
in the high-affinity open NBD dimer conformation, inducing increased affinity 
for ATP. Subsequently, ATP binding induces formation of the closed NBD 
dimer, which in turn induces a large conformational change in the TMDs 
sufficient to translocate ligand. Subsequently, ATP hydrolysis initiates 
dissolution of the closed NBD dimer releasing ADP to complete the transport 
cycle and restore the protein to a high-affinity state for ligand.  
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1.3.2.2.1 ATP binding cassette, subfamily B1 (ABCB1) 
 
The multi drug transporter efflux ABCB1 (MDR1) is a member of the ABC 
subfamily class B, encoding for the P-glycoprotein (P-gp), and is the best-
characterized ABC transporter since its isolation in 1976.(177) The ABCB1 
gene, containing 27 exons (6-204 bp) and spanning over 209 kb, is located on 
chromosome 7q21-31 and encodes a 1280 amino acid polypeptide 
(170kDa).(178)  Human ABCB1 is a phosphorylated and glycosylated protein 
consisting of 12 hydrophobic TMDs and 2 NBDs. One NBD connects two 
TMDs with a hydrophilic NBD loop; the TMDs form channels for the efflux of 
substrate drugs whereas NBDs located in the interior of cytoplasm participate 
in ATP binding and hydrolysis.(179) ABCB1 is localized in the plasma 
membrane, in the apical/luminal membrane in polarized cells and is also 
present in the brush border membrane of intestinal cells, the biliary canalicular 
membrane of hepatocytes, the luminal membrane of proximal tubule epithelial 
cells of the kidney, and in the endothelial cells at the blood-brain 
barrier.(75,176,180,181)  
 
ABCB1 plays a major role in conferring multidrug resistance phenotype to 
cancer cells due to its high transport capacity and broad substrate 
recognition.(182,183) Several in-vitro studies have identified ABCB1 as a major 
candidate mediating doxorubicin resistance.(184,185,186,187,188) Drug resistant cell 
lines treated with ABCB1 siRNA display increased intracellular doxorubicin 
accumulation, leading to increased doxorubicin sensitivity and 12-fold reversal 
of resistance.(188) The breast cancer Hs578T-Dox cell line overexpressing 
ABCB1 is approximately 200 times less sensitive to doxorubicin when 
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compared to non-ABCB1 expressing Hs578T cells.(188) Treatment with ABCB1 
inhibitors such as carvedilol and verapamil reduced the LD50 for doxorubicin in 
Hs578T-Dox cells while only marginally affecting the cytotoxicity of Hs578T 
cells. The expression of ABCB1 has also been shown to be rapidly 
upregulated by treatment with anthracyclines. In a study by Neilsen et al(189) 
approximately 75% of the various cell lines made resistant by exposure to 
anthracyclines exhibited a complete multidrug resistant phenotype, including 
ABCB1 expression. 
 
The possible influence of ABCB1 on doxorubicin disposition has been 
investigated in several studies. Doxorubicin elimination from intestinal tissue 
into the lumen by ABCB1 expressed in the intestinal epithelium has been 
proposed to play a role in the poor oral bioavailability of doxorubicin.(190) In-
vivo studies with ABCB1 inhibitors such as PSC-833 showed marked 
inhibition of biliary secretion of doxorubicin, probably by blocking ABCB1 
mediated transport in the hepatocyte canaliculus.(191) Studies in mdr1a 
knockout mice that lacked expression of the murine ABCB1 isoform(192) also 
support the role of ABCB1 in doxorubicin elimination via hepatic and extra 
hepatic mechanisms.(192)The increased hepatic and renal expression of 
ABCB1 in response to doxorubicin exposure suggest that the alterations in 
doxorubicin pharmacokinetics observed in multiple treatment regimens may 
be related to the induction of ABCB1 in hepatic and extrahepatic tissues.(193)  
 
At least 105 ABCB1 gene variants have been reported to date, the majority 
being located either in the noncoding or intronic regions.(194) However, 
majority of studies on genotype related function of ABCB1 have investigated 
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three high frequency variants in exons 12, 21 and 26 in relation to altered 
disposition of its putative drug substrates. Hoffmeyer et al(195) reported that 
that the c.3435C>T [exon 26] polymorphism in the ABCB1 gene is associated 
with lower ABCB1 expression resulting in 50% higher plasma concentration of 
digoxin. Studies in different populations and patient subgroups suggested that 
this synonymous transition is associated with decreased ABCB1 functionality 
and subsequently, increased bioavailability of ABCB1 substrates.(196,197)  
Reduced exposure of digoxin has been observed in subjects harboring the 
c.3435TT allele, whereas other reports indicated both increased digoxin 
exposure in c.3435T carriers and also a lack of influence on digoxin 
pharmacokinetics.(198,199) The alterations in the pharmacokinetics of other 
ABCB1 drug substrates such as fexofenadine(200,201,202) and 
cyclosporine(203,204)also showed conflicting patterns with regards to the 
c.3435C>T polymorphism. In the search for potential causal mechanisms 
involved, Kim et al(200) reported that the c.3435C>T polymorphism is linked to 
a synonymous c.1236C>T [exon 12] and a non-synonymous c.2677G>T/A 
(Ala893Ser) [exon 21] polymorphism. Independent studies have shown that 
the c.2677G>T variant has substrate dependent effects in cellular systems, 
causes alterations in mRNA levels and increases drug efflux(197,205,206) 
whereas patients carrying the c.1236CC reference genotype show lower peak 
drug concentrations and reduced drug exposure levels compared with 
mutated allele carriers.(207) 
 
Several studies have since highlighted the strong linkage disequilibrium 
associated with ABCB1 polymorphisms at exons 12, 21 and 26 and identified 
haplotypes revealing ethnicity specific patterns.(194,200,208) Consequently, 
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homozygosity for the variant forms at the three loci was associated with 
reduced ABCB1 activity and higher exposure levels of drug 
substrates.(208,209,210,211) The c.2677G/c.3435T haplotype was shown to be 
associated with significantly higher bioavailability of digoxin while the 
c.2677G/c.3435C haplotype correlated with lower exposure levels to 
digoxin.(209) In another study however, c.1236T/c.2677G/c.3435T carriers 
demonstrated higher P-gp activity when compared with non-carriers. Johne et 
al(209) reported that analysis of ABCB1 haplotypes is superior to unphased 
SNP analysis for predicting ABCB1 phenotypes and suggested that the 
c.2677GT/c.3435TT genotype is key to describing interindividual differences 
in drug disposition. The ABCB1 c.3435C>T, c.2677G>A/T and c.3435C>T 
polymorphisms have been studied in Asian ethnic groups in relation to 
alterations in drug disposition. Linkage disequilibrium analysis revealed strong 
association between the three ABCB1 polymorphisms and the haplotypic 
association of these polymorphisms was found to influence cyclosporine 
exposure levels in Asian heart transplant patients.(212) However, there have 
been no studies to date that investigated the role of functional genetic 
polymorphisms in the ABCB1 gene and their haplotypes in influencing the 
disposition of doxorubicin in Asian breast cancer patients.  
 
1.3.2.2.2 ATP binding cassette, subfamily G2 (ABCG2) 
 
ABCG2 [Breast cancer resistant protein (BRCP), placenta-specific ABC 
transporter, or mitoxantrone-resistant protein (MRP/MXR)], is a half-
transporter and the second member of the G-subfamily of ABC transporters. 
ABCG2 was first identified in human breast cancer cell lines selected in 
 35
presence of doxorubicin and verapamil (MCF-7/AdrVp)(213) and also in 
multidrug resistant tumor cells that showed absence of ABCB1 
expression.(140,213,214) The human ABCG2 gene, consisting of 16 exons and 
spanning over 66 kb, is located on chromosome 4q22 downstream from a 
TATA-less promoter and encodes a 655 amino acid polypeptide (72 kDa).(214) 
Unlike ABCB1, ABCG2 protein consists of one transmembrane domain with a 
single ATP-binding site requiring homodimerization to transport substrates.  
Apart from cancer cells, ABCG2 protein has been found to be physiologically 
expressed in the canalicular membrane of the liver, in the epithelia of small 
intestine, colon, lung, kidney, adrenal and sweat glands, as well as in the 
endothelia of veins and capillaries, suggesting a major defensive role of this 
protein in tissues.  
 
ABCG2 is a high capacity drug transporter with wide substrate specificity and 
transports large, hydrophobic, positively and negatively charged molecules, 
including cytotoxic compounds (mitoxantrone, topotecan, flavopiridol, SN-38, 
methotrexate and doxorubicin) and fluorescent dyes (Hoechst 
33342).(140,215,216) Overexpression of ABCG2 mediates resistance to several 
anticancer agents, limiting their efficacy. MCF-7 and K562 cells made 
resistant to nanosphere encapsulated doxorubicin demonstrated higher 
ABCG2 expression when compared to ABCB1.(217) A recent study 
demonstrated that epidermal growth factor receptor (EGFR) kinase activity 
regulates the percentage of ABCG2 marked side-population of cells in thyroid 
carcinoma.(218)  In a study that further explored the influence of EGFR tyrosine 
kinase inhibitors in circumventing doxorubicin resistance in treatment of 
thyroid malignancies, it was shown that the tyrosine kinase inhibitor geftinib 
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causes the translocation of ABCG2 away from the plasma membrane, 
resulting in a concomitant decrease in doxorubicin efflux in thyroid cancer cell 
lines.(219) On the basis of its tissue distribution and findings in knockout mice, 
ABCG2 is also assumed to have a major influence on drug pharmacokinetic 
profiles. In-vivo studies in ABCG2 knockout mice showed that the protein can 
significantly influence pharmacokinetics of drugs such as nitrofurantoin by 
markedly altering its hepatobiliary excretion.(220) Increased biliary secretion of 
the transported compounds by ABCG2 may also significantly contribute to a 
decreased bioavailability of various agents including anticancer drugs such as 
topotecan.(221,222)  However, despite its original isolation from multidrug 
resistant human breast cancer cells, the level of ABCG2 expression in clinical 
breast cancer cases appears to be minimal.(223,224) In breast cancer, it is likely 
that with the overlapping transport properties with ABCB1, ABCG2 plays a 
more important role in altering disposition of specific chemotherapeutic agents 
such as doxorubicin and thereby influencing its efficacy and toxicity than 
potentially contributing to tumor drug resistance. 
 
Several groups have reported more than 40 synonymous and 
nonsynonymous polymorphisms in the promoter as well as exon and intron 
sequences of the ABCG2 gene.(225,226,227,228,229)  The cloning of ABCG2 from 
expressed sequence tags (ESTs) and drug selected cell lines yielded 
sequences coding for different amino acids at position 482 and showed major 
differences in substrate recognition and transport.(230,231) The R482 mutants 
had increased transport and ATP hydrolytic activity and were considered as 
‘‘gain of function’’ mutants.(232) The altered substrate specificity of these 
mutants as compared to the wild type protein conferred increased doxorubicin 
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resistance suggesting that glycine mutations at position 482 have a significant 
impact on ABCG2 function by modifying its substrate specificity and its 
influx/efflux rates.(230,231)  In a study by Allen JD et al,(231) three mouse cell 
lines independently selected for doxorubicin resistance were found to acquire 
mutations of murine Bcrp1 at arginine 482, leading to greater resistance 
towards anthracyclines. 
 
A single nucleotide polymorphism in exon 5 of the ABCG2 gene has been 
described where a c.421C>A transversion results in an amino acid change of 
glutamine to lysine at codon 141. The c.421C>A ABCG2 transfected PA317 
cells show markedly decreased protein expression and low level drug 
resistance compared  to ABCG2 transfected cells carrying the reference 
genotype.(225)  However, these alterations in protein expression were not 
observed in human intestinal samples.(227) A recent study in humans linked 
altered pharmacokinetics of an ABCG2 substrate diflomotecan to the ABCG2 
c.421C>A variant suggesting that interindividual variability in substrate drug 
handling might be caused by ABCG2 genotypes.(233) The ABCG2 c.421A 
allele appears to be very common in Japanese and Chinese populations, with 
reported allele frequencies between 26 to 35%.(225,227) The polymorphism 
occurs at a frequency of 10 to 14% among Caucasians and <1% among 
Africans.(234) The wide ethnic variations in allele frequency distribution of the 
ABCG2 c.421C>A polymorphism and recent studies in cancer patients 
suggest that interindividual variability in disposition of drug substrates 
including doxorubicin might be due in part, to its functional influence.(233,234)    
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1.3.2.2.3 ATP binding cassette, subfamily B5 (ABCB5) 
 
ABCB5 [subfamily B (MDR/TAP), member 5] is a novel human ABC 
transporter and the third member of the human ABC transporter family and 
was originally designated based on its sequence homology to other ABCB 
family members, ABCB1 and ABCB4.(235,236,237,238,239) The human ABCB5 
gene, consisting of 16 exons and spanning over 108 kb, is located on 
chromosome 7p15 and encodes an 812 amino acid polypeptide (92 kDa). In 
contrast to six transmembrane helices and one intracellular ATP-binding 
domain per homologous half found in other known mammalian ABC 
transporters, studies suggest a surface plasma membrane localization of 
ABCB5 and a predicted membrane topology characterized by five 
transmembrane helices flanked by both extracellular and intracellular ATP-
binding domains.(240)  Screening a melanoma cDNA library and investigating 
the expression pattern of ABCB5 identified two isoforms of ABCB5 mRNA 
(ABCB5a and ABCB5b). Both isoforms were shown to be preferentially 
expressed in melanomas and in other pigmented cells. ABCB5a has seven 
exons (exons 1 to 7) and contains both a 5’ untranslated region (UTR) (exons 
1 to 4) and a 3’ UTR (exon 7). The deduced peptide sequence of ABCB5a 
has a molecular weight of 15 kDa and contains the ABC signature motif and 
Walker B consensus found in other ABC transporters. ABCB5a has no Walker 
A consensus sequence, and shows 60 to 70% homology with ABCB1. For 
ABCB5b, the protein topology predicts a half-transporter or more than a half-
transporter, with approximately 70% similarity to ABCB1. There is limited 
information on the pattern of ABCB5 expression, or associated function. 
Preliminary reports suggest a possible physiological role of the ABCB5b 
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isoform in the regulation of progenitor cell fusion(240) and its possible 
association with drug sensitivity.(241) In physiologic progenitor cells, ABCB5 
functions to maintain membrane hyperpolarization, thereby serving as a 
negative regulator of cell fusion and, as a consequence, of growth and 
differentiation.(240) 
 
It has been hypothesized that ABCB5, similar to ABCB1, functions as a drug 
resistance mediator in human cancer cells.(241) Assessment of the role of 
ABCB5 in cellular drug transport and chemoresistance to doxorubicin in 
ABCB5-expressing human G3361 melanoma cells showed that the cells are 
heterogeneous with regard to initial intracellular doxorubicin accumulation, 
with a distinct subpopulation (7.2 %) of cells exhibiting high doxorubicin 
uptake on drug incubation.(241) When ABCB5 expression and doxorubicin 
content were assayed concurrently, it was found that 80% of ABCB5 
expressing tumor cells exhibited the doxorubicin-high phenotype. In contrast, 
neither doxorubicin-high nor doxorubicin-low G3361 melanoma cells 
expressed ABCB1.  The ABCB5 expressing cells accumulated significantly 
less doxorubicin (up to 52% reduced accumulation at 24 hours) during all 
exposure times tested compared with melanoma cells that did not express 
ABCB5.(241) Reduction in ABCB5 mRNA levels by using siRNA induced drug 
sensitivity to several drugs including camptothecin, 5-FU, and mitoxantrone, 
implying that elevated ABCB5 expression may confer drug resistance to 
anticancer agents.(242) 
 
The potential role of ABCB5 in human malignant melanoma has been 
investigated since the skin had been earlier identified as a principal tissue 
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type for ABCB5 expression.(241) Doxorubicin was used as a chemotherapeutic 
probe to examine ABCB5 mediated drug transport since structurally related 
ABCB1 effluxes doxorubicin and because malignant melanoma is highly 
resistant to doxorubicin treatment. The results defined a novel molecular 
mechanism for doxorubicin resistance in human malignant melanoma and 
suggested that ABCB5 is a novel molecular marker for a distinct subset of 
chemoresistant, stem cell phenotype-expressing tumor cells among 
melanoma bulk populations, and can be specifically targeted to enhance 
cytotoxic efficacy.  To date, there are no reports of ABCB5 polymorphisms 
and their potential functional roles. Further studies are required to identify the 
presence of functional polymorphic variants in the gene encoding ABCB5 and 
relate them to the disposition of its drug substrates including doxorubicin. The 
potential role of the ABCB5 genetic polymorphisms in influencing efficacy and 
response to doxorubicin based chemotherapy in cancer patients of different 
ethnic groups also needs further examination.  
 
1.3.2.2.4 ATP binding cassette, subfamily C5 (ABCC5) 
 
ABCC5 [Canalicular multispecific organic anion transporter C, MRP5/ ABC33] 
was originally classified as an organic anion transporter and belongs to ABCC 
subfamily, one of the largest sub-families of the ATP-binding cassette (ABC) 
transporters.(171) The human ABCC5 gene, consisting of 29 exons and 
spanning over 98 kb, is located on chromosome 3q27 encoding a 1437 amino 
acid polypeptide (190kDa). ABCC5 belongs to the short type of ABCC 
proteins that differ from the long type by the lack of an N-terminal 
transmembrane domain.(243) Sequence analyses predict that ABCC5, similar 
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to other ABC transporters, contains the Walker A, B and C motifs, nucleotide-
binding folds, and 12 transmembrane spanning helices in 2 hydrophobic 
domains. The precise function of ABCC5 remains to be established, although 
it has been shown to transport nucleoside monophosphate analogs.(244)   
Northern blot analyses have revealed ubiquitous expression of a 6.6 kb 
ABCC5 transcript with highest levels in skeletal muscle followed by brain, 
kidney, testis, and heart.(245,246) In transfected epithelial cells, ABCC5 has 
been localized to the basolateral membrane.(244) ABCC5 tissue distribution 
analyzed using a polyclonal antibody directed against 14 amino acids in its C-
terminal detected ABCC5 in smooth muscle cells of the human genito-urinary 
tract and in epithelial cells of ureter and urethra and in blood vessels.(247) In 
the placenta, ABCC5 is found in the basal membrane of syncytiotrophoblasts 
and in fetal vessels.(248) In heart, ABCC5 expression has been found in 
cardiomyocytes, endothelial cells, and smooth muscle cells.(249) Quantitative 
analysis of ABCC5 in ventricular heart samples from patients suffering from 
ischemic cardiomyopathy compared with patients having dilated 
cardiomyopathy or a normal heart suggested an up-regulation of ABCC5 
under ischemic conditions. Recently, three novel isoforms of ABCC5 
generated by alternative splicing of newly identified exons within intron 5 of 
the ABCC5 gene have been characterized, suggesting that alternative splicing 
of the ABCC5 mRNA may provide a mechanism to achieve a tissue-
dependant regulation of ABCC5 gene expression.(250) 
 
There are no reports to date that suggest a role of ABCC5 in intestinal drug 
disposition. However, in a study that investigated the expression of multidrug 
resistance genes including ABCB1 and ABCB5 in the intestinal tract of 
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healthy subjects, ABCC5 localized to the basolateral membrane was shown to 
be expressed in the duodenum, terminal ileum, and all sites of the colon, with 
the expression levels decreasing from the proximal to the distal part.(251,252) As 
an efflux transporter, ABCC5 is also likely to have roles in mediating drug 
resistance. ABCC5 has been reported to confer resistance to several drugs 
including methotrexate, and the thymidilate synthase inhibitor raltitrexed.(253) 
ABCC5 localization in the luminal membrane of capillary endothelial cells, 
pyramidal neurons, human astrocytes, tumor capillaries of gliomas and in 
glioma cells suggest potential roles of ABCC5 in resistance of brain tumors 
against anticancer drugs such as thiopurines and methotrexate.(254) Pratt et 
al(255) demonstrated ABCC5 expression conferring resistance against 5-
fluorouracil, suggesting that ABCC5 mediated transport of chemotherapeutic 
agents may contribute to resistance in breast cancer chemotherapy. In the 
same study, ABCC5 transfectants also demonstrated a two-fold resistance to 
doxorubicin. Park et al(256) analyzed ABCC5 transporter gene expression 
profiles in breast cancer patients who underwent sequential weekly 
paclitaxel/FEC (5-fluorouracil, epirubicin and cyclophosphamide) neoadjuvant 
chemotherapy. Significantly higher expression of ABCC5 was observed in the 
residual disease group, along with ABCA12, ABCA1 ABCC13, ABCB6 and 
ABCC11. Quantitative RT-PCR analysis has showed that the expression of 
ABCC5 is increased in normal and tumor lung tissue from patients with 
previous exposure to platinum compounds.  Analysis of the mRNA levels of 
ABCC5 in the doxorubicin resistant cells by Northern blot analysis also 
showed markedly higher ABCC5 expression suggesting major roles of 
ABCC5 in mediating doxorubicin resistance.(257) 
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Screening the ABCC5 gene in Caucasian patients suffering from 
cardiomyopathy identified twenty polymorphisms among which five 
polymorphisms were in the putative promoter region, four synonymous 
polymorphisms in the exonic regions and two polymorphisms in the 3’-UTR 
region.(249) No significant associations of ABCC5 polymorphisms with gene 
expression were observed. Saito et al(258) sequenced the entire ABCC5 gene 
and its 3’- flanking region in 48 unrelated Japanese individuals and identified 
85 polymorphisms. Gwee PC et al(259) sequenced the entire length of the 
ABCC5 gene and observed 130 different ABCC5 haplotypes in five 
populations (Chinese, Malays, Indians, Caucasian and African-Americans). 
Similarities in ABCC5 haplotype profiles were observed between the Chinese 
and Malays and between the Caucasians and Indian ethnic groups.  
Significant strong linkage was observed between the intron 1 -1205C>T and 
intron 30 c.7161G>A polymorphisms that are separated by more than 100 kb 
in the ABCC5 gene, suggesting that the entire ABCC5 gene resides within a 
region of strong linkage disequilibrium.  Further studies in cancer patients 
belonging to different ethnic groups would be expected to identify influences if 
any, of the ABCC5 polymorphisms on the disposition of various anticancer 
agents and also on the clinical response to chemotherapy.  
 
1.3.2.2.5 Ral-Binding Protein 1; RALBP1 (RLIP76) 
 
RLIP76 (Ral-Binding Protein 1, 76-KD) is an ATP dependent non ABC 
multispecific transporter protein, initially predicted to be involved in regulation 
of membrane plasticity, movement, and endocytosis. RLIP76 was later 
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identified as responsible for removing glutathione-electrophile conjugate (GS-
E) from cells.(260,261)  The human RLIP76 gene, consisting of 9 exons and 
spanning over 62 kb, is located on chromosome 18p11.3 and encodes a 655 
amino acid polypeptide (76 kDa).(262) Splice-variants of RLIP76 including a 67 
kDa peptide and longer 80-102 kDa peptide, cytocentrin have been 
identified.(263) The mechanism of transport by RLIP76 appears to be through 
interaction with the membrane by antennapedia-homeodomain homologous 
sequences within the N-terminal, coupled with ATP-hydrolysis simulated by 
substrate binding.(264) The C-terminal domain has been shown to bind Reps-1 
and polymerase-α protein (POB1) linking RLIP76 to epidermal growth factor 
receptor (EGFR), insulin receptor and transforming growth factor-β (TGFβ) 
receptor.(265,266) The sequence of the ATP-binding sites in N terminal 
(69GKKKGK74) and C terminal domain (418GGIKDLSK425) of RLIP76 is 
similar with the consensus for the P-loop (Walker motif) in the ABC 
transporter proteins, but unlike the ABC transporters, no transmembrane 
helices are evident in the RLIP76 sequence.(267) 
 
Awasthi et al(268) identified RLIP76 to be involved in the energy-dependent 
efflux of other structurally unrelated amphiphilic compounds such as 
doxorubicin. Incorporation of the purified RLIP76 into erythrocyte inside out 
vehicles (IOVs) doubled the rate of doxorubicin transport. RLIP76 stimulated 
ATP hydrolysis in the presence of weakly cationic drugs (doxorubicin and 
dihydrodoxorubicin) and its uncharged metabolites (doxorubicinone, 
deoxydoxorubicinone, and dihydrodoxorubicinone) showing that protein may 
be involved in the protection against the toxic effects of amphiphilic toxins as 
well as their phase I and II biotransformation products. Physiological 
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significance of the ATP-dependent transport of doxorubicin by RLIP76 was 
further confirmed by transfection experiments where RLIP76-overexpressing 
cells showed increased efflux of doxorubicin and acquired resistance to both 
doxorubicin and hydroxynonenal (4-HNE).(269)  These observations combined 
with its ability to transport substances such as leukotrienes(270) and its 
ubiquitous expression in human tissues indicate that transport by RLIP76 may 
have toxicological as well as physiological relevance. 
 
Similar to ABCB1, the RLIP76 transport mechanism has been detected in the 
canalicular membrane of hepatocytes.(271) The wide tissue distribution and 
ability to transport doxorubicin with a Km in the range of clinically achievable 
serum doxorubicin concentrations suggests that the RLIP76 mediated 
transport mechanisms may be important in protecting normal or malignant 
tissues from doxorubicin toxicity. RLIP76 inhibition induces apoptosis in the 
absence of doxorubicin while synergistically enhancing cytotoxicity through 
increased cellular accumulation of the drug.(272) Consistent with these 
findings, augmentation of RLIP76 protect cells from doxorubicin cytotoxicity 
and confer resistance to apoptosis through increased doxorubicin efflux and 
reduced cellular doxorubicin accumulation.(273) Doxorubicin transport activity 
of RLIP76 in non-small cell lung cancer (NSCLC) is approximately twice that 
of in small cell lung cancer (SCLC).(274) In studies investigating doxorubicin 
resistance in NSCLC, it was shown that protein kinase C (PKC-α) mediated 
accumulation defect and doxorubicin resistance in NSCLC is primarily due to 
differential phosphorylation of RLIP76.(274) In-vitro studies showed that K562 
human erythroleukemia cells transfected with RLIP76 acquire resistance to 
doxorubicin, implicating RLIP76 in the mechanisms of drug resistance.(275) 
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The significance of RLIP76 mediated transport to the mechanisms of 
multidrug resistance may go beyond the protection of cells through drug efflux 
since RLIP76 could also impact on signaling mechanisms via the modulation 
of the intracellular concentration of GSHNE and its precursor, 4-HNE that is 
known to cause cell cycle arrest and promote differentiation and apoptosis in 
cancer cell lines.  
 
There have been few studies that investigated polymorphisms in the RLIP76 
gene. Ninteen polymorphisms in the entire RLIP76 gene obtained from the 
HapMap project and 6 tagged polymorphisms were investigated in a report 
associating RLIP76 with predisposition to epilepsy.(276) Neither individual 
RLIP76 polymorphisms nor their haplotypes revealed any significant 
associations with clinical outcomes in the study.  Further studies are required 
to identify the functional RLIP76 polymorphisms if any, in different population 
groups. Given the established role of RLIP76 in doxorubicin transport and 
mediating doxorubicin resistance, it is also important to investigate further the 
role of RLIP76 polymorphisms in the pharmacokinetics and 
pharmacodynamics of doxorubicin.  
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1.3.2.3 Doxorubicin Influx Transporters  
 
The solute carrier family (SLC) transporters transport specific substrates, such 
as amino acids, oligopeptides, sugars, monocarboxylic acid, organic cations, 
anions, phosphates, nucleosides, metals and water soluble vitamins, and are 
assumed to play important roles in mediating the uptake of drugs and 
endogenous metabolites.(277) Approximately 300 solute carrier (SLC) genes 
have been cloned and grouped into 43 families.(278) Major cellular uptake 
carrier systems include organic anion transporters (OATP, solute carrier 
protein (SLC21A), organic cation transporters (OCT, SLC22A), concentrative 
nucleoside transporters (CNT, SLC28A), dipeptide transporters (PEPT, 
SLC15A), and monocarboxylate carriers (MCT, SLC28A).(278)  The OATPs 
[OATP-C (SLC21A6), OATP8 (SLCO1B3) and OATP-A (SLC21A3)] are the 
main drug carrier proteins supporting the sodium-independent hepatic uptake 
of a variety of organic anions and have broad and partly overlapping substrate 
specificity.(279,280) The OCTs [hOCT1 (SLC22A1), hOCT2 (SLC22A2)] 
translocate a variety of organic cations with widely differing molecular 
structures(281) and are also able to translocate organic cations in an 
electrogenic manner across the plasma membrane in either direction, 
operating independently of Na+ and proton gradients.(282,283) Most 
substrates translocated by the OCT transporters are organic cations and 
weak bases that are positively charged at physiological pH.  Solute carrier 
family of transporters typically mediate uptake and chemosensitivity for 
hydrophilic anticancer drugs, with members of the SLC19 family (reduced 
folate carrier, RFC family), SLC28 and 29 families (CNT and ENT nucleoside 
transporters), SLC7A and 3A families (amino acid transporters) and SLC31A 
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(CTR copper transporter family) shown to be important determinants of 
chemosensitivity to anticancer agents.(284)  
 
1.3.2.3.1 Solute carrier family, member 16 (SLC22A16) 
 
The organic cation transporter SLC22A16 is also known as organic cation 
transporter 6 (hOCT6), carnitine transporter 2 (hCT2), Fly-like putative 
transporter 2 (hFLIPT2), or organic cation-binding protein 1 (OKB1).(285) The 
human SLC22A16 gene, consisting of 8 exons and spanning over 51.9 kb, is 
located on chromosome 6q21 and encodes a 577 amino acid polypeptide (65 
kDa). SLC22A16 has 12 predicted alpha-helical transmembrane domains and 
one large extracellular loop between domains 1 and 2.(286) SLC22A16 is 
known to transport L-carnitine, which is an essential cofactor of metabolism 
with definitive role in disease states.(287,288) In-vitro mutagenesis studies in 
transporters of the SLC22A family have shown that domains 4, 8, 10 and 11 
and possibly other additional domains determine the structure of substrate 
binding pockets.(289,290)  SLC22A16 is constitutively expressed in leukemic as 
well as a variety of cancer cell lines,(138) brain, kidney and the Sertoli and 
epithelial cells of the epididymal ducts in the testis.(291) 
 
Recent in-vitro studies in Xenopus oocytes expressing the SLC22A16 protein 
demonstrated a dose dependent and saturable kinetics with regards to influx 
of doxorubicin.(138) Studies with Jurkat cells overexpressing SLC22A16 
showed them to be increasingly susceptible to the cytotoxic effects of 
doxorubicin, and this was postulated to result from the increased influx of the 
drug. These studies suggest that alterations in the expression and activity of 
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SLC22A16 may have profound implications on pharmacokinetics and 
pharmacodynamics of doxorubicin in cancer patients.  Understanding the 
clinical relevance of genetic polymorphisms in newly identified transporter 
genes such as SLC22A16 may provide important insights on their contribution 
to differences in the pharmacokinetics of drug substrates such as doxorubicin 
in cancer patients belonging to ethnically distinct populations. However, there 
have been no studies to date that investigated polymorphisms in the 
SLC22A16 gene in relation to phenotypic outcomes such as disposition of 





1.3.2.4 Doxorubicin Metabolizing Enzymes  
 
The diverse group of metabolizing enzymes include the phase I oxido-
reductive family of drug metabolizing enzymes [Cytochrome P-450 enzymes 
(CYP450s) ,  NADPH cytochrome c reductases, Carbonyl reductases (CBRs)] 
and the phase II conjugative enzymes [UDP-glycosyltransferases (UGTs), 
Glutathione transferases (GSTs), Sulfotransferases (SULTs), and N-
acetyltransferases (NATs)]. Carbonyl reductases (CBRs) are ubiquitously 
expressed monomeric NADPH dependent cytosolic enzymes that catalyze the 
reduction of several chemically diverse substrates such as aldehydes, 
ketones, quinones and other xenobiotics.(292,293) Apart from cellular 
metabolism of endogenous compounds such as steroids and their role in drug 
detoxification, carbonyl reductases are also assumed to participate in 
apoptosis,(294) mutagenesis,(295) carcinogenesis,(296) drug resistance(297) and 
signal transduction.(298)  Originally assumed to belong to the aldo-keto 
reductase family, the four carbonyl reductases (CBR1, CBR2, CBR3 and 
CBR4) are now assigned to the family of short chain dehydrogenases (SDRs), 
one of the largest protein families identified to date.(299) Carbonyl reductase 2 
(CBR2) is not present in human tissues, and its gene has not been found in 
the human genome. The CBR4 gene is located on human chromosome 4 
(4q32.3) and encodes a protein comprised of 237 amino acids, but its 
enzymatic properties and tissue distribution remains unknown.(300) 
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1.3.2.4.1 Carbonyl Reductase 1 (CBR1) 
 
The human CBR1 gene, consisting of 3 exons and spanning over 3.1 kb, is 
located on chromosome 21 and encodes a 277 amino acid polypeptide (30 
kDa).(301)  The CBR1 gene lacks a CAAT and TATA box and contains a GC 
rich island extending into the first exon, a structure characteristic of genes 
having a housekeeping function.(298) Some of the identified substrates of 
human CBR1 include endogenous compounds such as prostaglandins and 
steroids and drugs such as loxoprofen,(302) metyrapone,(302) haloperidol,(303) 
bromoperidol,(304) timirepone,(305) and doxorubicin.(298) 
 
In-vitro studies have shown that genetic variations in CBR1 gene could have 
significant functional consequences. Substitution of highly conserved basic 
residues (Lys-15, Ala-37 and Arg 38) in the N–terminal of CBR1 by neutral or 
acidic residues showed reduction of enzyme kinetic parameters by order of 
several magnitudes, highlighting their significant role in coenzyme binding and 
catalysis.(306) Polymorphic variants in CBR1 have been reported earlier by 
different groups. Avramopolous et al(307) identified the CBR1 3’-UTR G>A 
transition for the linkage mapping of the carbonyl reductase gene on 
chromosome 21. However, the effect of the polymorphism on enzyme activity 
and tissue expression is not known. Gonzalez et al(142) reported the V88I 
(rs1143663), L73L (rs25678), A209A (rs20572) and V231V (rs2230192) 
polymorphisms by screening full length CBR1 cDNA samples isolated from 
liver donors. The non-synonymous V88I G>A polymorphism occurred at a low 
frequency among African-Americans (q = 0.014) and resulted in CBR1 
isoforms with distinct kinetic and thermodynamic properties. The V88 isoform 
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presented 50% higher Vmax values for the anthracycline daunorubicin and 
synthesized 47% higher levels of its C-13 alcohol metabolite daunorubicinol.  
Based on in-vitro studies, it was proposed that individuals with homozygous 
CBR1 88I genotype may exhibit a slower rate of synthesis of C-13 alcohol 
metabolites that may be associated with reduced risk of cardiotoxicity 
associated with anthracycline therapy. 
 
Several studies have suggested the possibility of alterations in the metabolism 
of drugs due to variability in carbonyl reductase activity.(102,302,308,309) 
Polymorphisms in the coding or regulatory regions of genes encoding 
carbonyl reductase drug metabolizing enzymes may have significant 
phenotypic influences due to their critical roles in the phase I metabolism of 
both endogenous and xenobiotic compounds.(310) However, there have been 
few studies to date that investigated polymorphisms in genes encoding 
carbonyl reductases and their influence on pharmacokinetics of its drug 
substrates. 
 
1.3.2.4.2 Carbonyl Reductase 3 (CBR3) 
 
The CBR3 gene which contains 3 exons spanning a region of 11.2 kb has a 
72% sequence similarity with CBR1 and is located 62 kb telomeric to the 
CBR1 gene. The relative expression of CBR3 is much lower than CBR1 in 
most of the tissues analyzed.(300)Lakhman et al(311) identified a CBR3 V244M 
polymorphism positioned in a region critical for interactions with the NADP(H) 
cofactor, occurring at higher frequency among the Africans (q = 0.51) 
compared to Caucasians (q = 0.31). Kinetic experiments with the recombinant 
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CBR3 protein variants using the prototypical carbonyl reductase quinone 
substrate menadione revealed that CBR3 M244 isoform has significantly 
higher Vmax than V244 isoform, although both had similar Km values. Further 
studies are required to identify polymorphic variants in the gene encoding 
CBR3 in different ethnic groups and to investigate their influences on the 




1.4 STUDY HYPOTHESIS 
 
Functional differences in the intrinsic activity of candidate proteins, enzymes 
and targets across the biochemical pathway of chemotherapeutic agents 
contribute significantly to their wide variations in efficacy and toxicity.  
Understanding the interethnic differences in variations in genes encoding 
these candidates will also help explain the population differences in drug 
pharmacokinetic and pharmacodynamic profiles. The present study 
hypothesized that the functional polymorphisms in candidate drug transporting 
and metabolizing genes and their regulatory nuclear receptors across the 
doxorubicin biochemical pathway are determinants of inter-individual and 
inter-ethnic variations in the pharmacokinetics of doxorubicin in Asian breast 




1) To estimate the baseline genotype and allele frequencies of polymorphisms 
in genes encoding regulatory orphan nuclear receptor (PXR), drug 
transporters (ABCB1, ABCG2, ABCB5, ABCC5, RLIP76, SLC22A16) and 
drug metabolizing enzymes (CBR1, CBR3) across the doxorubicin 
biochemical pathway in three healthy Asian ethnic groups (Chinese, Malays, 
and Indians) in Singapore.  
 
2) To identify the influence of polymorphisms identified in genes encoding 
nuclear receptors, drug transporter and drug metabolizing enzymes on their 
hepatic gene expression levels and define genotype-phenotype correlations.  
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3) To characterize the pharmacokinetics of doxorubicin and doxorubicinol in 
Asian breast cancer patients on adjuvant chemotherapy. 
 
4) To investigate the influence of polymorphic variants in genes across the 
doxorubicin biochemical pathway on the pharmacokinetics of doxorubicin and 
doxorubicinol in Asian breast cancer patients. 
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CHAPTER 2:  MATERIALS AND METHODS 
 












2.2 STUDY POPULATION  
 
2.2.1 Healthy Subjects 
 
The healthy subjects comprised three ethnic groups predominant in the Asian 
population [Chinese, Malay and Indians; (N = 100 in each group)] The 
ethnicities of the study subjects were confirmed by carefully screening and 
verifiying against their National Registry Identification Cards. The Chinese and 
Indians of Singapore were predominantly descendants of migrants originating 
from mainland China and Southern India, respectively, while the Singapore 
Malays were indigenous to the Malay Archipelago. All participants provided 
approved informed consent for the study that was approved by the ethics 
review committee of the National Cancer Center, Singapore. 
 
2.2.2 Breast Cancer Patients 
 
Patients who had histologically confirmed invasive breast cancer (N = 62) and 
deemed fit to receive adjuvant chemotherapy with doxorubicin 
(A)/cyclophosphamide (C) were recruited for the study. Majority of the breast 
cancer patients belonged to the Chinese ethnic group (74%), followed by 
Malays (18%) and Indians (8%). The patients did not receive any other 
anticancer cytotoxic therapy, immunotherapy, or biologic response modifiers 
during the study. All patients were required to be completely aware of the 
nature and severity of the disease process, and provided approved informed 
consent for the study after being informed of the procedures to be followed, 
the nature of therapy and standard therapy options for their disease process. 
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The patients were also required to have understood all alternatives, potential 
benefits, side effects, and risks of enrollment. The study was approved by the 
ethics review committee of the National Cancer Center, Singapore. 
 
2.2.2.1 Patient Definition 
 
All patients with histologically confirmed non-metastatic invasive breast 
cancer and eligible for adjuvant chemotherapy with 
doxorubicin/cyclophosphamide were considered eligible for the study. The 
inclusion and exclusion criteria for participation of breast cancer patients in 
the study were as follows:  
 
2.2.2.2 Inclusion Criteria 
 
• Histologically confirmed non-metastatic invasive breast cancer  
o Node  negative stage > T1c or T1b with poor prognostic features 
(high grade, Her2-neu FISH positive, ER negative) or stage 2 
(T2, N0),  
o Any non-metastatic node positive patients, 
o Locally advanced disease 
• Age ≥ 18 years 
• ≥ 2 weeks from major surgery (wide excision/lumpectomy/ 
mastectomy) 
• Adequate bone marrow, hepatic and renal functions (absolute 
neutrophil count ≥ 1,500/μL, platelet count ≤ 100,000/μL, serum 
creatinine < 2.0 mg/dl, total bilirubin < 2.0 x ULN) 
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• No pre-existing peripheral neuropathy symptoms as per the NCI 
CTC scale (NCI Common Toxicity Criteria Ver. 3, Appendix 1) 
 
2.2.2.3 Exclusion Criteria 
 
• Use of concomitant medications known to cause myelosuppression 
(neutropenia) and neuropathy  
• Eastern Cooperative Oncology Group (ECOG) functional status > 2  
• Serious comorbidities including poorly controlled diabetes mellitus, 
ischemic heart disease, uncontrolled hypertension or active 
infection 
• Pregnancy 
• Use of growth factors during cycle 1 of chemotherapy 
 
2.2.2.4 Screening Evaluations 
 
The following assessments were done on day 1 of cycle 1 of chemotherapy.  
 Weight and height assessment for calculation of body surface area 
(BSA) 
 Full blood count with differential counts and platelet count 
 Blood chemistries including  
o Serum sodium 
o Serum potassium 
o Blood Urea Nitrogen (BUN) 
o Aspartate aminotransferase (AST) 
o Alanine aminotransferase (ALT) 
 60
o Alkaline phosphatase (ALP) 
o Total bilirubin 
o Conjugated bilirubin 
 ECG assessment as appropriate 
 ECOG status 
 Vital signs (Blood pressure, Heart rate, Respiratory rate) 
 Urinalysis as clinically indicated 
 Radiography of tumor  
 
Hematological parameters including hemoglobin (Hb), total leukocyte count, 
platelet count, and the absolute neutrophil count (ANC) after the start of 
treatment (Day 7 and 14) and prior to the start of each cycle were measured. 
New treatment cycles were started only if the ANC count was > 1500/μl and 
platelet count > 100 000/μl.   
 
2.2.2.5 Doxorubicin Administration and Dosing Schedule 
 
Doxorubicin was administered at a dose of 60 mg/m2 intravenously (IV) over 
20 minutes, once every 3-week cycle after standard premedications with IV 
dexamethasone 10 mg, diphenhydramine 50 mg, cimetidine 300 mg or 
ranitidine 50 mg. The adjuvant regimen also included IV cyclophosphamide 
600 mg/m2 administered over 30 minutes once every 3 weeks.  Blood 
samples for pharmacokinetic analysis were drawn from breast cancer patients 
at the following time points after the start of infusion of doxorubicin on the first 
day of the first cycle of chemotherapy: at predose, 5, 15 and 30 minutes and 
at 1, 4, 8 and 24 hours. Blood samples were collected in plain EDTA 
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containing vacutainer tubes and immediately centrifuged at 1000 g for 10 
minutes and the plasma fraction was collected and stored at –20°C until 
analysis. 
 
2.2.2.6 Concomitant Therapy 
 
 Analgesic treatment for the patient in pain was adjusted according to 
the patient’s need before entry to the study to provide maximum patient 
relief. The adjuvant drugs for analgesia (NSAIDs, tricyclic 
antidepressants and anticonvulsants) were administered according to 
the WHO “analgesic ladder” (Appendix 2) 
 No other investigational drug was allowed during the study period and 
the patients were not allowed to participate concurrently in any other 
clinical study 
 Medications taken by the patient during the trial were registered in the 
Case Record Form (CRF). For concomitant medications other than 
analgesics and adjuvant drugs for pain control, the name of the 
compound, indication, the administration type (prescribed/self 
prescribed) the route of administration and dates of treatment start and 
end were recorded 
 
2.2.3 Liver Tissues  
 
Healthy, non-cancerous liver tissues (N = 41) were obtained from Chinese 
cancer patients undergoing hepatectomy for metastasis from a colonic 
primary malignancy for genotyping and gene expression studies. All patients 
provided approved informed consent for the study that was approved by the 
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ethics review committee of the National Cancer Center, Singapore. The liver 




2.3 CHEMICALS AND REAGENTS  
 
All chemicals were of analytical (99% purity) or molecular biology grade 
unless specifically stated (Table 2.1). 
 
Table 2.1 List of chemicals, reagents and suppliers. 
 
Reagents and Chemicals Company 
 
Taq polymerase, PCR Buffer, Magnesium 
Chloride 
Fermentas Life Sciences, ON,Canada 
GeneAmp® PCR Core Reagents kit Perkin Elmer, USA 
Deoxynucleotide triphosphate (dNTP)mix Epicenter technologies, Wisconsin, USA 
HPLC purified oligonucleotides Research Biolabs, Singapore  
SeaKem GTG Agarose Bio Whittaker Molecular USA 
DNA Ladder & Loading Dye New England Biolabs, MA, USA 
QIAGEN PCR Purification Kit  Qiagen, Germany 
CEQ DTCS Quick Start Kit  Beckman Coulter, Singapore 
Glycogen  Beckman Coulter Inc, US 
Ethylenediamine-tetraacetic acid (EDTA) Merck, NJ, USA 
Ethanol Merck, NJ, USA 
Sodium acetate 
 
Merck, NJ, USA 
Real-Time RT PCR reagents Applied Biosystems, USA 
Analytical-grade sodium dihydrogen 
phosphate 
Merck, NJ, USA 
Phosphoric acid Merck, NJ, USA 
Ethidium Bromide Sigma Life Science, Washington, USA 
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Reagents and Chemicals Company 
Ammonium Chloride  Sigma-Aldrich, USA 
Sodium Diethyldithiocarbamate Trihydrate  Sigma Life Science, Washington, USA 
Glycerol Sigma-Aldrich, Washington, USA 
Dipotassium phosphate Sigma-Aldrich, Washington, USA 
Triethylamine Sigma-Aldrich, Washington, USA 
Chloroform Sigma-Aldrich, Washington, USA 
Tetrahydrofuran Sigma-Aldrich, Washington, USA 
Doxorubicin 
(LOT 0011BS47F) 
Pharmacia & Upjohn S.p.A.  
(Via Pasteur 10-20014 Nerviano (MI) Italy). 
Adriamycinone  
(LOT GF 10821-60) 
Pharmacia & Upjohn S.p.A.  
(Via Pasteur 10-20014 Nerviano (MI) Italy). 
13-Dihydroadriamycinone  
(LOT AS 15116-10) 
Pharmacia & Upjohn S.p.A.  
(Via Pasteur 10-20014 Nerviano (MI) Italy). 
Daunorubicin (IS) Pharmacia & Upjohn S.p.A.  
(Via Pasteur 10-20014 Nerviano (MI) Italy). 
13-Dihydrodoxorubicin HCl  
(PNU 153713A, LOT AS 15116-09) 
Pharmacia & Upjohn S.p.A.  
(Via Pasteur 10-20014 Nerviano (MI) Italy). 
HPLC-grade methanol Labscan Limited Co. Dublin, Ireland
 
Acetonitrile Labscan Limited Co. Dublin, Ireland
 
1-propanol Labscan Limited Co. Dublin, Ireland
 
Polypropylene Vial Kit, 12x32, 300uL 
9mm Screw Cap With Silicone/PTFE Septa 
Phenomenex, CA, USA 
 
HPLC Column HyperClone 3u ODS (C18) 
120A, 100 x 4.6 mm 
Phenomenex, CA, USA 
SecurityGuard Cartridges 
C18 4x3.0mm 
Phenomenex, CA, USA 
SEP-PAK C8 Cart 1CC/100mg 
 
Waters Asia Limited, Singapore 
 
SEP-PAK VAC CN 1CC 50MG 
 
Waters Asia Limited, Singapore 
HPLC Column  
150 mm x 4.6 mm I.D., 5 μm XTerra RP-8  
Waters, MA, USA 
HPLC Column  
150 mm x 3.9 mm I.D., 5 μm Symmetry C8 
Waters, MA, USA 
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2.4 PHARMACOGENETIC ANALYSIS 
 
Pharmacogenetic analysis across the biochemical pathway of doxorubicn 
involved screening the exon and exon-intron boundaries of the PXR, ABCB5, 
RLIP76, SLC22A16 and carbonyl reducatse (CBR1 and CBR3) genes, as 
there were no prior information on polymorphisms in these candidate genes 
among Asian popultions.  With regards to genes encoding the ABCB1, 
ABCG2 and ABCC5 efflux transporters, frequently occuring functional 
polymorphisms whose genotype and allelic frequencies were previously 
reported in the Asian populations, were investigated. 
 
2.4.1 DNA Extraction  
 
2.4.1.1 Whole Blood 
 
Whole blood (6 mL) was collected from healthy subjects and breast cancer 
patients for DNA extraction in ethylenediaminetetraacetic acid (EDTA) 
vacutainers and kept chilled until processed. Genomic DNA was extracted 
from blood using the QIAamp® DNA Blood Mini kit (Qiagen, Germany). 
Samples were equilibrated to room temperature before the procedure and up 
to 200 µl of specimen were added to a sterile 1.5 ml microcentrifuge tube that 
contained 20 µl of QIAGEN protease. Lysis buffer (Buffer AL) was then mixed 
thoroughly to the specimen to yield a homogeneous solution, to ensure 
efficient lysis of the sample. The solution was incubated at 56°C for 10 
minutes to denature contaminants.  Upon incubation, the microcentrifuge tube 
was briefly centrifuged and 200 µl of 100% ethanol was added to the solution, 
pulse vortexed for 15 seconds before a second brief centrifugation step. The 
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resultant mixture was then transferred to a spin column (in a 2 ml collection 
tube) and was centrifuged at 6000 g for 1 minute. The supernatant was 
discarded and the spin column was placed in a clean 2 ml tube. 
 
A total of 500 µl of clean-up buffer (Buffer AW1) was added into the spin 
column and centrifuged again at 6000 g for 1 minute. The collection tube 
containing the filtrate was discarded and replaced with a clean 2 ml collection 
tube. In the second clean-up step, 500 µl of washing buffer (Buffer AW2) was 
added into the column and centrifuged at > 130000 g for 3 minutes. After 
discarding the supernatant, centrifugation was repeated (> 30000 g) for 1 
minute to eliminate possible buffer carryover and the collection tube was 
discarded and replaced with a new sterile microcentrifuge tube. 200 µl of 
elution buffer (Buffer AE) was added into the spin column, incubated at room 
temperature for 5 minutes to increase DNA yield. Finally, the spin column was 
centrifuged at 6000 g for 1 minute to elute the DNA and was stored at 4°C for 
downstream applications.  The DNA concentration was determined by 
measuring the optical absorption at 260 nm and the sample purity was 
estimated from the 260/280 ratio using the NanoDrop spectrophotometer 
(ThermoFisher Scientific, MA, USA). 
 
2.4.1.2 Liver Tissues 
 
DNA was extracted from liver tissues using the Qiagen DNAeasy kit. The 
tissues were cut to approximately 10 mg pieces and placed in 1.5 ml 
microcentrifuge tubes to which 180 μl tissue lysis buffer (Buffer ATL) was 
added followed by 20 μl of proteinase K.  The contents were mixed by 
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vortexing and incubated at 56°C until completely lysed (1-1.5 hours). The 
tubes were vortexed (15 seconds) followed by addition of 200 μl lysis buffer 
(Buffer AL). After mixing thoroughly by vortexing, 200 μl ethanol (96–100%) 
was added and the mixture was pipetted into a spin column in a 2 ml 
collection tube and centrifuged at 6000 g (8000 rpm) for 1 minute. The flow-
through and collection tube was discarded and the spin column placed in a 
new 2 ml collection tube. 500 μl of cleanup buffer (Buffer AW1) was added 
and centrifuged for 1 minute at 6000 g.  The flow-through and collection tube 
was discarded and the spin column was placed in a new 2 ml collection tube 
followed by addition of 500 μl of washing buffer (Buffer AW2). The tube was 
centrifuged for 3 minute at 20,000 g (14,000 rpm), the flow-through and 
collection tube was discarded and the spin column was transferred to a new 
1.5 ml microcentrifuge tube. 200 μl of elution buffer (Buffer AE) was added for 
elution and incubated for 1 minute at room temperature and centrifuged for 1 
minute at 6000 g. The DNA concentration was determined by measuring the 
optical absorption at 260 nm and the sample purity was estimated from the 
260/280 ratio. 
 
2.4.2 Polymerase Chain Reactions (PCR)   
 
The oligonucleotides for pharmacogenetic analysis of genes encoding the 
nuclear receptors (PXR), drug transporters (ABCB1, ABCG2, ABCB5, 
ABCC5, RLIP76, and SLC22A16) and drug metabolizing enzymes (CBR1 and 
CBR3) were obtained from Research Biolabs Pte Ltd., Singapore. The 
GeneAmp® PCR Core Reagents kit were purchased from Perkin Elmer and 
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used to perform PCRs on all deoxyribonucleic acid (DNA) templates.  The 
components of the PCR kit are shown in Table 2.2.   
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Table 2.2 General components of the PCR kit core reagents used for 











The PCR mixture consisted of 1X PCR buffer (75 mM Tris-HCl, 20 mM 
(NH4)2SO4, 0.1% Tween 20), 1.5 mM MgCl2, 0.2 mM dNTPs, 0.4 µM of each 
primer and Taq DNA polymerase (2 U) in a final volume of 10 µL.  The 
components of individual PCR reactions are listed in Table 2.3. All reactions 
were done on BIO-RAD DNAEngine Thermal Cycler (Biorad Laboratories, 
CA, USA). Individual PCR cycling conditions for the pharmacogenetic analysis 
of genes encoding drug transporter and drug metabolizing enzymes in the 
study are described in detail under respective sections. 
 
Table 2.3 Standard components of individual PCR reactions for 
pharmacogenetic analysis of various genes. 
Reagents Volume Concentration 
PCR buffer II 1.5 ml  10 x 
MgCl2 solution 1.5 ml 25 mM 
dATP 320 μL 10 mM 
dTTP 320 μL 10 mM 
dGTP 320 μL 10 mM 
dCTP 320 μL 10 mM 
Taq polymerase   50 μL 5  U/μl 
Components Concentrations Volume (µl) 
PCR buffer 10 x 1.0 
MgCl2 1.5 uM 0.6 
dNTPs 0.3 mM 0.3 
Primer (forward) 10 uM 0.2 
Primer (reverse) 10 uM 0.2 
Taq Polymerase 1.5 U 0.3 
Template DNA  20 ng/µl 2.0 
H2O  5.4 
Total volume              10.0 
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2.4.3 Purification of PCR Fragments   
 
Purification of amplified DNA fragments of various genes was done using 
QIAquick PCR Purification Kit (QIAGEN Inc., Germany).  Briefly, 5 volumes of 
the provided binding buffer (Buffer PB) was added to 1 volume of the PCR 
sample and mixed. The buffer PB allows the efficient binding of single- or 
double-stranded PCR products as small as 100 bp and the quantitative 
(99.5%) removal of primers up to 40 nucleotides. The reaction mix was then 
applied to a QIAquick column and centrifuged for 60 seconds at 14000 g. The 
flow-through was discarded and the QIAquick column was placed back into 
the same tube. Unwanted primers and impurities that has passed through the 
column were washed with 750 μL of the ethanol-containing washing buffer 
(Buffer PE) and centrifuged for 60 seconds. The flow-through was discarded 
and the column was centrifuged for an additional 1 minute at 14000 g. The 
QIAquick column was then placed in a clean 1.5 ml microcentrifuge tube and 
30 μL of elution buffer (buffer EB) was added to the centre of the QIAquick 
membrane, allowed to stand for 1 minute, and then centrifuged at 14000 g for 
60 seconds. The purified DNA fragments were stored at 4°C. 
 
2.4.4 DNA Sequencing  
 
All sequencing reactions were done using the CEQ Dye Terminator Cycle 
Sequencing (DTCS) Quick Start Kit and a CEQ 2000 automated sequencer 
(Beckman Coulter). The components of the CEQ DTCS Quick Start Kit 
consisted of the following: 
• DTCS Quick Start Master Mix 
 71
• Glycogen (20 mg/ml) 
• Mineral oil (5 ml) 
 
The sequencing reaction consisted of a 3-stage process: 
Stage I - Sequencing PCR  
A DNA sequencing PCR reaction was prepared on a 96-well plate and the 
sequencing reactions were added in the order listed below: 
Milli-Q water    7.0 μL 
Purified DNA template  4.5 μL 
Primer    0.5 μL 
DTCS Quick Start Master Mix 8.0 μL 
Total volume    20.0 μL  
 
The reaction components were thoroughly mixed and the following thermal 
cycling conditions were used for all sequencing PCRs as described in the 
Beckman Coulter DTCS sequencing protocol: 
96°C for 20 seconds, 
50°C for 20 seconds, and  
60°C for 4 minutes. 
 
The above steps were repeated for 30 cycles before proceeding to stage II. 
 
Stage II - Ethanol precipitation 
5 μL of a stop solution consisting of a mixture of 1.5 M sodium acetate (pH 
5.2), 50 mM EDTA (pH 8.0) and 4 μg glycogen were added to each PCR 
mixture from stage 1. This was followed by addition of 60 μL ice-cold 95% 
ethanol, inverting the plate 5-10 times vigorously to ensure thorough mixing 
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and cooling the reaction mixture at –20°C for 10 minutes. The reaction 
mixture in the 96-well plate was then centrifuged at 3500 g for 10 minutes 
using a Beckman JT-25 centrifuge. The supernatant was carefully removed by 
inverting the plate on paper towels and centrifuged again with the plate in an 
inverted position, for 20 seconds. The DNA pellets were then rinsed twice with 
200 μL ice-cold 70% ethanol. Each rinse was followed by centrifuging 
immediately at 3500 g for 3 minutes and removing the supernatant as 
described above. The samples were then vacuum dried for 10 minutes, 
followed by resuspension in 40 μL formamide. Each sample was then overlaid 
with mineral oil. 
 
Stage III - CEQ 2000 automated sequencing 
The sample plate was loaded into the CEQ 2000 for sequencing analysis. A 
CEQ separation buffer (Beckman Coulter) and a CEQ polyacrylamide 
separation gel (Beckman Coulter) were used for sequencing. Data analysis 
was carried out using CEQ version 1.1. 
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2.4.5 Pharmacogenetics of Nuclear Receptors 
 
2.4.5.1 Pregnane X Receptor (PXR) 
 
Table 2.4 lists the primers and PCR conditions employed in amplifying the 
various segments of the PXR gene (GenBank accession number: AF364606). 
Genotyping involved screening of polymorphisms in amplified PXR gene 
fragments (9 exons and 2 kb of the 5’- and 3’-UTR regions) spanning the 
complete exons and exon-intron junctions. The PCR conditions consisted of 
denaturation for 3 minutes at 95°C, followed by 35 cycles of denaturation at 
94°C for 30 seconds, annealing at 60°C to 68°C for 45 seconds and 
elongation at 72°C for 40 seconds, and followed by a final extension at 72°C 
for 10 minutes.   
 
Table 2.4 Primers and PCR conditions used for sequence analysis of PXR 
gene polymorphisms. 
 
Location Primer sequences Fragment size (bp) Tm 




















Introns 5 - 6 F 5’-GGTTGTGAGGGGAGAGATGAGAGGC-3’ 
R 5’- GGTATAGAAGCCCCTTTCTGGGCCA-3’ 
 
1242 68.0 
Exon 9 and 
3’-UTR 
F 5’-GCCAAGCCTTGTCTCTTGGCTGACC-3’ 
R 5’-GCGTATGTTTCTATTTCCACACCCC-3’ 1612 61.0 
Tm: Melting temperature 
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2.4.6 Pharmacogenetics of Doxorubicin Transporters  
 
2.4.6.1 ATP binding cassette, subfamily B1 (ABCB1) 
 
Genotyping for the ABCB1 c.1236C>T (exon 12), c.2677G>T/A (exon 21) and 
c.3435C>T (exon 24) polymorphisms were done after amplifying the 
respective gene regions by PCR. The oligonucleotides used for PCR were 
designed based on Genbank accession no: AY425007 and are shown in 
Table 2.5. The PCR conditions consisted of denaturation for 3 minutes at 
95°C, followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing 
at 60°C to 62°C for 45 seconds and elongation at 72°C for 40 seconds, and 
followed by a final extension at 72°C for 10 minutes.   
 





and location Primer sequences 
Fragment 





F 5’- TCTTTGTCACTTTATCCAGC -3’ 









F 5’- TGCAGGCTATAGGTTCCAGG -3’ 









F 5’- TGCTGGTCCTGAAGTTGATCTGTGAAC -3’ 






Tm: Melting temperature 
 
The amplified reaction products were digested with specific restriction 
enzymes for at least 2 hours at 37°C : Eco01091 for exon 12, BanI/RsrI for 
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exon 21 and MboI for the exon 26 fragments. The digested PCR products 
were analyzed by electrophoretic separation on either agarose or 
polyacrylamide gels, followed by direct visualization under ultraviolet (UV) 
light.  
 
2.4.6.2 ATP binding cassette, subfamily G2 (ABCG2) 
 
Genotyping for the ABCG2 c.421C>A (exon5) polymorphism was done by 
PCR followed by restriction fragment length polymorphism using MseI. The 
oligonucleotides used for PCR (designed based on Genbank accession no: 
NM004827)are shown in Table 2.6. The PCR conditions consisted of 
denaturation for 3 minutes at 95°C, followed by 35 cycles of denaturation at 
94°C for 30 seconds, annealing at 58°C for 45 seconds and elongation at 
72°C for 40 seconds, and followed by a final extension at 72°C for 10 minutes 
 




Tm: Melting temperature 
 
The amplified products were digested with restriction enzyme MseI for 2 hours 
at 37oC and the DNA fragments were analyzed by electrophoretic separation 
on a 40% polyacrlyamide gel, followed by direct visualization under UV light. 
Polymorphism 
and location Primer sequences 
Fragment 












2.4.6.3 ATP binding cassette, subfamily C5 (ABCC5) 
 
Genotyping for polymorphisms in the ABCC5 gene [ (5’-UTR; -1990G>A, -
1821T>C, -1679T>A, -1205C>T, -793C>A, -889T>C), (intron 5; i.374C>T),  
(exon 8; c.1145A>G), (exon 9; c.1185T>C),  (exon 12; c.1782T>C), (intron 1; 
i.1834C>T),  (intron 2; i.7980C>T), (exon 25; c.3624C>T),  (exon 30; 
c.4896G>A, c.5557A>G) and (intron 30; i.6272A>G, i.7161G>A)] was carried 
out by direct DNA sequencing following amplification of respective gene 
regions by PCR.  The oligonucleotides used for PCR (designed based on 
Genbank sequence BC142670) shown in Table 2.7. The PCR conditions 
consisted of denaturation for 3 minutes at 95°C, followed by 35 cycles of 
denaturation at 94°C for 30 seconds, annealing at 50.7°C to 64.3°C for 45 
seconds and elongation at 72°C for 40 seconds, and followed by a final 
extension at 72°C for 10 minutes. 
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Table 2.7 PCR primers and conditions used for genotyping ABCC5 
polymorphisms 
 
Tm: Melting temperature 
Polymorphisms 
and location Primer sequences 
Fragment 














F 5’- GACTGTGCTTCTCGGTTGTGT-3’ 




F 5’- CATAACATTTGGCCCATCCT-3’ 




F 5’- CTTGTTTGGAGGTGGAGGAA-3’ 




F 5’-  TCCTCAAGTCCTTAGCGATGA-3’ 




F 5’- CTCCTGTGCTCCACTGATTCTAC-3’ 




F 5’-  TCGGTGACTCAGCAGATTTTC3’ 




F 5’- GGTGGCAGCTACCTCTGTGTGG-3’ 





F 5’- TCTTCTCTAGCTGGTGGTTTCAC-3’ 




F 5’- TGGAATCTTTTCTGTGTCCTGTT-3’ 
R 5’- AATGCCAGCGATTATATCAAATG-3’ 1130 62.0 
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2.4.6.4 ATP binding cassette, subfamily B5 (ABCB5) 
 
The ABCB5 gene located on chromosome 7p14 contains 16 exons and spans 
approximately 108 kb. Screening for polymorphisms in the exon and exon-intron 
boundaries of the ABCB5 gene was carried out by direct sequencing of PCR 
fragments.  The oligonucleotides used for screening the exon regions (designed 
based on Genbank accession no: AB353947) are listed in Table 2.8.  The PCR 
conditions consisted of denaturation for 3 minutes at 95°C, followed by 35 
cycles of denaturation at 94°C for 30 seconds, annealing at 57°C to 59.5°C for 
45 seconds and elongation at 72°C for 40 seconds, and followed by a final 
extension at 72°C for 10 minutes 
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Table 2.8 PCR primers and conditions used for amplifying ABCB5 exon and 




Tm: Melting temperature 
Location  Primer sequences  Fragment size (bp) Tm 
Exon 1 
 F 5’-GGTGCCCATCTACCAGAAAA-3’ R 5’-CACCCCTACTATTCTGCATCA-3’  490 57.5 
Exon 2 
 F 5’-AGCACCCAGAGGCTGAAGTA-3’ R 5’-ACCAACCACAGCATCTCCTT-3’  493 58.0 
Exon 3 
 F 5’-TGCTGGAATTACAGGCATGA-3’ R 5’-AAACCTTGGTTGCTTTTTGAA-3’  394 56.0 
Exon 4 
 F 5’-TTCAATAGCAAAGGCGATAACA-3’ R 5’-TGGGAAAGACATGTTTTGTGAG-3’  376 58.0 
Exon 5 
 F 5’-CCCTGCTGTCTGTTATGTTTGA-3’ R 5’-AAGTCCCAATTTTCCCCTTG-3’  365 58.0 
Exon 6/7 
 F 5’-GGCGACAGAGCAAGATTCTG-3’ R 5’- TTGCTGCTTAGAACAAAAAGAGTG-3’  586 57.5 
Exon 8 
 F 5’- CTGTGAGTGAGGAGGCAGGT-3’ R 5’-ATGTGGGTCATCTCAGCACA-3’  300 57.5 
Exon 9 
 F 5’-CTGGGTGACAGAGTGGGACT-3’ R 5’-TTGGTCTGTATGCATTTCTCTCTC-3’  592 56.0 
Exon 10 
 F 5'- TGTCCCCAGTGTGAGTGACTA-3' R 5'- AGGCAAACCACTGGAGTCAT-3'  275 57.0 
Exon 11 
 F 5'- TTCGAAAAATGCCTTTCCAC-3' R 5'- CAGGCTGATCTCAAACTCCTG-3'  374 56.0 
Exon 12 
 F 5'- TTAGGGGTGCCGTCTACATC-3' R 5'- GGTTAGTTTTTCAGCCCTTGC-3'  386 57.0 
Exon 13 
 F 5'- AAGGGCTCTGGAAACATGC-3' R 5'- CAAACCAGTGGGGATGCTTA-3'  396 57.0 
Exon 14 
 F 5'- TCCTTCTTGTTATGATTTGTGTGTG-3' R 5'- CCAAGGAATACATAAAAACAACTGC-3'  398 59.5 
Exon 15 
 F 5'- TTCAACATTTGTTGGGACACA-3' R 5'- CAATTCTTTCCAGGCCTTTG-3'  384 59.5 
Exon 16 
 F 5'- CCTTTGGGGACAAGCAAATA-3' R 5'- TGAAGGTCAGATGGTGTGTGA-3'  477 57.0 
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2.4.6.5 Ral-Binding Protein 1; RALBP1 (RLIP76) 
 
The RLIP76 gene located on chromosome 18 contains 9 exons and spans 
approximately 63 kb. Identification of polymorphisms in the RLIP76 gene 
consisted of direct sequencing of PCR fragments for exon and exon-intron 
regions.  The list of oligonucleotides used for genotyping the RLIP76 gene 
(designed based on Genbank accession no: NM_006788) are listed in Table 
2.9.  The PCR conditions consisted of denaturation for 3 minutes at 95°C, 
followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 
57.5°C to 64.3°C for 45 seconds and elongation at 72°C for 40 seconds, and 
followed by a final extension at 72°C for 10 minutes. 
 
Table 2.9 PCR primers and conditions used for amplification of RLIP76 exon 
and exon-intron regions. 
 
 
Tm: Melting temperature 
Location Primer sequences Fragment size (bp) Tm 
Exon 1 F 5’-TGCTGTGGTGTTTTTGTTCC-3’ 
R 5’-TGCTACTGCACTCCAACCTG-3’ 479 57.5 
Exon 2 F 5’-GGAATTGGCCAAGAAGTGAA-3’ 
R 5’-AGGATCCAGGCCAAATTTTC-3’ 697 57.5 
Exon 3 F 5’-TAGCAAGGGTGGGGATAATG-3’ 
R 5’-GGAAAAGACCCGTATTCAAGC-3’ 577 64.3 
Exon 4 F 5’-TTTATGTGTCCAGGATTAAAGGA-3’ 
R 5’-CAGTGTGCCTAACATAGCTCCA-3’ 380 64.3 
Exon 5 F 5’-TCTTTAGAAATTGCACGTGTTG-3’ 
R 5’-CCGAGGTGGGAGGATTAC-3’ 366 57.0 
Exon 6 F 5’-CGTGTAGATTGGTGGTGGTG-3’ 
R 5’-GCGAGACTTTGTCTCAAAAAC-3’ 261 59.9 
Exon 7 F 5’-GCAACATGGGAGACCCTAAA-3’ 
R 5’-GGAAAGTCTGAGAGCTAAAACAA-3’ 283 59.9 
Exon 8 F 5’-AGAGTCCTGAAAACGTGGTAAA-3’ 
R 5’-AAGGACAATTCTGAGGGGAAA-3’ 293 59.0 
Exon 9 F 5’-CTCTGTAGGATGCCCTTGCT-3’ 
R 5’-CGTGTGACAGAGGAAGAGTCTG-3’ 499 61.0 
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2.4.6.6 Solute carrier family, member 16 (SLC22A16) 
 
The SLC22A16 gene is located on chromosome 6 and spans approximately 
52 kb. Identification of polymorphisms in the SLC22A16 gene was done by 
direct sequencing of exon and exon-intron regions.  The oligonucleotides 
used for amplifying the SLC22A16 exonic regions (designed based on 
Genbank accession no: NM_033125) are listed in Table 2.10.  The PCR 
conditions consisted of denaturation for 3 minutes at 95°C, followed by 35 
cycles of denaturation at 94°C for 30 seconds, annealing at 50.7°C to 66.3°C 
for 45 seconds and elongation at 72°C for 40 seconds, and followed by a final 
extension at 72°C for 10 minutes. 
 
Table 2.10 PCR primers and conditions for amplification of SLC22A16 exon 
and exon-intron regions. 
Tm: Melting temperature 
Location  Primer sequences  Fragment size (bp) Tm 
Exon 1 




R 5’-CATAATTCCTTGTGTCCCAAG-3’  651 61.8 
Exon 3 
 F 5’-AAAGGCCTCTCCACTGAACA-3’ R 5’-CGACACAGAGGCAAACACAC-3’  546 60.5 
Exon 4 
 F 5’-GGAGGATGAGGGAAGATGAA-3’ R 5’-GCCATTTTTCCATGAACTGG-3’  952 61.8 
Exon 5 
 F 5’-CATTTCACAGGAAACGCTCA-3’ R 5’-GTCATTGCACCCAGGTTAGG-3’  577 61.8 
Exon 6 
 F 5’-CACACTGAAACTTTCCTCCACA-3’ R 5’-GGCCAAATACAATGAAATGACA-3’  393 59.5 
Exon 7 
 F 5’-GCCTGACCACCCTTATCCTT-3’ R 5’-AGCTGTTGGTAATGGGGTTG-3’  361 66.3 
Exon 8 
 F 5’-TCAAATCCATTACCCTCTGAAAA-3’ R 5’-TGGGAGATGAGAATAAGATTCCT-3’  397 50.7 
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2.4.7 Pharmacogenetics of Doxorubicin Metabolizing Enzymes 
 
2.4.7.1 Carbonyl Reductase 1 (CBR1) 
 
The CBR1 gene is located on chromosome 10q24, contains 3 exons and 
spans approximately 45 kb. Identification of polymorphisms in the CBR1 gene 
consisted of direct sequencing of PCR fragments for the 3 exons and the 
exon-intron regions.  The oligonucleotides used for genotyping the CBR1 
gene (designed based on Genbank accession no: NM_001757) are listed in 
Table 2.11.  The PCR conditions consisted of denaturation for 3 minutes at 
95°C, followed by 35 cycles of denaturation at 94°C for 30 seconds, 
annealing at 58.5°C to 61°C for 45 seconds and elongation at 72°C for 40 
seconds, and followed by a final extension at 72°C for 10 minutes   
 
Table 2.11 PCR primers and conditions used for amplification of CBR1 exon 
and exon-intron regions. 
 
 




Location Primer sequences Fragment size (bp) Tm 
Exon 1 F 5’-GCACCCCGGCGAGGTTCCG-3’ 
R 5’-CCAGTGCATCGGTTCTTCT-3’ 
553 58.5 
Exon 2 F 5’-GGCAGAGGGCACTAAGTTTTT-3’ 
R 5’-GGACAAAGTCCTGAGGCAAA-3’ 
390 58.5 




2.4.7.2 Carbonyl Reductase 3 (CBR3)  
 
The CBR3 gene is located on chromosome 10q24, contains 3 exons and 
spans approximately 45 kb. Identification of polymorphisms in the CBR3 gene 
was done by direct sequencing of PCR fragments for the exon and the exon-
intron regions.  The oligonucleotides used for genotyping the CBR3 gene 
(designed based on Genbank accession no: NM_001236) are listed in Table 
2.12.  The PCR conditions consisted of denaturation for 3 minutes at 95°C, 
followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 
59.5°C to 62°C for 45 seconds and elongation at 72°C for 40 seconds, and 
followed by a final extension at 72°C for 10 minutes 
 
Table 2.12 PCR primers and conditions used for amplification of CBR3 exon 
and exon-intron regions. 
 
Location Primer sequences Fragment size (bp) Tm 
Exon 1 F 5’-ATTTGGCTTCGGACACCTC-3’ 
R 5’-ACCCTCCTCGGTCACTCAAG-3’ 
681 59.5 
Exon 2 F 5’-AGGATCCACTTTGTCATGTGAG-3’ 
R 5’-GCACCCCTGAGTGATTTCTG-3’ 
281 62.0 




   Tm: Melting temperature 
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2.5 HEPATIC EXPRESSION  
 
2.5.1 RNA Extraction from Liver Tissues 
 
Total RNA was extracted from the liver tissues using Qiagen RNeasy Mini Kit 
(Qiagen, Germany). The liver tissue samples were disrupted and completely 
homogenized by a rotor–stator homogenizer after adding 600 μL of lysis 
buffer (Buffer RLT). The tissue lysate was centrifuged for 3 minutes at 8000 g 
and the supernatant was carefully removed by pipetting and transferred to a 
new microcentrifuge tube. 70% ethanol (1 volume) was added to the cleared 
lysate and mixed immediately by pipetting. Up to 700 μl of the sample was 
transferred to a spin column placed in a 2 ml collection tube and centrifuged 
for 15 seconds at 8000 g (10,000 rpm). The flow through was discarded and 
700 μl of buffer RW1 was added to the spin column and centrifuged for 15 
seconds at 8000 g (10,000 rpm) to wash the spin column membrane. The 
flow through was discarded again and 500 μl washing buffer (Buffer RPE) 
was added to the RNeasy spin column and centrifuged again for 15 seconds 
at 8000 g (10,000 rpm) to wash the spin column membrane. The spin column 
was placed in a new 2 ml collection tube and centrifuged at full speed for 1 
minute. The spin column was then placed in a new 1.5 ml collection tube and 
30–50 μl RNase-free water was added directly to the spin column membrane 
and centrifuged for 1 minute at 8000 g (10,000 rpm) to elute the RNA.  Optical 
density (OD) ratios (A260:A280) were used to assess quality of RNA and the 
RNA concentration was estimated using the equation below: 
 RNA concentration (μg/mL) = A
260 
× 40 μg/mL × dilution factor  
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2.5.2 Real Time Reverse Transcription PCR (RT-PCR)  
  
Reverse transcription was conducted in a reaction mix containing 10 μL of the 
extracted total RNA (10 μg/mL), 1X Promega AMV reverse transcriptase 
reaction, 1 mM of dNTPs (dATP, dUTP, dCTP, dGTP), 0.5 μg of random 
hexamer, 40 units of ribonuclease inhibitor, and 4.5 μL of Promega AMV 
reverse transcriptase (Promega Corp., USA). The mixture was incubated at 
25oC for 10 minute and subsequently at 42oC for 45 minutes. Reverse 
transcriptase reaction was terminated by heating at 65oC for 5 minutes, 
followed by cooling at 4oC for 5 minutes.   
 
Primers pairs for the genes encoding drug transporters and drug metabolizing 
enzymes and for glyceraldehyde-3-phosphate dehydrogenase (GAPDH)  as 
endogenous control were designed using the Primer Express v1.0 (Applied 
Biosystems) and are listed in Table 2.13.  The 20 μL of each reaction mixture 
contained 10 μL of SYBR green PCR master mix (Applied Biosystems, USA), 
1 μL of cDNA template, 2 μL each of forward and reverse primers and 5 μL of 
RNase-free water and cDNA derived from 5 ng of total RNA. All the reactions 
were performed in triplicates. 
 
The amplification of mRNA for the candidate genes and endogenous controls 
was carried out as follows: a 10 minute initial denaturation at 95°C, followed 
by 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. SYBR green 
fluoresces when bound to DNA and the dye emission was monitored in real 
time-PCR (RT-PCR) using an ABI prism 7000 Sequence Detection System 
(Applied Biosystems, USA). The fluorescent dye emission was a function of 
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cycle number and was determined using the sequence detector software 
(Applied Biosystems, USA), giving the threshold cycle number (CT) at which 
PCR amplification reached a significant threshold. The mRNA levels of each 
gene in the healthy liver tissue were expressed as the amount of target 
normalized to the endogenous control and relative to the gene expression 
level in the liver tissue harboring the reference genotype at all loci. 
 
Table 2.13 RT-PCR primers used for hepatic expression analysis of drug 
transporters and drug metabolizing enzymes in Chinese liver tissues. 
 








































2.6  PHARMACOKINETICS OF DOXORUBICIN AND DOXORUBICINOL 
 
 
2.6.1 High performance liquid chromatography (HPLC) assay 
 
Doxorubicin (LOT 0011BS47F), daunorubicin and the metabolites 
[doxorubicinol (LOT AS 15116-09), doxorubicinone (LOT GF 10821-60) and 
doxorubicinolone (13-dihydroadriamycinone) (LOT AS 15116-10)] were 
purchased from Pharmacia Upjohn S.p.A. Analytical grade sodium 
dihydrogen phosphate and phosphoric acid were from Merck (Schuchardt, 
Germany). The HPLC grade methanol and acetonitrile were obtained from 
Labscan Limited Co. (Dublin, Ireland). Water was purified on a Milli-Q system 
(Millipore Corporation, Bedford, MA). 
 
2.6.1.1 Instrumentation and Chromatographic Conditions 
 
Analyses were performed on a reverse-phase HPLC system consisting of a 
Waters 2690 separations module (Waters Assoc. Milford, MA) coupled to a 
Waters 474 scanning fluorescence detector (Waters Assoc.). The excitation 
wavelength was set at 480 nm and emission at 560 nm, and the gain was set 
at x 100. Chromatogram was acquired, stored, and processed using the 
Millennium software program (version 3.20, Waters Assoc.). Chromatographic 
separations were carried out using an Xterra C-18 analytical column (particle 
size 5 µm, 150 mm long,/4.6 mm i.d.; Waters). The mobile phase consisted of 
50 mM sodium phosphate buffer (pH 2.0), acetonitrile and 1-propanol 
(65:25:2, v/v/v). The flow rate was kept constant at 1.0 ml/minute. 
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2.6.1.2 Standard Stock Solutions, Calibration and Quality Control (QC) 
Samples 
 
Stock solutions of doxorubicin, doxorubicinol, doxorubicinone, and 
doxorubicinolone were prepared by dissolving weighed amounts of the 
respective reference materials in methanol to obtain concentrations of 40 000, 
20 000, 20 000, and 20 000 ng/ml, respectively. A working solution containing 
doxorubicin and its three metabolites was prepared by mixing the stock 
solutions to obtain final concentrations of 10 000 ng/ml for doxorubicin and 
5000 ng/ml for each metabolite. The working solution was then successively 
diluted with methanol. A stock solution of daunorubicin (4000 ng/ml) was 
prepared in Milli-Q water and used as the internal standard (I.S.). All the stock 
solutions, working solutions and QC samples were protected from light and 
stored at –20oC. 
 
2.6.2 HPLC Determination of Doxorubicin and Doxorubicinol 
 
2.6.2.1 Sample Preparation and Analysis 
 
At the time of analysis, 30 μl of sodium acetate buffer (1M, pH 5.3) and 270 μl 
of 2.0 M sodium sulfate solution was added to 200 μl of plasma samples 
spiked with calibration standards and the internal standard (I.S) working 
solution. The mixture was vortexed briefly for 10 seconds, then 1 ml of 
chloroform:n-propanol (4:1, v/v) was added and the tubes were shaken using 
Eppendorf mixer for 10 minutes. Samples were then centrifuged at 3,000 rpm 
for 10 minutes to separate the layer. The supernatant (i.e. the organic layer) 
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was transferred into a clean 1.5 ml microtube, in which one anti-bumping 
granule was added and then dried under a stream of nitrogen (or air). The 
extraction was repeated once by adding 1 ml of chloroform:n-propanol (4:1, 
v/v) to the aqueous layer followed by the same procedure described above. 
The residue was reconstituted with 100 μl of methanol, and an aliquot (50 μl) 
was injected by autosampler into the HPLC system. The mobile phase 
consisted of 50 mM sodium phosphate buffer (pH 2.0), acetonitrile and 1-
propanol (65:25:2, v/v/v). The flow rate was kept constant at 1.0 ml/min. The 
excitation wavelength was set at 480 nm and emission at 560 nm, and the 
gain was set at × 100. The lower limits of quantitation were 10 ng/ml for 
doxorubicin, and 5 ng/ml for doxorubicinol. The calibration curves were linear 
over a concentration range of 10-2500 ng/ml for doxorubicin, and 5-1250 
ng/ml for doxorubicinol.  The average recoveries were greater than 89% for 
all analytes and the within-day and between-day coefficients of variation was 
less than 13%.   
 
2.6.2.2 Estimation of Pharmacokinetic Parameters 
 
Pharmacokinetic analysis consisted of a noncompartmental assessment of 
the plasma concentrations of doxorubicin and doxorubicinol. All 
pharmacokinetic parameters are described in Table 2.14.  
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     AUC0-∞ 
 
Area under plasma concentration time curve, from 0 to 
infinity  
     AUC0-24 
 
Area under plasma concentration time curve, from 0 to 
24 hours 
     ß  Terminal rate constant 
     λz  Elimination rate constant 
     Cmax  Maximum observed plasma concentration 
     CL  Plasma clearance  
     MRT  Mean residence time 
     tmax  Time to reach maximum concentration 
     t1/2  Terminal half life of the drug 
     Vd  Volume of distribution 
 
Cmax and tmax were determined directly from the data and AUC0-24 and AUC0-∞ 





CAUCAUC += −∞ 0-0  
 
where Ct refers to the last quantifiable doxorubicin concentration. ß was 
estimated from a regression of ln(C) vs time over the terminal log-linear drug 
disposition portion of the concentration-time profiles. The terminal half life was 
calculated according to the equation below:  
     β
)2ln(
2/1 =t  
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The main pharmacokinetic parameters analyzed in the present study were 
Cmax, AUC0-∞, and t1/2. Pharmacokinetic parameters were determined using a 
nonlinear regression program WinNonLin version 2.1 (Pharsight Inc, 
Mountain View, CA, USA).  The area under the plasma concentration-time 
curve (AUC) was calculated from time zero to the time (t) of the last 
detectable concentration (AUC0→t) using the trapezoidal rule. The area was 
extrapolated to infinity (AUC0-∞) by adding Ct/λz to AUC0→t, where Ct was the 
last detectable plasma concentration and λz is the elimination rate constant. 
Peak plasma concentrations (Cmax) were directly identified from individual 
subject concentration-time curves. 
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2.7 STATISTICAL ANALYSIS 
 
2.7.1 Pharmacogenetic Analysis  
 
Fisher’s exact test was used to determine conformity with Hardy-Weinberg 
equilibrium and Pearson’s Chi-squared (χ2) test was used to analyze 
interethnic variability in genotype and allele distributions in different groups in 
healthy subjects and cancer patients. Linkage disequlibrium analysis of 
polymorphisms in individual genes and pairwise linkage disequilibrium 
between polymorphisms were quantified by |D’| and rho square (r2) values 
(Haploview software, version 4.0, Daly lab, Broad Institute, Cambridge, USA).  
Estimation of haplotypes was performed by the maximum likelihood 
estimation based on the expectation-maximization (EM) algorithm (Haploview 
software, version 4.0, Daly lab, Broad Institute, Cambridge, USA). Diplotypes 
were generated from the haplotype information using Helixtree software 
(HelixTree® Genetics Analysis Software Golden Helix, Inc.). The likelihood 
ratio test was used to determine the significance of associations between 
polymorphisms in each gene.  The minimum level of statistical significance 
was set at P = 0.05 for all pairwise comparisons unless otherwise stated. All 
statistical analysis was carried out using Stata (STATA Statistical Software 
release 7.0, Stata Corporation, TX, USA). 
 
2.7.2 Analysis of Hepatic Expression 
 
Relative quantification of gene expression levels for candidate genes provides 
accurate comparisons between the intial levels of template, and is determined 
by raising 2 to the power of the negative value of delta-delta Ct for each 
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sample, expressed as the relative-quantitation (RQ) value.  Association of 
candidate gene polymorphisms with their hepatic expression RQ values were 
analyzed by the Mann-Whitney U-test and Kruskal-Wallis test. Non-
parametric tests were used for analysis since the data was found to be non-
normally distributed.  Associations were assessed by Spearman rank 
correlation and expressed by the corresponding correlation coefficient. The 
minimum level of statistical significance was set at P = 0.05 for all pairwise 
comparisons. All analysis was carried out using Prism version.4.0 (GraphPad 
Software Inc., San Diego, California, USA).  
 
2.7.3 Pharmacokinetic-Pharmacogenetic Correlations 
 
Pharmacokinetic parameters of doxorubicin and doxorubicinol are reported as 
median values. The nonparametric Mann-Whitney U test was used for 
pairwise comparisons of pharmacokinetic parameters between genotype 
groups. The minimum level of statistical significance was set at P = 0.05 for 
all pairwise comparisons. The possible contribution of covariates such as 
ethnicity, age, height and body surface area (BSA) on pharmacokinetics of 
doxorubicin and doxorubicinol were determined using univariate analysis. 
Other independent variables investigated to evaluate their relative 
contribution to the variability in pharmacokinetic parameters of doxorubicin 
and doxorubicinol included patient biochemical parameters such as albumin, 
total protein and markers of hepatic [aspartate amino transferase (AST), 
alanine amino transferase (ALT), alkaline phosphatase and bilirubin] and 
renal function (serum creatinine). All statistical analysis was carried out using 
Stata (STATA Statistical Software release 7.0, Stata Corporation, TX, USA).   
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CHAPTER 3: RESULTS AND DISCUSSION 
 
3.1 DEMOGRAPHICS OF ASIAN BREAST CANCER PATIENTS 
 
The demographics of Asian breast cancer patients are summarized in Table 
3.1 Majority of the breast cancer patients belonged to the Chinese ethnic 
group (74%), followed by Malays (18%) and Indians (8%). The median age, 
height and body surface area (BSA) of the patients were 51 years (range: 29-
73 years), 154 cm (range: 144-168 cm) and 1.52 m2 (range: 1.23-1.95 m2), 
respectively.   
 
 





Patient characteristics Median (range)        N (%) 
Total number of patients          62 (100)
   Age (yrs)          51 (29-73)  
   Height (cm)        154 (144-168)  
   Weight (kg)          53.2(35.7-87.4)  
   BSA (m2)            1.5 (1.2-1.9)  
 Estrogen receptor (ER) status    
   Positive      41 (68.3)
   Negative      19 (31.7) 
 Progesterone receptor (PR) status    
   Positive      29 (48.3) 
   Negative     31 (51.7) 
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3.2 PHARMACOKINETICS OF DOXORUBICIN  
 
Table 3.2 summarizes the pharmacokinetic parameters of doxorubicin and 
doxorubicinol in Asian breast cancer patients. Plasma samples for 
pharmacokinetic analysis were available in 52 of the 62 patients.  
 
Table 3.2 Summary of doxorubicin and doxorubicinol pharmacokinetic 
























          
          *CV: Coefficient of variation 
 
Pharmacokinetic parameters  Median (range) CV* (%) 
Doxorubicin    
   Cmax/dose/BSA (m-5)  34.1 (4.5 – 97.7) 57.9 
   AUC0-∞/dose/BSA (hm-5)  17.5 (6.2 – 67.2) 49.9 
   t1/2 (h)  15.4 (4.7 – 24.6) 20.5 
   CL/BSA (Lh-1m-2)  22.9 (8.7 - 55.7) 34.1 
   Vss/BSA (Lm-2)  237.5 (53.9 – 703.7) 47.5 
Doxorubicinol    
   Cmax/dose/BSA (10-2m-5)  0.33 (0.15 – 2.0) 76.0 
   AUC0-∞/dose/BSA (hm-5)  9.6  (3.7 – 24.3) 41.9 
   t1/2 (h)  27.5  (6.3– 112.4) 52.7 
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Figure 3.1 shows the averaged individual concentration-time profile of 











Fig 3.1 Plasma concentration-time profile of doxorubicin in Asian breast 
cancer patients (N=52). Each concentration-time point represents the mean ± 
SD.  
 
The median AUC0-∞ of doxorubicin in Asian breast cancer patients normalized 
by dose and body surface area (BSA) was 17.5 hm-5 (1575 µghrL-1) and is 
comparable to earlier reports that investigated doxorubicin 
disposition.(104,111,312,313) In a multicentric study where patients received 
doxorubicin (60 mgm-2, 110.4 µmolm-2) intravenously over 15 minutes 
followed by a 15-minute infusion of cyclophosphamide (600 mgm-2), the 
AUC0-∞ of doxorubicin was observed to range between 3.9-4.7 µmolhrL-1.(313) 
Similar to earlier reports by Speth et al(124) and Ackland et al(126) that showed 
almost 10-fold inter-patient variation in doxorubicin exposure levels in patients 
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receiving chemotherapy, doxorubicin AUC0-∞ in the present study also 
showed a high degree of inter-individual variability (range 6.2-67.2 hm-5).  
 
The median clearance of doxorubicin in Asian breast cancer patients was 
estimated as 22.9 Lhr-1m-2. Approximately 6-fold [range: 8.7-55.7 Lhr-1m-2, CV 
34%)] variation in doxorubicin clearance was observed among the cancer 
patients. Considering a median BSA of 1.52 m2, the doxorubicin clearance of 
22.9 Lh-1m-2 observed in the present study is 30-40% lower compared to 
earlier reports in different cancer patients where doxorubicin clearance 
ranged between 54.0-63.6 Lh-1.(104,111,314) Rudek et al(314) evaluated the 
pharmacokinetics of doxorubicin in cancer patients receiving different 
chemotherapeutic regimens that included doxorubicin administration as a 
bolus (5 minutes), a short infusion (15-20 minutes), or as a 1-3 hour infusion 
at doses ranging from 40-75 mgm-2 and reported the mean plasma 
doxorubicin clearance to be 63.7 ± 22.6 Lhr-1(CV: 35.5%) in their patients.  In 
a report on HIV patients with advanced Kaposi’s sarcoma receiving 
doxorubicin (20 mgm-2), bleomycin (15 Um-2) and vincristine (2 mg as 30 
minutes intravenous infusion), doxorubicin clearance was estimated to be 
61.8 Lhr-1 by non-compartmental analysis.(104) Freyer et al(315) studied 24 
patients diagnosed with small cell lung carcinoma who received doxorubicin 
at a dose of 50 mgm-2 and doxorubicin clearance was observed to be 54 Lhr-1 
among the patients whose median weight was 69 kg (range 54-93 kg).  
Callies et al(111) studied doxorubicin pharmacokinetics in cancer patients 
receiving doxorubicin as 30 minutes continuous infusion along with the P-gp 
modulator zosuquidar.3HCl as a 48 hr continuous intravenous infusion. The 
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patients enrolled in the study had a median weight of 82.7 kg (range 43.1 -
137.0 kg) and had a median age of 57 years (range 27-73 years). 
Doxorubicin clearance was reported to be 62.3 Lh-1 in the absence or low 
doses of zosuquidar.3HCl whereas reduced by 25% in the presence of high 
doses (> 500 mg) of zosuquidar.3HCl suggesting that compounds that alter 
the efflux of doxorubicin from the liver or biliary system can significantly alter 
its disposition.  
 
Several factors may have contributed to the reduced doxorubicin clearance in 
the Asian breast cancer patients. Firstly, higher dose of doxorubicin (greater 
than 50 mgm-2) has been linked to decreased clearance of doxorubicin, 
possibly due to non-linear disposition at higher dose levels.(316,317) Secondly, 
the presence of concomitant medications might have influenced the 
disposition of doxorubicin. In the study by Rudek et al(314) doxorubicin 
clearance was reduced up to 30% in the subset of patients who received 
doxorubicin along with cyclophosphamide. Similar findings of extended 
elimination phase of doxorubicin have also been observed when doxorubicin 
is administered along with cyclophosphamide in children(318) and has been 
attributed to the reduced formation of the doxorubicin 7-deoxyaglycone 
metabolite, thereby decreasing the elimination of the parent drug.(319) The 
adjuvant chemotherapy regimen in the present study also consisted of 
cyclophosphamide and may have resulted in similar potential interactions, 
leading to reduced doxorubicin clearance observed in the breast cancer 
patients. Thirdly, the clearance of doxorubicin is reported to be significantly 
reduced in breast cancer patients when compared to patients with other 
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malignancies.(320) In the study by Dobbs et al,(320) doxorubicin clearance was 
significantly lower in patients with breast cancer than in those with other 
tumors (median values: 26 and 53 Lh-1m-2, respectively; P = 0.0008). 
However, the same study observed a higher clearance of doxorubicin among 
men compared to women and it is highly likely that the observed influence of 
tumor types on doxorubicin clearance was confounded by the significantly 
higher proportion of non-breast tumor types among males.  
 
Intravenous infusion of doxorubicin is followed by a triphasic plasma 
clearance characterized by two successive half lives (t½α: 3-5 minutes, t½β: 1-
2 hours), followed by a terminal half life t½γ of 24-36 hours).(113)  A fourth half 
life (t½δ of 110 hours), representing up to 30% of the total area under the 
plasma concentration-time curve (AUC0-∞) has also been reported.(110) The 
terminal half life of doxorubicin in the present study was observed to be 15.4 
hour (range 4.7–24.6 hours). The apparent shorter doxorubicin half-life 
observed in the present study could be due to the limited sampling study 
design that limited the estimation of pharmacokinetic parameters beyond 24 
hours. Approximately 13-fold (median: 237.5; range: 53.9-703.7 Lm-2) 
variation in the steady state volume of distribution (Vss) of doxorubicin was 
observed among the cancer patients. Such large inter-individual variations in 
volume of distribution of doxorubicin are probably related to the variations in 
its initial distribution, dependent on factors such as body weight and age 
where individual patients have different capacity for drug uptake. This could 
be particularly relevant for drugs such as doxorubicin that strongly bind to 
tissues, often in proportion to their DNA content.(321)  
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3.3 PHARMACOKINETICS OF DOXORUBICINOL  
 
Doxorubicinol is the primary metabolite found in the plasma of patients 
treated with doxorubicin. The pharmacokinetic parameters of doxorubicinol in 
Asian breast cancer patients are shown in Table 3.2. Interpatient variability 
was high with regards to doxorubicinol pharmacokinetic parameters with more 
than 6-fold variation observed in the exposure level of doxorubicinol [AUC0-∞ 
(median: 9.6; range: 3.7-24.3 hm-5)]. In a study by Joerger et al,(104) the mean 
AUC of doxorubicinol was observed to be 298 µghL-1 when doxorubicin was 
administered at a dose 20 mgm-2. The same study reported the terminal 
mean t1/2 of doxorubicinol to be 27.8 hours with mean Cmax of 8.43 µgL-1. This 
was similar to the doxorubicinol half-life of 27.5 hours observed in the present 
study. The representative median individual concentration-time profile of 
doxorubicinol among Asian breast cancer patients is shown in Figure 3.2. 
Consistent with earlier reports, the present study also showed that the 
increase in plasma concentration of doxorubicinol was followed by a slow 
decline in the terminal phase, parallel to the decline of doxorubicin 
concentration (Figure 3.1). It has been suggested that doxorubicinol also 
undergoes entero-hepatic circulation which occurs 4-8 hours after 
administration of doxorubicin infusion.(114,322) However, this phenomenon was 














Fig 3.2 Plasma concentration-time profile of doxorubicinol in Asian breast 
cancer patients (N=52). Each concentration point represents the mean ± SD. 
 
With regards to doxorubicin metabolism, the ratio of metabolite to the parent 
compound is indicative of the extent of metabolic conversion following 
doxorubicin administration. The ratio of exposure levels of doxorubicinol to 
doxorubicin has been reported to be in the range of 0.28 to 0.5 (at doses 
ranging from 20 to 60 mgm-2, respectively) in earlier studies.(114,323, 
324,325,326,327) However, during instances of prolonged infusion of doxorubicin, 
the concentration of doxorubicinol might exceed that of doxorubicin, and the 




The  doxorubicinol:doxorubicin ratio among the Asian breast cancer patients 
was observed to be 0.84 indicating reduced metabolic clearance of 
doxorubicin. Several factors may have accounted for this observation 
including 1) age of the patients which was found to be an important covariate 
affecting the half-life of doxorubicin, particularly among patients above 60 
years of age (as discussed below);  2) presence of liver metastasis that may 
have influenced the biotransformation rate of doxorubicin; and 3) prior 
chemotherapy that may have resulted in a reduction in efficiency of hepatic 
detoxification mechanisms and caused reduced metabolic conversion of 
doxorubicin to doxorubicinol.  Earlier studies on doxorubicin pharmacokinetics 
in patients with abnormal liver biochemistry tests have shown reduced 
doxorubicin clearance in patients with a raised bilirubin level, although no 
clear relationship between the extent of this elevation and the reduction in 
doxorubicin clearance were established.(328)  
 
The present study did not find any significant influence of body surface area 
(BSA) on doxorubicin pharmacokinetic parameters. Positive association of the 
body surface area (BSA) and doxorubicin clearance has been shown in 
earlier reports, with doxorubicin clearance approximately 20% higher in 
patients with BSA > 1.97m2 and BMI ≥ 30 kgm-2.(314) Several other factors 
(genetic and non-genetic) might contribute to the variability in 
pharmacokinetic parameters of doxorubicin. Factors such as age, ethnicity, 
height and weight were evaluated in the present study among the Asian 
breast cancer patients to identify their significant influences if any, on 
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doxorubicin pharmacokinetics. Univariate analysis revealed patient’s height 
and weight to be significant covariates influencing the AUC0-∞ (P < 0.015 and 
P < 0.0001, respectively) and Cmax of doxorubicin (P < 0.028 and P < 0.0001), 
respectively.   
 
Age and ethnicity were identified as significant covariates in relation to the t1/2 
(h) of doxorubicin (P < 0.018) in the present study. The relationship between 
half life of doxorubicin and age was analyzed following stratification according 
to their age (below and above 60 years). The t1/2 (h) of doxorubicin was 
significantly higher in patients above 60 years of age (median: 15.73; range 
4.7-24.6) compared with patients below 60 years of age (median 12.54; 
range: 8.1-17.8, P < 0.02). The increased half life of doxorubicin in the elderly 
could be the consequence of reduction in renal or metabolic clearance. Renal 
function, hepatic blood flow and drug metabolism have been shown to be 
reduced in the elderly.(329) However covariate analysis indicated that liver 
function tests in breast cancer patients were not associated with doxorubicin 
pharmacokinetic parameters. No significant influences of other covariates 
were observed on pharmacokinetics of doxorubicin and doxorubicinol.  
 
In a study by Rudek et al,(314) gender was reported to influence doxorubicin 
pharmacokinetics with approximately 13% reduced doxorubicin clearance 
observed in females compared to males. However the gender effect was 
absent when the clearance was normalized to BSA which suggested that 
BSA was a more critical covariate influencing doxorubicin clearance. Dobbs 
et al(320) also reported that men had a significantly higher doxorubicin 
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clearance (N = 6; 59 Lh-1m-2) than women (N = 21; 27 Lh-1m-2). The present 
study in breast cancer patients was not designed to validate the influence of 
gender on the pharmacokinetics of doxorubicin. Since the liver is largely 
involved with both the metabolic biotransformation and excretion of 
doxorubicin, the pharmacokinetics of doxorubicin has been investigated in 
states of hepatic dysfunction. Studies by Frenay et al(330) Piscitelli SC et al(125) 
and Benjamin RS et al(331) in patients with compensated liver function 
validated the hypothesis that liver abnormalities as evidenced by raised 
aspartate amino transferase (AST) or serum bilirubin levels lead to reduced 
clearance of doxorubicin. The elimination of doxorubicinol has also been 
shown to be impaired in hepatoma patients(332) and has been confirmed in 
subsequent studies on patients with liver dysfunction.(125,330,333)  
 
In summary, the pharmacokinetics of doxorubicin and doxorubicinol observed 
in Asian breast cancer patients in the present study are in confirmation with 
the findings previously described by the pharmacological analysis of 
doxorubicin in different study groups. High degree of variability in 
pharmacokinetic parameters of both doxorubicin and its major metabolite 
doxorubicinol was observed. Apart from genetic variables, factors such as the 
age and weight of the patients, use of co-medications such as 
cyclophosphamide, influence of gender and tumor types were some of the 
variables identified as being important in influencing the the pharmacokinetics 
of doxorubicin.  
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3.4 PHARMACOKINETIC-PHARMACOGENETIC CORRELATES OF 
NUCLEAR RECEPTORS 
 
 3.4.1 Pregnane X Receptor (PXR) 
 
3.4.1.1 PXR Pharmacogenetics  
 
The PXR genotype and allele frequencies in the healthy Chinese, Malay and 
Indian populations and the Asian breast cancer patients are summarized in 
Table 3.3. A total of sixteen single nucleotide polymorphisms were identified 
from a complete screening of all nine exons and exon-intron boundaries that 
spanned approximately 40 kb of the PXR gene. There were three 
polymorphisms in the proximal 5’-region (-1570C>T, -566A>C, -298G>A), four 
coding region polymorphisms (c.1437G>A, c.1448G>A, c.1792A>G, 
c.1944T>C), six intronic variants (IVS2+55A>G, IVS2+78A>G, IVS3+72T>G, 
IVS4+285G>A, IVS5-93A>G, IVS6-17C>T), and three polymorphisms 
(+2180A>G, +2617A>C, +2654T>C) in the 3’-UTR region. Fisher’s exact tests 
validated that all the PXR genotype frequencies conformed to Hardy-Weinberg 
equilibrium. The sample homogeneity was confirmed by Ewens-Watterson test 
and Tajima’s test (Chinese, Malays and Indians; P > 0.05). 
 
Significant interethnic differences were observed in the genotype frequencies of 
the 5’-UTR polymorphisms in the three healthy Asian populations (-1570C>T, P 
= 0.004; -566A>C, P = 0.002 and -298G>A, P = 0.022). The allele frequency of 
the -1570C>T polymorphism was significantly higher among Indians (0.33) as 
compared to Chinese (0.17, P = 0.001) and Malays (0.21, P = 0.028). The 
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frequencies of the -566A>C and -298G>A polymorphisms were also significantly 
higher among Indians than Chinese (0.34 vs 0.16, P < 0.001 and 0.31 vs 0.18, 
P = 0.004, respectively). 
 
The coding region polymorphisms were confined to exon 9 in all three Asian 
ethnic groups. The c.1437G>A polymorphism was monomorphic in all the Asian 
ethnic groups whereas the c.1448G>A polymorphism was monomorphic in the 
Chinese population. Significant interethnic differences (P < 0.001) were 
observed in the population distribution of c.1792A>G and c.1944T>C 
polymorphisms, which were significantly higher in Indians compared with 
Chinese (0.59 vs 0.43; P = 0.006) and Malays (0.59 vs 0.33; P < 0.001).  
 
The intronic variants were highly polymorphic in all three Asian ethnic groups. 
Significant interethnic variability was observed for the IVS5-93A>G and IVS6-
17C>T polymorphisms among Asian healthy population (P < 0.002). The 
frequency of IVS5-93A>G polymorphism was significantly higher in Indians 
(0.53) than Chinese (0.41, P = 0.038) and Malays (0.33, P < 0.001). The allele 
frequency of IVS6-17C>T was significantly lower in Indians than Chinese and 
Malays (Indian vs Chinese; 0.24 vs 0.45, P < 0.001; Indian vs Malay; 0.24 vs 





Table 3.3. Genotype and allele frequencies of PXR gene polymorphisms in 
Asian healthy subjects and breast cancer patients. 
 
     
  
Populations Location N Genotype frequencies, N (%)  Allele frequencies
-1570C>T 5’-UTR  CC CT TT  C T 
Healthy subjects 
 
       
 Chinese  100 68(68) 30(30) 2(2)  0.83 0.17 
 Malays  100 63(63) 32(32) 5(5)  0.79 0.21 
 Indians  100 45(45) 44(44) 11(11)  0.67 0.33 
Asian cancer patients    62 36(58.06) 23(37.10) 3(4.83)  0.77 0.23 
-566A>C 5’-UTR  AA AC CC  A C 
Healthy Subjects         
 Chinese  100 71(71) 25(25) 4(4)  0.84 0.16 
 Malays  100 57(57) 35(35) 8(8)  0.75 0.24 
 Indians  100 42(42) 47(47) 11(11)  0.66 0.34 
Asian cancer patients    62 36(58.06) 24(38.71) 2(3.23)  0.77 0.23 
-298G>A Intron 1  GG GA AA  G A 
Healthy Subjects         
 Chinese  100 69(69) 27(27) 4(4)  0.82 0.18 
 Malays  100 61(61) 33(33) 6(6)  0.78 0.22 
 Indians  100 46(46) 45(45) 9(9)  0.69 0.31 
Asian cancer patients    62 37(59.68) 23(37.10) 2(3.23)  0.78 0.22 
IVS2+55A>G Intron 2  AA AG GG  A G 
Healthy subjects    
 Chinese  100 34(34) 50(50) 16(16)  0.59 0.41 
 Malays  100 26(26) 50(50) 24(24)  0.51 0.49 
 Indians  100 42(42) 40(40) 18(18)  0.62 0.38 
Asian cancer patients    62 21(33.87) 27(43.55) 14(22.58)  0.56 0.44 
IVS2+78A>G Intron 2  AA AG GG  A G 
Healthy subjects         
 Chinese  100 34(34) 52(52) 14(14)  0.60 0.40 
 Malays  100 30(30) 47(47) 23(23)  0.54 0.46 
 Indians  100 42(42) 41(41) 17(17)  0.63 0.37 
Asian cancer patients    62 21(33.87) 28(45.16) 13(20.97)  0.56  0.44 
IVS3+72T>G Intron 3  TT TG GG  T G 
Healthy subjects         
 Chinese  100 82(82) 18(18) 0(0)  0.91 0.09 
 Malays  100 77(77) 21(21) 2(2)  0.88 0.12 
 Indians  100 80(80) 18(18) 2(2)  0.89 0.11 
Asian cancer patients    62 50(80.65) 10(16.13) 2(3.23)  0.89 0.11 
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               Table 3.3 Genotype and allele frequencies of PXR gene polymorphisms in   
               Asian healthy subjects and breast cancer patients. (Contd) 
 
 
         
 
Populations Location N Genotype frequencies, N (%)  Allele frequencies
IVS4+285G>A Intron 4  GG GA AA  G A 
Healthy subjects 
 
       
 Chinese  100 10(10) 51(51) 39(39)  0.36 0.64 
 Malays  100 21(21) 50(50) 29(29)  0.46 0.54 
 Indians  100 19(19) 41(41) 40(40)  0.40 0.60 
Asian cancer patients    62 11(17.74) 30(48.39) 21(33.87)  0.42 0.58 
IVS5-93A>G Intron 5  AA AG GG  A G 
Healthy Subjects         
 Chinese  100 35(35) 48(48) 17(17)  0.59 0.41 
 Malays  100 44(44) 45(45) 11(11)  0.67 0.33 
 Indians  100 25(25) 43(43) 32(32)  0.47 0.53 
Asian cancer patients    62 13(20.97) 25(40.32) 24(38.71)  0.41 0.59 
IVS6-17C>T Intron 6  CC CT TT  C T 
Healthy Subjects         
 Chinese  100 31(31) 47(47) 22(22)  0.55 0.45 
 Malays  100 33(33) 47(47) 20(20)  0.57 0.43 
 Indians  100 58(58) 35(35) 7(7)  0.76 0.24 
Asian cancer patients    62 20(32.26) 29(46.77) 13(20.97)  0.56 0.44 
c.1437G>A Exon 9  GG GA AA  G A 
Healthy subjects         
 Chinese  100 99(99) 1(1) 0(0)  0.99 0.01 
 Malays  100 98(98) 2(2) 0(0)  0.99 0.01 
 Indians  100 98(98) 2(2) 0(0)  0.99 0.01 
Asian cancer patients    62 62(100) 0 0  1.00 0 
c.1448G>A Exon 9  GG GA AA  G A 
Healthy subjects         
 Chinese  100 97(97) 3(3) 0(0)  0.98 0.02 
 Malays  100 100(100) 0(0) 0(0)  1.00 0 
 Indians  100 100(100) 0(0) 0(0)  1.00 0 
Asian cancer patients    62 60(96.77) 2(3.23) 0  0.98 0.02 
c.1792A>G Exon 9  AA AG GG  A G 
Healthy subjects         
 Chinese  100 34(34) 46(46) 20(20)  0.57 0.43 
 Malays  100 46(46) 40(40) 14(14)  0.66 0.34 
 Indians  100 21(21) 39(39) 40(40)  0.41 0.59 
Asian cancer patients   62 11(17.74) 28(45.16) 23(37.10)  0.40 0.60 
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           Table 3.3 Genotype and allele frequencies of PXR gene polymorphisms in  
           Asian healthy subjects and breast cancer patients. (Contd) 
 
    
   N; number of subjects  
 
With regards to polymorphisms in the 3’-UTR region, the allelic frequencies 
differed significantly among the healthy Asian ethnic groups (P < 0.001). The 
frequency of +2180A>G polymorphism was significantly lower in the Chinese 
compared to the Malays and Indians (Chinese vs Malay; 0.08 vs 0.21, P = 
0.003; Chinese vs Indian; 0.08 vs 0.16, P = 0.037). The frequencies of the 
Populations Location N Genotype frequencies, N (%)  Allele frequencies
c.1944T>C Exon 9  TT TC CC  T C 
Healthy subjects 
 
       
 Chinese  100 34(34) 46(46) 20(20)  0.57 0.43 
 Malays  100 47(47) 39(39) 14(14)  0.67 0.33 
 Indians  100 21(21) 39(39) 40(40)  0.41 0.59 
Asian cancer patients    62 11(17.74) 28(45.16) 23(37.10)  0.40 0.60 
+2180A>G 3’-UTR  AA AG GG  A G 
Healthy Subjects         
 Chinese  100 83(83) 17(17) 0(0)  0.92 0.08 
 Malays  100 65(65) 28(28) 7(7)  0.79 0.21 
 Indians  100 68(68) 31(31) 1(1)  0.84 0.16 
Asian cancer patients    62 50(80.65) 12(19.35) 0  0.90 0.10 
+2617A>C 3’-UTR  AA AC CC  A C 
Healthy subjects         
 Chinese  100 29(29) 51(51) 20(20)  0.55 0.46 
 Malays  100 37(37) 42(42) 21(21)  0.58 0.42 
 Indians  100 59(59) 34(34) 7(7)  0.76 0.24 
Asian cancer patients    62 18(29.03) 27(43.54) 14(22.58)  0.53 0.47 
+2654T>C 3’-UTR  TT TC CC  T C 
Healthy subjects         
 Chinese  100 29(29) 51(51) 20(20)  0.55 0.46 
 Malays  100 37(37) 42(42) 21(21)  0.58 0.42 
 Indians  100 59(59) 34(34) 7(7)  0.76 0.24 
Asian cancer patients    62 18(29.03) 27(43.54) 14(22.58)  0.53 0.47 
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+2617A>C and +2654T>C polymorphisms were approximately two-fold lower in 
Indians as compared to Chinese and Malays (Indian vs Chinese; 0.24 vs 0.46, 
P < 0.001; Indian vs Malay; 0.24 vs 0.42, P = 0.002). 
 
The genotype and allele frequencies of PXR polymorphisms among the healthy 
Chinese liver tissues and breast cancer patients conformed to the frequencies 
found among the healthy study subjects.  
 
3.4.1.1.1 Linkage Disequilibrium and LD Blocks  
 
Pairwise LD analysis for the identified PXR polymorphisms in all three ethnic 
groups showed strong linkage between the following polymorphisms: -1570C>T 
with -566A>C and -298G>A (|D’| > 0.82); the c.1792A>G with c.1944T>C (ID’I = 
1); the intronic polymorphisms IVS2+55A>G with IVS2+78A>G, IVS3+72T>G 
and IVS4+285G>A, (|D’| > 0.82), and IVS6-17C>T with IVS5-93A>G (|D’| > 
0.85). The 3’-UTR polymorphism +2617A>C was in complete linkage with 
+2654T>C polymorphism, (|D’| = 1) across all three ethnic groups. 
 
The pairwise LD matrix showed four LD blocks within the PXR gene in Chinese 
and Malays and three LD blocks in the Indian population (Figures 3.3 – 3.5). 
The LD blocks were highly similar in the Chinese and Malay populations. In both 
populations, block 1 was represented by two highly linked 5’-UTR 
polymorphisms, -566A>C and -298G>A (|D’| = 0.92), block 2 by the 
IVS2+55A>G and IVS2+78A>G intronic polymorphisms (|D’| = 1.00) and block 4 
by the 3’-UTR +2617A>C and +2654T>C polymorphisms. Block 3 was also 
similar in the Chinese and Malay populations and differed only by the presence 
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of the IVS5-93A>G polymorphism in the Chinese (Figure 3.3) and the 
+2180A>G polymorphism in the Malays (Figure 3.4). The linkage disequilibrium 
between blocks 1, 2 and 3 in the Chinese were relatively weak (block 1 vs block 
2, |D’| = 0.13; block 2 vs block 3, |D’| = 0.32) but blocks 3 and 4 were strongly 
linked (|D’| = 0.77). Similar linkage disequilibrium patterns were observed in the 
Malay population (block 1 vs block 2, |D’| = 0.25; block 2 vs block 3, |D’| = 0.40). 
Strong linkage disequilibrium between blocks 3 and 4 was also observed in the 
Malay population (|D’| = 0.74). 
 
Among Indians, block 1 was represented by the three intronic IVS2+55A>G, 
IVS2+78A>G and IVS3+72T>G polymorphisms whereas block 2 represented a 
combination of IVS5-93A>G, IVS6-17C>T, c.1437G>A, c.1448G>A, 
c.1792A>G, c.1944T>C and +2180A>G polymorphisms (Fig 3.6). The genetic 
constitution of block 3 in Indians was identical to those observed in the Chinese 
and Malay populations and comprised of the 3’-UTR +2617A>C and +2654T>C 
polymorphisms. The inter-block linkage was stronger in the Indian population 
































            Fig 3.3  Pairwise linkage disequilibrium of PXR polymorphisms and LD blocks in Chinese population. 































Fig 3.4 Pairwise linkage disequilibrium of PXR polymorphisms and LD blocks in Malay population. 

































Fig 3.5 Pairwise linkage disequilibrium of PXR polymorphisms and LD blocks in Indian population. 
 (LD values are denoted as |D’|*100) 
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3.4.1.2 PXR Haplotypes and Network Analysis 
 
The inferred haplotypes across all ethnic groups are shown in Table 3.4. A 
total of 15 haplotypes were determined in the Chinese population and four 
high frequency haplotypes (H1-C, H2-C, H3-C and H4-C) accounted for a 
cumulative frequency of 62.2%. Among the 20 haplotypes inferred in Malay 
population, seven were identified as high frequency haplotypes (H1-M, H2-M, 
H3-M, H4-M, H5-M, H6-M and H7-M) and had a cumulative frequency of 
63.2%. There were 19 haplotypes identified in Indian population and four high 
frequency haplotypes (H1-I, H2-I, H3-I and H4-I) constituted 52.7% of the 
total haplotype frequencies.  
 
The relationships between haplotypes were further analyzed by calculating 
the haplotype network using the median-joining (MJ) algorithm.(334) The 
derived genealogic tree showing the relationship among the common 
haplotypes indicated the emergence of three distinct, highly divergent 
haplotype clusters in each Asian ethnic group that were designated as 
PXR*1A, PXR*1B and PXR*1C (Figure 3.6). The PXR*1A, PXR*1B and 
PXR*1C haplotype clusters were each distinguished by a similar set of two 
tagged polymorphisms in the three Asian ethnic groups (Figures 3.6A-C). The 
c.1792A>G and c.1944T>C polymorphisms were representative of PXR*1A 
haplotype cluster whereas PXR*1B was delineated by IVS6-17C>T and 
+2654T>C polymorphisms. The PXR*1C haplotype was tagged by the 
IVS2+55A>G and IVS2+78A>G polymorphisms. PXR*1A cluster haplotypes 
were most common in the Indian population (52.4%) compared to Chinese 
and Malay ethnic group (37.2% and 29.4%, respectively). The proportion of 
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PXR*1B haplotype cluster was relatively common in the Malay (35%) and 
Chinese (28.7%) populations compared with the Indian ethnic group (19.4%). 
The frequency of PXR*1C haplotype cluster was similar in all three Asian 
ethnic groups (Chinese, 26.6%; Malays, 20.3%; Indians, 22.5%). The 
individual haplotypes having frequency of less than 1% were grouped as 
















































H1-C 0.275 C A G A A T A A C G G G C A A T 
H5-C 0.049 C A G G G T A A C G G G C A A T 
H7-C 0.030 C A G G G T G A C G G G C A A T 
H11-C 0.018 T C A A A T A A C G G G C A A T 
*1B 
H2-C 0.195 C A G A A T A G T G G A T A C C 
H9-C 0.020 C A A A A T A G T G G A T A C C 
H14-C 0.011 T C G A A T A G T G G A T A A C 
H15-C 0.010 C A A A A T G G T G G A T A A C 
*1C 
H3-C 0.100 C A G G G T G G T G G A T A C C 
H4-C 0.052 T C A G G T G G T G G A T A C C 
H6-C 0.041 C A G G G G G G C G G A T G A T 
H8-C 0.022 T C G G G T G G C G G A T A C C 
H10-C 0.019 C A G G G T G G C G G A T G A T 
H12-C 0.017 C A G G G T G G T G G A T A A T 
H13-C 0.015 T C G G G T A G T G G A T A A C 
Malays 
*1A 
H2-M 0.120 C A G A A T A A C G G G C A A T 
H4-M 0.062 C A G G G T G A C G G G C A A T 
H5-M 0.060 T C A A A T A A C G G G C A A T 
H9-M 0.025 C C A G G T G A C G G G C A A T 
H13-M 0.015 C A G A A G A A C G G G C A A T 
H17-M 0.012 C A G A A T A A C G G G C A C C 
*1B 
H1-M 0.195 C A G A A T A G T G G A T A C C 
H6-M 0.057 T C A G G T G G T G G A T A C C 
H7-M 0.055 C A G G G T G G T G G A T A C C 
H12-M 0.018 C A G G A T A G T G G A T A C C 
H14-M 0.015 C C G G G T G G T G G A T A C C 
H20-M 0.010 C A G G G T A G T G G A T A C C 
*1C 
H3-M 0.083 C A G G G G G G C G G A T G A T 
H8-M 0.039 C A G G G T G G C G G A T G A T 
H10-M 0.022 T C A G G T G G C G G A T G A T 
H11-M 0.021 C A G G G G G G C G G A T G C C 
H15-M 0.014 T C A G G T G G T G G A T A A T 
H16-M 0.013 C A G A A T A G C G G A T G A T 
H18-M 0.011 C A G A A T A A C G G G C A C C 
                   
















































H1-I 0.320 C A G A A T A G C G G G C A A T 
H2-I 0.088 T C A A A T A G C G G G C A A T 
H11-I 0.020 T C A A A T A G C G G G C A C C 
H8-I 0.030 T C A G G T G A C G G G C A A T 
H12-I 0.016 C A G G G T G G C G G G C A A T 
H15-I 0.015 C A G A A T G G C G G G C A A T 
H17-I 0.015 C A G A A T A G C G G G C A C C 
H18-I 0.010 T C A G G T G A C G G G C A A T 
H19-I 0.010 C A G G G T A G C G G G C A A T 
*1B 
H3-I 0.075 T C A G G T G A T G G A T A C C 
H4-I 0.044 C A G G G T G A T G G A T A C C 
H9-I 0.029 C A G G G G G A T G G A T A C C 
H13-I 0.016 C A G A A T A A T G G A T A C C 
H14-I 0.015 C A G A A T G A T G G A T A C C 
H16-I 0.015 C C G G G T G A T G G A T A C C 
*1C 
H5-I 0.040 T C A G G G G A C G G A T G A T 
H6-I 0.035 C A G G G T G A C G G A T G A T 
H7-I 0.030 C A G A A T A A C G G A T G A T 
H10-I 0.020 C A G G G G G A C G G A T G A T 
                   



































Fig 3.6 PXR haplotype families and tagged polymorphisms in (A) Chinese, (B) Malay and (C) Indian ethnic groups. 
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3.4.1.2 PXR Haplotypes and ABCB1 Hepatic Expression 
 
PXR is expressed predominantly in the liver.(335) Earlier reports which 
investigated hepatic expression of PXR in relation to its influence on its 
downstream targets such as CYP3A4 identified positive correlations.(336) The 
inter-subject variability was large with regards to PXR hepatic expression in 















  Fig 3.7 Inter-individual variability in PXR expression among Chinese healthy 
liver tissues. (N = 41) RQ: Relative Quotient 
 
The genotype and allele frequencies of PXR polymorphisms in liver tissues 
















 N; number of subjects 
 
The frequencies of PXR*1A, PXR*1B and PXR*1C haplotype clusters in the 
liver tissues were 29%, 33% and 38%, respectively. The PXR hepatic mRNA 
expression levels showed significant associations with PXR haplotype 
Polymorphisms Genotype frequencies, N (%)  Allele frequencies 
-1570C>T CC CT TT  C T 
 23(56.10) 14(34.14) 4(9.76)  0.73 0.27 
-566A>C AA AC CC  A C 
 23(56.10) 15(36.59) 3(7.32)  0.74 0.26 
-298G>A GG GA AA  G A 
 27(65.85) 12(29.27) 2(4.88)  0.80 0.20 
IVS2+55A>G AA AG GG  A G 
 10(24.39) 15(36.59) 16(39.02)  0.43 0.57 
IVS2+78A>G AA AG GG  A G 
 10(24.39) 15(36.59) 16(39.02)  0.43 0.57 
IVS3+72T>G TT TG GG  A G 
 33(80.49) 7(17.07) 1(2.44)  0.89 0.11 
IVS4+285G>A GG GA AA  A G 
 13(31.71) 18(43.90) 10(24.39)  0.54 0.46 
IVS5-93A>G AA AG GG  A G 
 21(51.22) 16(39.02) 4(9.76)  0.71 0.29 
IVS6-17C>T CC CT TT  A G 
 9(21.95) 23(56.10) 9(21.95)  0.50 0.50 
c.1437G>A GG GA AA  A G 
 41(100) 0 0  1.00 0 
c.1448G>A GG GA AA  A G 
 39(95.12) 2(4.88) 0  0.98 0.02 
c.1792A>G AA AG GG  A G 
 16(39.02) 21(51.22) 4(9.76)  0.65 0.35 
c.1944T>C TT TC CC  A G 
 16(39.02) 21(51.22) 4(9.76)  0.65 0.35 
+2180A>G AA AG GG  A G 
 32(78.05) 8(19.51) 1(2.44)  0.88 0.12 
+2617A>C AA AG GG  A G 
 9(21.95) 22(53.66) 10(24.39)  0.49 0.51 
+2654T>C TT TC CC  A G 
 9(21.95) 22(53.66) 10(24.39)  0.49 0.51 
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clusters (Figure 3.8A). The mean mRNA expression level of PXR in liver 
tissues harboring the PXR*1B haplotypes was approximately 4-fold lower 
compared to liver tissues carrying the *1A and *1C haplotypes [PXR*1A vs 
PXR*1B; RQ: 4.01 ± 1.11 vs 0.94 ± 0.24, P = 0.015; PXR*1B vs PXR*1C; 
RQ: 0.94 ± 0.24 vs 3.5 ± 0.74, P = 0.023]. No significant difference was 
observed in hepatic PXR mRNA expression between liver tissues carrying the 
*1A and *1C haplotype clusters (P > 0.05) which were combined to form the 
non-PXR*1B group for further analysis. The phenotypic effect of the different 
PXR haplotype clusters were investigated by examining their influence on the 
expression of their downstream target gene ABCB1.The hepatic mRNA 
expression of ABCB1 was lower in liver tissues carrying the PXR*1B 
haplotype cluster compared with liver tissues carrying the non-PXR*1B 
haplotype cluster (PXR*1B vs non-PXR*1B; RQ: 0.81 ± 0.51 vs 1.25 ± 0.34, P 


































Fig 3.8 Hepatic expression of PXR (A) and ABCB1 (B) in relation to PXR haplotype families.   
non-*1B represents PXR*1A + PXR*1C haplotype families. *NS= not significant 
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3.4.1.3 Pharmacokinetic-Pharmacogenetic Associations 
 
The effects of PXR*1A, PXR*1B and PXR*1C haplotype clusters on the 
pharmacokinetics of doxorubicin were investigated in Asian breast cancer patients. 
The frequencies of the PXR*1A, PXR*1B and PXR*1C haplotype clusters in the 
breast cancer patients were 40%, 27% and 33%, respectively. Since the PXR 
haplotype clusters were associated with altered expression levels of ABCB1, their 
impact on the clearance of doxorubicin, which is an ABCB1 substrate, was 
investigated. The pharmacokinetic parameters of doxorubicin in relation to PXR 
haplotype family are shown in Table 3.6. The clearance of doxorubicin was 
significantly lower in patients harboring the PXR*1B haplotypes compared to patients 
carrying the non-PXR*1B (*1A and *1C) haplotypes [PXR*1B vs non-PXR*1B; 
CL/BSA(Lh-1m-2): 20.84; range: 8.68-29.24 vs 24.85; range: 13.80-55.66, P = 0.023]. 
 
 125


















                   
   * P < 0.05 considered statistically significant. 
 
Pharmacokinetic parameters PXR haplotype clusters  Pairwise P values*
         *1B (N =12)     non-PXR*1B (N= 37)  *1B  vs   non-PXR*1B 
Doxorubicin     
AUC0-∞/dose/BSA (hm-5)   18.76 (11.88 – 67.17)      16.41 (6.18 –38.03)  0.204 
t1/2 (h)   16.21 (4.67– 24.63)      15.18 (8.09 – 20.60)  0.348 
Cmax/dose/BSA (m-5)   41.81 (10.42 – 73.53)      31.40 (4.55 – 97.70)  0.369 
CL/BSA (Lh-1m-2)   20.84 (8.68 – 29.24)      24.85 (13.80 – 55.66)  0.023 
Vss/BSA (Lm-2) 239.00 (53.97 – 410.10)    237.50 (91.69– 703.70)  0.529 
Doxorubicinol     
AUC0-∞/dose/BSA (hm-5)   11.55 (7.57 – 24.34)       9.15 (3.68 – 20.63)  0.044 
t1/2 (h)   32.19 (20.55 – 112.40)     27.07 (6.34 –51.09)  0.845 
Cmax/dose/BSA (m-5)     0.38 (0.18 –0.76)       0.33 (0.15 – 2.00)  0.240 
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3.4.1.4 Discussion  
 
Pregnane X receptor induces the expression of several hepatic and intestinal 
phase I enzymes (CYP2C9, CYP2B6, CYP3A7, CYP3A4, CYP24, CYP2C19, 
CYP2C8), phase II conjugating enzymes (UGT1A1, GSTs) and phase III drug 
transporters [efflux transporters such as ABCB1, ABCC2, ABCC3, and uptake 
transporters such as OATP2 (SLC21A6)].(337,338,339,340) Characterizing PXR 
genetic variations and identifying functionally linked polymorphisms in 
different ethnic groups would provide valuable insights into the interethnic and 
interindividual variations in disposition of several drugs that are known PXR 
ligands or substrates of its target genes.  
 
In the present study, the genotype and allele frequencies of PXR 
polymorphisms identified by screening the 5’- and 3’-UTRs, exons and exon-
intron boundaries showed significant interethnic variations among the 
Chinese, Malay and Indian healthy populations as well as with reported 
genotype frequencies in other ethnic populations. The allelic frequency of the 
-1570C>T polymorphism was found to be significantly higher among Indians 
(0.34) and was similar to reported frequencies in European (0.36), Caucasian 
(0.39), and African American (0.32) populations.(341,342) The -1570C>T 
polymorphism lies within a NF-κb binding element in the PXR promoter region 
and has previously been shown to have potential functional roles. In a study 
by Zhang et al (342) individuals harboring the -1570TT genotype showed a two-
fold higher rifampicin induction of CYP3A4 as compared to subjects with a -
1570CC genotype. The 5’-UTR -566A>C polymorphism that exhibited varying 
frequencies among the Asian ethnic groups in the present study (0.16 in 
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Chinese, 0.24 in Malays, 0.34 in Indians) is present at a higher frequency in 
other populations (0.40 in Caucasians, 0.70 in African Americans).(341,342) The 
-566C allele was previously reported to be associated with a significant 
increase in ABCB1 (P = 0.04) and CYP3A4 (P = 0.04) mRNA levels in colon 
tumor specimens.(343) Taken together, these previously reported in-vitro 
findings suggest that homozygosity for the variant allele at either loci may be 
associated with increased transcription of downstream PXR target genes.  
 
More than fifteen allelic variants in the DBD and LBD regions of the PXR gene 
have been known to have significant functional consequences, including 
aberrant DNA binding and alterations in transactivation and expression of 
downstream targets such as ABCB1 and CYP3A4.(162,343,344) Zhang et al(342) 
reported a 365G>A (R122Q) polymorphism in exon 4 that reduces DNA 
binding activity resulting in minimal attenuation of rifampicin-induced CYP3A4 
promoter activity. Hustert et al(344) reported the exon 4 418G>A (V140M), 
488A>G (D163G), and exon 8 1108G>A (A370T) polymorphisms in the PXR 
LBD, of which the 488A>G polymorphism was associated with reduced basal 
and rifampicin-induced activity toward a reporter gene construct containing 
the CYP3A4 proximal promoter and distal enhancer. However the allelic 
frequencies of these polymorphisms are low in different populations and were 
not detected in the present study. Other earlier reported non-synonymous 
PXR polymorphisms [exon 2: 52G>A (E18K), 79C>T (P27S), 106G>A 
(G36R), exon 4: 443G>A (R148Q), exon 8: 1135C>G (C379G), 1141C>T 
(R381W) and exon 9: 1207A>G (I403V)](343) were not identified in the Asian 
ethnic groups screened in the present study. The exon 9 c.1437G>A 
polymorphism occurs at a high frequency among African Americans (0.36) but 
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was present at low frequency in all the three Asian ethnic groups (0.01), 
similar to the Japanese population (0.02).(341,343) The c.1792A>G and 
c.1944T>C polymorphisms previously reported in the Dutch population 
(0.24)(341) were present at a higher frequency among the Chinese (0.43), 
Malays (0.34) and Indians (0.59).  
 
Among the six intronic polymorphisms identified, the IVS4+285G>A variant 
was highly polymorphic in the Chinese (0.64), Malay (0.54) and Indian (0.60) 
populations and was similar to reports in the Dutch population (0.69).(341) The 
allelic frequency of the 3’-UTR +2180A>G polymorphism displayed a four-fold 
higher frequency in the Malay ethnic group (0.21) compared to Caucasians 
(0.05)(342) whereas the completely linked +2617A>C and +2654T>C 
polymorphisms (ID’I = 1) were present at a three-fold higher allele frequency 
among Chinese (0.46) compared to Caucasians (0.16).(342)  
 
Haplotype and LD structures derived from several polymorphisms provide a 
better tool for characterization of the relationship between genetic variability 
and phenotypes.(345,346,347) In the present study, individual haplotypes did not 
reveal any significant correlations with PXR hepatic mRNA expression. To 
further clarify genotype-phenotype correlations, haplotype clusters that 
influence PXR hepatic mRNA expression were identified. Haplotype 
association through network based analysis holds the assumption that 
constituent haplotypes has minimal intra- and large inter-variations due to 
their sequence similarities (r2 > 0.75).(334) Pairwise analysis revealed that the 
PXR*1A and PXR*1C were associated with a significantly higher PXR hepatic 
mRNA expression when compared to PXR*1B.  
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The PXR*1A tagged polymorphisms (c.1792A>G and c.1944T>C) have 
earlier been shown to be in strong linkage(341); however there are no reports of 
functional influences of these polymorphisms. The intronic IVS2+55A>G and 
IVS2+78A>G polymorphisms that tagged the PXR*1C was previously 
reported to be significantly associated with altered oral midazolam 
clearance.(348) Midazolam clearance was significantly lower in African 
American subjects homozygous for the intronic IVS2+55A>G and 
IVS2+78A>G reference genotypes compared to subjects who were 
homozygous for the variant allele at both loci. However this association was 
absent among the European Americans suggesting that the observed 
association of the PXR*1C with increased PXR mRNA expression could be 
due to possible linkage of the IVS2+55A>G and IVS2+78A>G polymorphisms 
with other yet unidentified ethnically dependent functional polymorphisms. 
The linked IVS2+55A>G and IVS2+78A>G polymorphisms occur at a higher 
frequency among African Americans (0.89 and 0.65 respectively) and in 
European Americans (0.64 and 0.28) when compared to the Chinese (0.41 
and 0.45), Malay (0.49 and 0.46) and Indian (0.38 and 0.37) ethnic groups. 
The interethnic variations in frequencies of IVS2+55A>G and IVS2+78A>G 
polymorphisms and their varying association with drug clearance suggest the 
potentially important role of PXR*1C in interethnic variations in drug 
disposition. PXR*1B that was associated with a significantly reduced PXR 
mRNA hepatic expression was tagged by the +2654T>C and IVS6-17C>T 
polymorphisms. In a study by Zhang et al(342) the +2654T>C polymorphism 
was shown to be associated with reduced intestinal ABCB1 expression 
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whereas the IVS6-17C>T polymorphism has been shown to be related to 
intestinal CYP3A inducibility. 
 
Several studies have shown that the low frequencies of CYP3A4 allelic 
variants associated with altered activity do not adequately explain the 
variation in basal CYP3A4 expression observed in different study 
groups.(349,350) Also, the influence of ABCB1 polymorphisms on variations in 
ABCB1 expression in in-vitro and in-vivo models have been 
inconclusive.(195,351,352) The expression of both CYP3A4 and ABCB1 are under 
the transcriptional control of the PXR gene,(162,353,354) and it is possible that 
phenotypic variations in their activity or expression levels could result from the 
effect of functional polymorphisms in their upstream regulatory genes such as 
PXR. To investigate if PXR pharmacogenetics was associated with altered 
hepatic expression of its downstream target genes, the association between 
PXR*1A, *1B and *1C haplotype clusters in relation to hepatic expression of 
CYP3A4 and ABCB1 mRNAs as well as the pharmacokinetics of doxorubicin 
in breast cancer patients was examined. The PXR*1B haplotype cluster was 
associated with a significantly reduced hepatic mRNA expression of CYP3A4 
(P = 0.030) and a trend towards statistical significance with regards to 
expression of ABCB1 (P = 0.060) compared with hepatic tissues carrying the 
non-PXR*1B haplotype constitution. The PXR genotype-phenotype 
relationships were further associated with decreased doxorubicin clearance in 
breast cancer patients harboring the PXR*1B haplotype compared with 
patients carrying the non-PXR*1B haplotype. These findings suggest that 
PXR genetic constitution or haplotypes may significantly influence the 
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expression and activity of its downstream target genes and the disposition of 
its putative drug substrates. Furthermore, the relationship between reduced 
PXR expression associated with PXR*1B among Indians (19.4%) compared 
to the Malay (35%) and Chinese (28.7%) subjects may have further 
implications in studies on interethnic variability in expression of PXR 
targets(355) and disposition of their drug substrates reported in Asian ethnic 
groups.(208)  
 
PXR controls transcriptional events as a heterodimer with RXR by binding to 
distinct DNA response elements. Several other nuclear receptors that form 
heterodimer complexes with RXR also utilize the same binding elements, 
including vitamin D receptor (VDR; NR1I1) and the constitutive androstane 
receptor (CAR; NR1I3). It has been established that PXR overlaps functionally 
with CAR in terms of ligand binding and gene activation due to their structural 
homology.(155) Recent studies indicate that the overlap in PXR and CAR target 
genes extends well beyond the members of the CYP3A, CYP2C, GSTs, 
UGTs and the canalicular ABCC2 transporter.(356) Functional polymorphisms 
have been identified for both PXR and CAR but interethnic genetic variation in 
humans has not yet been well characterized.(162,357) Interethnic differences in 
PXR haplotype constitution as observed in the present report suggest that 
future studies should also take into consideration polymorphisms in other co-
regulators such as CAR while investigating for interethnic and interindividual 
variations in drug disposition related to PXR target genes.  
 
In conclusion, significant differences were observed in the genotype and allele 
frequencies of PXR polymorphisms and their linkage patterns among the 
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distinct Asian ethnic groups. The PXR*1B haplotypes that occurred at a 
higher frequency in Chinese and Malays compared to Indians, was found to 
be associated with significantly decreased hepatic mRNA expression of PXR 
and also its downstream target gene ABCB1.  The PXR*1B haplotype was 
also found to be significantly associated with reduced clearance of 
doxorubicin. Taken together, these findings suggest that genetic 
polymorphisms and specific haplotype clusters in the PXR nuclear receptor 
could have significant contributory roles in affecting interethnic variations in 
doxorubicin disposition in the Asian populations. Further studies in different 
population groups would be required to delineate the influence of PXR 
polymorphisms and haplotypes on the expression and acitivity of other 
pharmacogenetic candidates across the doxorubicin biochemical pathway and 
further characterize its role in influencing doxorubicin disposition in cancer 
patients on chemotherapy.  
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3.5 PHARMACOKINETIC-PHARMACOGENETIC CORRELATES OF DRUG 
TRANSPORTERS  
 
3.5.1 ATP binding cassette, subfamily B1 (ABCB1) 
 
3.5.1.1 ABCB1 Pharmacogenetics 
 
The genotype and allele frequencies of the ABCB1 [c.1236C>T, 
c.2677G>T/A, c.3435C>T] polymorphisms in Asian breast cancer patients are 
shown in Table 3.7. The observed genotype distribution conformed to Hardy-
Weinberg proportions. The allelic frequency of the ABCB1 c.1236T, c.2677T 
and c.2677A, and c.3435T variants among Asian breast cancer patients were 
60%, 38%, 7%, and 22% respectively. In a previous study by Chowbay et 
al(208) in healthy Asian populations, the c.2677TT variant frequency was much 
lower in the Malays (19%) compared to the Indians (41%) and the Chinese 
(26%). The c.2677GG variant was similar in the Chinese and Indian 
populations (17% and 14%, respectively) compared to 28% in the Malays 
while the frequency of the homozygous c.3435TT variant was 45% in the 
Indian subjects compared to c.3435CC variant (18%). The genotype and 
allele frequencies of the ABCB1 polymorphisms in the breast cancer patients 
in the present study were comparable to the previously published reports in 
the Asian populations. 
 
Linkage disequlibrium analysis showed moderate degree of linkage between 
all the three ABCB1 polymorphisms [c.2677G>T/A and c.3435C>T, ID’I = 
0.63; c.1236C>T and c.3435C>T, ID’I = 0.56 and c.1236C>T and 
c.2677G>T/A, ID’I = 0.57] (Figure 3.9). 
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Table 3.7 Genotype and allele frequencies of ABCB1 polymorphisms in Asian 





























Fig 3.9 Pairwise linkage disequilibrium (LD) between the ABCB1 c.1236C>T, 
c.2677G>T/A  and c.3435C>T polymorphisms in Asian cancer patients.  Tone 
of color indicates the degree of linkage between polymorphisms.  
Polymorphisms  
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3.5.1.2 Pharmacokinetic-Pharmacogenetic Associations 
 
The influence of ABCB1 polymorphisms on the pharmacokinetic parameters 
of doxorubicin in Asian breast cancer patients are summarized in Table 3.8.  
Since no significant differences were observed in pharmacokinetic parameters 
between cancer patients carrying one or two variant alleles at the ABCB1 
1236 locus, patients harboring the c.1236CT and c.1236TT genotypes were 
grouped together and compared with the reference genotype. Breast cancer 
patients carrying a least one c.1236T allele had significantly higher (69%) 
peak plasma concentrations of doxorubicin [Cmax/dose/BSA(hm-5), median: 
36.8; range: 10.4-97.7]  when compared to the patients carrying the reference 
genotype [Cmax/dose/BSA(hm-5), median: 21.8; range: 4.6-57.9, P = 0.033]. 
The exposure level of doxorubicin was 42% higher in patients who carried at 
least one c.1236T allele [AUC0-∞/dose/BSA (hm-5): median: 18.8; range: 8.2-
38.0] compared to patients who were homozygous for the reference genotype 
[AUC0-∞/dose/BSA (hm-5), median: 13.2; range: 6.2-67.2, P = 0.066].  The 
clearance of doxorubicin was approximately 25% lower in patients carrying at 
least one variant T allele compared with patients carrying the reference 
genotype (P = 0.14). 
 
As depicted in Table 3.8, patients who were heterozygous for the 
c.2677G>T/A polymorphism showed a trend towards higher doxorubicin 
exposure levels [AUC0-∞/dose/BSA (hm-5), median: 19.8; range: 6.2-38.0] 
compared to patients homozygous for the reference allele [AUC0-∞/dose/BSA 
(hm-5), median: 15.2; range: 7.1-67.2, P > 0.05].  The clearance of doxorubicin 
was significantly higher among patients who harbored the homozygous 
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variant alleles for the c.2677G>T/A polymorphism [CL/BSA(Lh-1m-2), median: 
30.3; range: 13.8-55.7] when compared to patients who were heterozygous 
[CL/BSA(Lh-1m-2), median: 21.7; range: 15.0-49.4, P = 0.012] and 
homozygous for the reference allele [CL/BSA(Lh-1m-2), median: 22.3; range: 
8.7-36.9, P = 0.035].  Pairwise analysis failed to reveal any significant 
influences of the c.3435C>T polymorphism on pharmacokinetic parameters of 
doxorubicin. No significant influences of ABCB1 polymorphisms on the 
pharmacokinetic parameters of doxorubicinol were observed.  
 137







































(N=43) CC vs CT+TT  
Doxorubicin      
AUC0-∞/dose/BSA (hm-5)  13.20 (6.20-67.20) 18.80 (8.20-38.00)  0.066 
Cmax/dose/BSA (m-5)  21.80 (4.60-57.90)     36.80 (10.40-97.70)  0.033 
CL/BSA (Lh-1m-2)  29.90 (8.70-49.40)     22.50 (13.80- 55.70)  0.14 
Doxorubicinol      
AUC0-∞/dose/BSA (hm-5)  8.40 (3.70-13.70)    9.90 (5.80-24.30)  0.076 
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   AA+TT
Doxorubicin         
AUC0-∞/dose/BSA (hm-5)  15.20 (7.10-67.20) 19.80 (6.20-38.00) 13.20 (8.20-30.20)  0.119 0.076 0.547 
Cmax/dose/BSA (m-5)  36.20 (7.00-77.40) 35.80 (4.50-97.70) 23.30 (13.60-80.70)  0.340 0.188 0.699 
CL/BSA (Lh-1m-2)  22.30 (8.70-36.90) 21.70 (15.00-49.40) 30.30 (13.80-55.70)  0.46 0.012 0.035 
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5)  9.10 (3.70-21.70) 10.50 (5.60-24.30) 8.90 (6.10-20.60)  0.139 0.665 0.574 







CC vs CT+TT 
 
Doxorubicin      
AUC0-∞/dose/BSA (hm-5)  16.90 (6.20-38.00) 18.20 (9.00-67.20)  0.588 
Cmax/dose/BSA (m-5)  35.50 (4.60-97.70)     33.10 (10.40- 80.70)  0.720 
CL/BSA (Lh-1m-2)    22.40 (16.40-49.40)  22.40 (8.70- 55.70)  0.89 
Doxorubicinol      
AUC0-∞/dose/BSA (hm-5)  9.20 (3.70-24.30) 11.04 (6.30-18.70)  0.124 
Cmax/dose/BSA (m-5)  0.33 (0.16-1.50) 0.38 (0.15-2.00)  0.576 
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The doxorubicin pharmacokinetic parameters by the three major genotypes of 
ABCB1 exon 12, 21 and 26 polymorphisms in Asian breast cancer patients are 
shown in Table 3.9. Patients homozygous for the CC-GG-CC genotype had 
significantly lower doxorubicin exposure levels [AUC0-∞/dose/BSA (hm-5), median: 
11.13; range: 7.12-13.21] compared to the patients who had heterozygous (CT-
GT-CT) [AUC0-∞/dose/BSA (hm-5), median: 19.0; range: 11.88-31.6, P = 0.02 ] 
and homozygous (TT-TT-TT) genotypes [AUC0-∞/dose/BSA (hm-5), median: 
17.59; range: 12.55-30.16, P = 0.03] at the three loci (Figure 3.10A). 
 
Patients harboring the CC-GG-CC genotypes also had significantly lower peak 
plasma concentrations of doxorubicin [Cmax/dose/BSA(hm-5), median: 14.63; 
range: 7.0-22.23] compared to patients who harbored the CT-GT-CT 
[Cmax/dose/BSA(hm-5), median: 32.99; range: 18.3-73.5, P = 0.02] and TT-TT-TT 
genotypes [Cmax/dose/BSA(hm-5), median: 37.98; range: 20.9-80.7, P = 0.03]. 
The significantly lower exposure levels of doxorubicin in patients harboring CC-
GG-CC genotypes was also associated with a significantly increased clearance 
of doxorubicin [CL/BSA(Lh-1m-2), median: 31.73; range: 24.8-36.9] when 
compared to patients harboring the CT-GT-CT genotype [CL/BSA(Lh-1m-2), 
median: 21.9; range: 15.0-28.5, P = 0.01] (Figure 3.10B). With regards to 
doxorubicinol, patients harboring the CC-GG-CC genotypes had significantly 
lower peak plasma concentrations of doxorubicinol [Cmax/dose/BSA(hm-5), 
median: 0.22; range: 0.16-0.32] compared to the patients who had TT-TT-TT 
genotypes [Cmax/dose/BSA(hm-5), median: 0.39; range: 0.31-0.57, P = 0.03]. 
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N; number of subjects. Values expressed in median (range). * P < 0.05 considered statistically significant. 
 








Pairwise P values* 
 
CC-GG-CC








 vs   
TT-TT-TT 
Doxorubicin       
  AUC0-∞/dose/BSA (hm-5) 11.13 (7.12 – 13.21) 19.00 (11.88 – 31.60) 17.59 (12.55 – 30.16) 0.02 1.00 0.03 
  Cmax/dose/BSA (m-5) 14.63 (7.00 – 22.23) 32.99 (18.30 – 73.50) 37.98 (20.90 – 80.70) 0.02 0.76 0.03 
  CL/BSA (Lh-1m-2) 31.73 (24.80 – 36.9) 21.90 (15.00 – 28.50) 24.98 (13.80 – 40.90) 0.01 0.20 0.91 
Doxorubicinol       
  AUC0-∞/dose/BSA (hm-5) 7.21 (3.70– 10.8) 11.85 (7.90 – 18.70) 11.64 (6.60 – 15.60) 0.067 0.79 0.064 























A)           B)  
 
 
Fig 3.10 The influence of the ABCB1 genotypes on the A) exposure levels [AUC0-∞/dose/BSA(hm-5)] and B)  clearance [CL/BSA(Lh-
1m-2) ] of doxorubicin. N; number of subjects 
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3.5.1.3 ABCB1 Hepatic Expression 
 
ABCB1 gene polymorphisms has earlier been proposed to alter its tissue 
specific expression and function(200,210,358,359) but there has been few studies 
that analyzed the influence of ABCB1 polymorphisms on ABCB1 hepatic 
expression. Hoffmeyer et al(195) analyzed the ABCB1 sequence in 21 healthy 
volunteers and found that the synonymous c.3435C>T variant was associated 
with reduced ABCB1 intestinal expression levels whereas studies by Wang et 
al(360) have also shown reduced hepatic and renal ABCB1 mRNA levels to be 
associated with the c.3435C>T genotype. Understanding the influence of 
ABCB1 polymorphisms on its hepatic expression would be beneficial in 
identifying the mechanistic basis of the contribution by ABCB1, in variability of 
doxorubicin disposition. Increased ABCB1 activity or expression associated 
with ABCB1 polymorphisms could result in higher clearance of doxorubicin 
due to increased efflux activitiy, reducing exposure levels and possibly 
altering efficacy of therapy. 
 
The genotype and allele frequency of ABCB1 polymorphisms in the healthy 
Chinese liver tissues and the hepatic ABCB1 expression levels with respect 
to c.1236C>T, c.2677G>T/A and c.3435C>T genotypes are shown Table 
3.10. The ABCB1 genotype and allele frequencies were in accordance to the 
frequency reported in healthy Chinese population. No significant influence of 
ABCB1 polymorphisms on its hepatic expression levels were observed in the 
present study, although a high degree of inter-individual variability in the 




Table 3.10 ABCB1 genotype frequencies in Asian healthy liver tissues and 
influence on ABCB1 mRNA levels.  
 
N; no of subjects. Values expressed as mean ± SD. RQ: Relative Quotient, * P < 










Fig 3.11 Inter-individual variability in ABCB1 expression in Chinese healthy 




Polymorphisms Genotypes N  (%) 
RQ 
(mean ± SD) Pairwise P values* 
c.1236C>T CC 4 0.42 ± 0.57 CC vs CT CC vs TT CT vs TT 
 CT 12 0.33 ± 1.81 0.37 0.87 0.15 
 TT 23 0.42 ± 1.49    
c.2677G>T/A GG 24 0.37 ± 1.78 GG vs GT GG vs AA GA vs AA 
 GT 9 0.46 ± 1.33 0.17 0.76 0.30 
 AA 5 0.39 ± 0.76    
c.3435C>T CC 15 0.36 ± 1.37 CC vs CT CC vs TT CT vs TT 
 CT 9 0.42 ± 0.18 0.24 0.78 0.36 















The possibility that ABCB1 variant transport function could influence drug 
response and toxicity led to several studies that investigated the genotype 
related function of three high frequency ABCB1 polymorphisms in exon 12 
(c.1236C>T), 21 (c.2677G>T/A) and 26 (c.3435C>T). Initial investigations of 
the relationship between the ABCB1 polymorphisms and drug exposure 
focused on the role of P-gp in limiting intestinal bioavailability. Several studies 
have reported higher bioavailability of ABCB1 drug substrates in carriers of 
the T allele at the ABCB1 c.3435 locus, attributed to lower functional activity 
of the protein or reduced ABCB1 expression.(360) The search for causal 
mechanisms later confirmed varying degree of contribution from the ABCB1 
c.1236C>T and c.2677G>T/A polymorphisms. The c.1236C>T, c.2677G>T/A 
and c.3435C>T polymorphisms are known to be in linkage disequilibrium, and 
population studies in different ethnic groups have revealed significant 
heterogeneity in the patterns of haplotype structures.  Although several 
studies have been performed, there is no consensus regarding a definitive 
influence of major ABCB1 polymorphisms on drug disposition both 
independently and as part of different haplotypes.(200,361,362)   
 
In the present study, pairwise analysis suggested that the ABCB1 c.1236C>T 
polymorphism may have a functional influence on doxorubicin 
pharmacokinetics resulting in increased exposure levels to doxorubicin in 
patients harboring at least one c.1236T allele. This finding was similar to an 
earlier report of the effect of the c.1236C>T polymorphism on the 
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pharmacokinetics of cyclosporine where subjects with c.1236CC genotype 
had slight but significantly lower dose-adjusted Cmax and AUC0-4h of 
cyclosporine compared with mutated allele carriers.(422)  With regards to the 
influence of the c.2677G>T/A polymorphism, a trend of higher exposure 
levels and significantly decreased clearance of doxorubicin was observed in 
c.2677G>T/A heterozygote patients when compared to patients who were 
homozygous for the c.2677T and c.2677A alleles. The non synonymous 
c.2677G>T/A polymorphism has been previously shown to be associated with 
alterations in saturation kinetics of vincristine(361) and bioavailability of other 
ABCB1 substrates, but most often has been analyzed in conjunction with the 
c.3435C>T polymorphism. The possible mechanistic roles of naturally 
occurring synonymous variations were highlighted in a recent report that 
investigated the effect of the ABCB1 c.3435C>T polymorphism. The study by 
Kimchi-Sarfaty et al(363) showed that alterations in ABCB1 conformation 
following changes in translation kinetics due to the rare codon usage at 
c.3435T resultis in variations in the structure of substrate and inhibitor binding 
sites. The results however, failed to reveal any significant influence of the 
ABCB1 c.3435C>T polymorphism on doxorubicin disposition in the present 
study. This could be due to the minimal phenotypic influence of the 
c.3435C>T polymorphism or due to its effects being masked by the multiple 
determinants of doxorubicin disposition including those from other transporter 
proteins and metabolizing enzymes. 
 
Recent studies have suggested that the association of the ABCB1 
polymorphisms with phenotypic correlates might be better explained by 
considering the composite influence of genetic information from the ABCB1 
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1236, 2677 and 3435 loci.(208,209)  Haplotype analysis of ABCB1 gene blocks in 
the Japanese population have earlier shown a genotype dependent renal 
clearance of irinotecan.(364) Haplotype-phenotype evaluations of the drug 
metabolizing enzyme CYP2C8 have also been shown to delineate the subset 
of patients having altered pharmacokinetics of paclitaxel(365)  suggesting that 
haplotype analysis of candidate gene polymorphisms may have significant 
roles in understanding interindividual variations in the pharmacokinetics of 
antineoplastic agents. In order to observe the net effect of all the three 
ABCB1 polymorphisms on the pharmacokinetics of doxorubicin and 
doxorubicinol, the contribution of these polymorphisms was analyzed using 
the composite genotype information from the ABCB1 1236-2677-3435 loci.  
Patients with the CC-GG-CC genotype constitution were associated with 
lower exposure levels and increased clearance of doxorubicin when 
compared to the subjects harboring the TT-TT-TT genotype. The observation 
of reduced peak plasma concentrations of doxorubicin in these subjects who 
were homozygous for the reference allele at all the three loci is similar to 
earlier reports on the influence of ABCB1 haplotypes on cyclosporine 
levels.(15) In a study investigating the influence of ABCB1 haplotypes on 
cyclosporine disposition in heart transplant recipients, it was observed that 
patients homozygous for the CC-GG-CC genotypes had lower peak and 
trough cyclosporine concentrations as well AUC0-4h and AUC0-12h, while higher 
levels were observed in patients carrying mutations at all three loci. The study 
also showed that the C allele at exon 12 was associated with G and A allele 
at 2677 loci that in turn linked significantly with the c.3435C allele. The tight 
linkage of the ABCB1 c.1236C>T polymorphism with the c.2677G>T/A and 
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c.3435C>T polymorphisms has also been shown to serve as an important 
marker influencing irinotecan clearance in Japanese cancer patients.(364) 
Taken together, the results suggest that linkage between ABCB1 
polymorphisms may be important in influencing doxorubicin disposition. The 
study however do not address the possibility of doxorubicin disposition being 
subject to influence by other ABCB1 polymorphisms that has been shown to 
be part of important haplotype structures in different populations.(194)  Given 
the modest sample size of patients analyzed, these findings should be 
considered exploratory in nature and larger studies are required to validate 
these findings. The results suggest that the linked ABCB1 1236-2677-3435 
genotypes significantly influence the disposition of doxorubicin in Asian breast 
cancer patients resulting in significantly increased exposure levels, peak 
plasma concentrations and reduced clearance in patients who were 
homozygous for the variant allele at the three loci.  
 
The healthy liver tissues which showed an absence of ABCB1 hepatic 
expression did not conform to a specific genotypic distribution with respect to 
the ABCB1 c.1236C>T, c.2677G>T/A or c.3435C>T polymorphisms. The high 
variability in the ABCB1 hepatic expression levels and the lack of influence of 
ABCB1 polymorphisms observed in the present study could be due to several 
factors. The liver is enriched in regulatory molecules such as hepatocyte 
nuclear factors (HNF's) among which, HNF1α and HNF4 are involved in 
transcription of hepatic drug transporters.(366,367) The Stimulating Protein 1 is a 
ubiquitously expressed transcription factor(368) reported to regulate the ABCB1 
hepatic expression.(369,370) Drug transporters including ABCB1,(338) are also 
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known to be under transcriptional control of nuclear receptors such as the 
pregnane X receptor (PXR), with PXR binding nuclear response elements in 
either proximal promoter or enhancer regions.(162) A combination of these 
regulatory mechanisms could have contributed to the inter-individual 
variability in ABCB1 hepatic expression levels observed in the present study.  
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3.5.2 ATP binding cassette, subfamily G2 (ABCG2) 
 
3.5.2.1 ABCG2 Pharmacogenetics  
 
The genotype and allele frequency of the ABCG2 c.421C>A polymorphism in 
Asian breast cancer patients are shown in Table 3.11. The frequency of the 
ABCG2 c.421A allele was 23% and patients homozygous for the variant allele 
were absent in the cancer patients. The allele frequency of the c.421C>A 
polymorphism was comparable to earlier reports in the Asian population.(371) 
      
3.5.2.2 Pharmacokinetic-Pharmacogenetic Associations 
 
The influence of ABCG2 polymorphisms on the pharmacokinetic parameters 
of doxorubicin in Asian breast cancer patients are summarized in Table 3.12. 
Pairwise comparisons failed to show any significant influences of the ABCG2 
c.421C>A polymorphism on the pharmacokinetic parameters of doxorubicin 
and doxorubicinol. 
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             N: number of subjects 
 












            N; number of subjects. Values expressed in median (range). * P < 0.05 considered statistically significant.
Polymorphisms  
 
Genotypes; N (%) 
 
Allele frequencies 
c.421C>A  CC CA AA C A  
  28 (45.2) 34 (54.8) 0 0.77 0.23  
Pharmacokinetic parameters  ABCG2 genotypes  Pairwise P values*
c.421C>A  CC (N=23) 
CA 
(N=29) 
 CC vs CA 
Doxorubicin      
AUC0-∞/dose/BSA (hm-5)  17.40 (6.20-67.20) 17.60 (9.80-29.30)  0.971 
Cmax/dose/BSA (m-5)  32.90 (4.60-81.20)   34.80 (10.40-97.70)  1.000 
CL/BSA (Lh-1m-2)  21.90 (8.70-55.70)   23.27 (19.20-33.60)  0.472 
Doxorubicinol      
AUC0-∞/dose/BSA (hm-5)  9.80 (3.70-21.70) 9.60 (5.40-24.30)  0.631 
Cmax/dose/BSA (m-5)  0.30 (0.15-1.20)    0.38 (0.16-2.00)  0.151 
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3.5.2.3 ABCG2 Hepatic Expression 
 
The genotype and allele frequency of ABCG2 polymorphisms in the hepatic 
tissues are shown in Table 3.13 and were in accordance to the frequency of 
the polymorphisms reported in the local population from which the subjects 
were recruited. The high degree of interindividual variability observed in the 
expression of ABCG2 in the present study (CV = 89.6%) (Figure 3.12) could 
not be explained by the ABCG2 c.421C>A genotypes.  
 
 
Table 3.13 ABCG2 genotype frequencies in Chinese healthy liver tissues and   
influence on ABCG2 mRNA levels. 
 
 
N; no of subjects. Values expressed as mean ± SD. RQ: Relative quotient. *P < 0.05 









Fig 3.12 Inter-individual variability in ABCG2 expression in Chinese healthy 
liver tissues. (N = 41) RQ :Relative Quotient 
 
 
Polymorphisms Genotypes N (%) RQ; (mean ± SD) 
Pairwise P 
values* 
c.421C>A CC 22 1.06 ± 0.85  AA vs AG  













3.5.2.4 Discussion  
 
Physiological expression of ABCG2 in organs important for absorption (the 
small intestine), distribution (the placenta and blood brain barrier), and 
elimination (the liver and small intestine) of drugs, has led to studies that 
investigated its role in influencing drug disposition.(372) Cell lines over-
expressing the ABCG2 protein have been shown to be several fold resistant 
to drugs including doxorubicin.(373,374) The exclusive upregulation of the 
ABCG2 mRNA and the amplification of the ABCG2 gene has been shown to 
circumvent toxicity of drugs such as mitoxantrone.(140,375) The association of 
ABCG2 mRNA levels with in-vitro sensitivity to its substrate flavopiridol in 
AML cells raised the possibility that ABCG2 expression could be related to 
poor response to agents that are ABCG2 substrates.(376,377,378) The increased 
expression of ABCG2 in hepatic metastases from colon tumors after 
irinotecan chemotherapy also suggested that the expression of ABCG2 in a 
subpopulation of tumor cells may be responsible for failure of 
chemotherapy.(379) In a study in non small-cell lung carcinoma patients, Yoh 
et al(380) reported that ABCG2 negative non small-cell lung carcinomas had a 
better rate of response to platinum based chemotherapy (44%) than did 
ABCG2-positive tumors (24%).  
 
The non-synonymous ABCG2 c.421C>A (Q141K) polymorphism in exon 5 is 
located in the functionally important ATP-binding region between Walker A 
and B motifs and is associated with a differentially charged amino acid 
substitution, suggesting that the variant alters the tertiary structure of the 
ABCG2 protein leading to greater susceptibility to degradation.(225)  In earlier 
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studies, the c.421C>A polymorphism resulted in markedly decreased protein 
expression and low-level drug resistance compared to ABCG2 transfected 
cells carrying the reference genotype.(225) The c.421C>A polymorphism 
occurs with a higher frequency among Asians (30-60%) when compared to 
Caucasians and African-Americans (5-10%).(234) The wide ethnic variations in 
allele frequency distribution of the ABCG2 c.421C>A polymorphism suggests 
their potential contribution to interindividual variability in drug 
disposition.(233,234) Reports of the c.421A allele associated with a reduced 
protein level when compared with those without the variant are consistent 
with the report that c.421A ABCG2 transfected PA317 cells and KB-3-1 
human epidermoid carcinoma cells showed a markedly decreased protein 
expression and low-level drug resistance.(225) Sparreboom et al(233) evaluated 
the effects of the c.421C>A variant on the pharmacokinetics of diflomotecan, 
a synthetic derivative of camptothecin in cancer patients, linking the ABCG2 
polymorphism to altered drug exposure. Patients heterozygous for the 
c.421C>A polymorphism had about 3-fold higher plasma levels of 
diflomotecan than did patients with wild-type alleles suggesting that 
interindividual variability in substrate drug effects might be influenced, in part, 
by ABCG2 genotype.   
 
The results of the present study however failed to show any influence of the 
c.421C>A polymorphism on pharmacokinetics of doxorubicin and 
doxorubicinol in Asian breast cancer patients. It is possible that the multiplicity 
of transporters involved in the transport of doxorubicin across membranes 
may mask the contribution if any, of the ABCG2 c.421C>A polymorphism.  
The higher contribution of ABCG2 to the hepatobiliary excretion of 
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nitrofurantoin compared to other substrates such as topotecan has been 
attributed to the fact that nitrofurantoin is not an ABCB1 substrate.(220,381) 
Further studies are therefore required to identify mechanisms behind the 
observed disparate pharmacokinetic modulation of drugs such as doxorubicin 
that have similar substrate specificities for ABCB1 and ABCG2 
transporters.(382)  
 
The localization and expression of ABCG2 in tissues including canalicular 
membrane of hepatocytes and apical membrane of small intestine and colon 
epithelial cells(383,384) suggests that the physiologic role of ABCG2 may 
include regulation of intestinal absorption and biliary secretion of potentially 
toxic xenobiotics by active transport mechanisms.(221,385) Reduced hepatic 
expression levels of ABCG2 might hence reduce hepatic elimination of 
ABCG2 substrates such as doxorubicin, increasing its systemic levels. The 
ABCG2 c.421C>A polymorphism has earlier been associated with reduced 
protein expression.(225) Studies by Kobayashi et al(229) indicated that the 
c.421C>A variant may affect the placental expression of ABCG2, the 
expression being significantly lower in homozygotes for the c.421A allele than 
those for the c.421C allele. Several factors including endogenous regulatory 
mechanisms of ABCG2 expression include estrogen response elements 
(EREs)(386) and hypoxia-inducible transcription factor complex (HIF-1)(387) are 
known to influence ABCG2 expression and could have contributed to the 
variability in ABCG2 hepatic expression levels in the present study. However, 
no significant influence of the c.421C>A polymorphism on hepatic ABCG2 
expression levels were observed.   
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3.5.3 ATP binding cassette, subfamily C5 (ABCC5) 
 
3.5.3.1 ABCC5 Pharmacogenetics  
 
The genotype and allele frequency of the ABCC5 polymorphisms in Asian 
breast cancer patients are shown in Table 3.14. Seventeen polymorphisms 
[5’-UTR: g.-1990G>A,g.-1821T>C, g.-1679T>A, g.-1205C>T, g.-793C>A, g.-
889T>C; intron 5: i.374C>T; exon 8: c.1145A>G; exon 9: c.1185T>C; exon 
12: c.1782T>C; intron 1: i.1834C>T; intron 2: i.7980C>T; exon 25: 
c.3624C>T; exon 30: c.4896G>A, c.5557A>G and 3’-UTR g.+6272A>G, 
g.+7161G>A] were examined for their influence on doxorubicin disposition in 
the Asian breast cancer patients. These ABCC5 polymorphisms were earlier 
identified as haplotype tagged polymorphisms in the three Asian ethnic 
groups (Chinese, Malay, Indians) in Singapore population.(259) Fisher’s exact 
tests validated that all the ABCC5 genotype frequencies conformed to Hardy-
Weinberg equilibrium and the allelic frequency of the ABCC5 polymorphisms 
among Asian breast cancer patients were in agreement with the previously 
published reports in Asian healthy populations.(259) 
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Table 3.14 Genotype and allele frequencies of ABCC5 polymorphisms in 
Asian breast cancer patients. 
 
 
N: number of subjects 
 
Polymorphisms Location Genotypes, N (%) Allele frequencies 
g.-1990G>A 5’-UTR GG GA AA G A 
  40 (64.5) 21 (33.9) 1 (1.6) 0.81 0.19 
g.-1821T>C 5’-UTR TT TC CC T C 
  40 (64.5) 21 (33.9) 1 (1.6) 0.81 0.19 
g.-1679T>A 5’-UTR TT TA AA T A 
  27 (43.5) 35 (56.5) 0 0.72 0.28 
g.-1205C>T 5’-UTR CC CT TT C T 
  8 (12.9) 26 (41.9) 28 (45.2) 0.66 0.26 
g.-889T>C 5’-UTR TT TC CC T C 
  60 (96.8) 2  (3.2) 0 0.98 0.02 
g.-793C>A 5’-UTR CC CA AA C A 
  27 (43.5) 34 (54.8) 1  (1.6) 0.71 0.29 
i.374C>T Intron 5 CC CT TT C T 
  26 (41.9) 26 (41.9) 10 (16.1) 0.63 0.37 
c.1145A>G Exon 8 AA AG GG A G 
  27 (44.3) 27 (44.3) 7 (11.5) 0.66 0.37 
c.1185T>C Exon 9 TT TC CC T C 
  12 (19.4) 5  (8.1) 45  (72.6) 0.23 0.77 
c.1782T>C Exon 12 TT TC CC T C 
  5  (8.5) 16  (27.1) 38 (45.8) 0.22 0.78 
i.1834C>T Intron 1 CC CT TT C T 
  35 (56.5) 22 (35.5) 5  (8.1) 0.74 0.26 
i.7980C>T Intron 2 CC CT TT C T 
  26 (41.9) 35 (56.5) 1  (1.6) 0.70 0.30 
c.3624C>T Exon 25 CC CT TT C T 
  30 (50.8) 25 (42.4) 4  (6.8) 0.72 0.28 
c.4896G>A Exon 30 GG GA AA G A 
  24 (38.7) 27 (43.5) 11 (17.7) 0.60 0.40 
c.5557A>G Exon 30 AA AG GG A G 
  24 (38.7) 27 (43.5) 11 (17.7) 0.60 0.40 
g.+6272A>G 3’-UTR AA AG GG A G 
  11 (17.7) 28 (45.2) 23 (37.0) 0.40 0.60 
g.+7161G>A 3’-UTR GG GA AA G A 
  32 (51.6) 23 (37.1) 7  (11.3) 0.70 0.30 
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3.5.3.2 Pharmacokinetic-Pharmacogenetic Associations 
 
The influence of ABCC5 polymorphisms on the pharmacokinetic parameters 
of doxorubicin in Asian breast cancer patients are summarized in Table 3.15. 
A significant correlation was observed between ABCC5 g.+7161G>A 
polymorphism and doxorubicin pharmacokinetic parameter. Breast cancer 
patients homozygous for the variant g.+7161A allele had significantly higher 
clearance of doxorubicin [CL/BSA (Lh-1m-2), median: 30.34; range: 25.41-
33.60] when compared to the patients who were homozygous for the 
g.+7161A allele [CL/BSA (Lh-1m-2), median: 22.46; range: 15.04-49.4, P = 
0.04]. With regards to the influence of ABCC5 polymorphisms on the 
pharmacokinetics of doxorubicinol, breast cancer patients homozygous for 
the g.-1679T allele had significantly higher exposure levels of doxorubicinol 
[AUC0-∞/dose/BSA (hm-5), median: 15.48; range: 6.18-67.17] when compared 
to the patients who were heterozygous for the polymorphism [AUC0-
∞/dose/BSA (hm-5), median: 8.88; range: 3.68-21.71, P = 0.0001]. No 
significant influences of other ABCC5 polymorphisms on doxorubicin and 
doxorubicinol pharmacokinetics were observed in the present study. 
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Table 3.15 The influence of ABCC5 polymorphisms on pharmacokinetics of doxorubicin and doxorubicinol in Asian 


























       N; number of subjects. Values expressed in median (range). * P < 0.05 considered statistically significant.
Pharmacokinetic 
parameters   ABCC5 genotypes   Pairwise P values*  
g.-1990G>A  GG (N=35) GA (N=17) AA (N=0)  GG vs GA   
Doxorubicin         
AUC0-∞/dose/BSA (hm-5) 17.03 (7.12-67.17) 17.59 (6.18-38.03)   0.86   
Cmax/dose/BSA (m-5)      34.79 (7.0-97.7) 31.08 (4.55-77.67)   0.73   
CL/BSA (Lh-1m-2) 22.53 (8.68-55.67) 23.67 (15.04-49.40)   0.77   
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5) 9.63 (3.68-24.34) 9.53 (5.59-21.71)   0.66   
Cmax/dose/BSA (m-5) 0.33 (0.16-2.0) 0.39 (0.15-1.49)   0.51   
g.-1821T>C  TT (N=35) TC (N=17) CC (N=0)  TT vs TC   
Doxorubicin         
AUC0-∞/dose/BSA (hm-5) 17.03 (7.12-67.17) 17.59 (6.18-38.03)   0.86   
Cmax/dose/BSA (m-5)      34.79 (7.0-97.7) 31.08 (4.55-77.67)   0.73   
CL/BSA (Lh-1m-2) 22.53 (8.68-55.67)  23.67 (15.04-49.40)   0.77   
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5) 9.63 (3.68-24.34) 9.53 (5.59-21.71)   0.66   
Cmax/dose/BSA (m-5) 0.33 (0.16-2.0) 0.39 (0.15-1.49)   0.51   
g.-1679T>A  TT (N=26) TA (N=26) AA (N=0)  TT vs TA   
Doxorubicin         
AUC0-∞/dose/BSA (hm-5) 19.78 (9.04-31.63) 15.48 (6.18-67.17)   0.17   
Cmax/dose/BSA (m-5) 41.28 (10.90-97.70) 29.06 (4.55-77.67)   0.23   
CL/BSA (Lh-1m-2) 22.34 (13.80-55.66) 24.52 (8.68-49.40)   0.47   
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5) 15.48 (6.18-67.17) 8.88 (3.68-21.71)   0.0001   
Cmax/dose/BSA (m-5) 0.33 (0.15-2.00) 0.37 (0.18-0.79)   0.38   
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parameters   ABCC5 genotypes   Pairwise P values* 
g.-1205C>T  CC (N=6) CT (N=22) TT (N=24)  CC vs TT CC vs CT CT vs TT
Doxorubicin         
AUC0-∞/dose/BSA (hm-5)     19.78 (8.2-22.62) 18.76 (6.18-38.03) 16.54 (7.12-67.17)  0.94 0.84 0.58 
Cmax/dose/BSA (m-5) 32.03 (23.25-57.96) 33.97 (4.55-81.22)       35.79 (7.0-97.7)  0.89 0.89 0.84 
CL/BSA (Lh-1m-2) 20.91 (19.57-40.75)   23.67 (13.80-55.66) 24.22 (8.68-36.94)  0.55 0.48 0.89 
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5) 11.62 (6.06-16.79) 10.40 (5.59-20.63) 9.31 (3.68-24.34)  0.42 0.79 0.44 
Cmax/dose/BSA (m-5) 0.39 (0.26-1.49) 0.33 (0.18-2.0)        0.33 (0.15-1.09)  0.39 0.59 0.85 
g.-889T>C  TT (N=50) TC (N=2) CC (N=0)     
Doxorubicin         
AUC0-∞/dose/BSA (hm-5)  17.48 (6.18-67.17) 16.45 (12.06-20.84)      
Cmax/dose/BSA (m-5) 34.01 (4.55-97.7) 45.60 (22.23-68.97)      
CL/BSA (Lh-1m-2)  22.90 (8.68-55.66) 22.90 (21.04, 24.77)      
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5) 9.61 (3.68-24.34) 10.67 (10.55-10.78)      
Cmax/dose/BSA (m-5) 0.33 (0.15-1.45) 1.16 (0.32-2.00)      
g.-793C>A  CC (N=24) CA (N=28) AA (N=0)  CC  vs CA   
Doxorubicin         
AUC0-∞/dose/BSA (hm-5) 19.78 (7.12-67.17) 16.91 (6.18-38.03)   0.40   
Cmax/dose/BSA (m-5)       36.50 (7.0-97.7) 25.78 (4.55-80.72)   0.23   
CL/BSA (Lh-1m-2) 21.83 (8.68-55.66) 24.85 (13.80-49.40)   0.26   
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5) 9.473 (3.68-21.71) 10.44 (5.41-24.34)   0.31   
Cmax/dose/BSA (m-5) 0.37 (0.18-2.0) 0.33 (0.15-0.79)   0.24   
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               N: Number or subjects. Values expressed in median (range). * P < 0.05 considered statistically significant 
Pharmacokinetic 
parameters   ABCC5 genotypes   Pairwise P values*  
i.374C>T  CC (N=20) CT (N=21) TT (N=8)  CC vs TT CC vs CT CT vs TT
Doxorubicin         
AUC0-∞/dose/BSA (hm-5) 19.87 (11.17-67.17) 15.44 (7.12-31.63) 17.78 (9.03-29.33)  0.53 0.98 0.83 
Cmax/dose/BSA (m-5) 41.59 (4.55-81.22) 28.21 (7.0-80.72) 30.63 (13.57-97.70)  0.29 0.07 0.79 
CL/BSA (Lh-1m-2) 22.39 (8.68-49.40) 22.20 (13.80-40.75) 23.67 (18.22-55.66)  0.64 0.71 0.86 
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5) 10.92 (5.59-24.34) 9.15 (3.68-20.63) 8.68 (6.48-15.62)  0.46 0.16 0.98 
Cmax/dose/BSA (m-5) 0.39 (0.15-2.0) 0.30 (0.16-0.59) 0.39 (0.22-1.09)  0.91 0.33 0.11 
c.1145A>G  AA (N=23) AG (N=19) GG (N=6)  AA vs GG AA vs AG AG vs GG
Doxorubicin         
AUC0-∞/dose/BSA (hm-5) 18.46 (8.2-31.63) 17.08 (6.18-67.17) 14.79 (9.03-29.33)  0.44 0.88 0.42 
Cmax/dose/BSA (m-5)      33.24 (14.52-77.36) 35.50 (4.55-81.22) 31.25 (12.80-97.70)  0.69 0.56 0.80 
CL/BSA (Lh-1m-2)      24.07 (15.04-40.86) 21.98 (8.68-49.40) 28.60 (21.04-55.66)  0.17 0.47 0.11 
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5) 9.76 (6.06-18.71) 9.61 (3.68-21.71) 10.01 (6.79-24.34)  0.73 0.59 0.55 
Cmax/dose/BSA (m-5) 0.29 (0.15-0.73) 0.39 (0.16-1.45) 0.41 (0.29-2.00)  0.71 0.06 0.48 
c.1185T>C 
  TT (N=10) TC (N=3) CC (N=39)  TT  vs CC TT  vs TC TC vs CC
Doxorubicin         
AUC0-∞/dose/BSA (hm-5) 13.97 (7.12-27.87) 22.43 (13.83-25.82) 18.46 (6.18-67.17)  0.19 0.22 0.69 
Cmax/dose/BSA (m-5) 24.23 (7.00-81.22) 52.70 (36.21-61.45) 36.78 (4.55-97.7)  0.21 1.61 0.24 
CL/BSA (Lh-1m-2) 28.89 (17.31-40.86) 21.21 (17.92-26.55) 22.53 (8.68-55.66)  0.20 0.21 0.63 
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5) 9.02 (3.68-16.79) 9.76 (5.79-13.62) 9.92 (5.41-24.34)  0.70 1.00 0.76 
Cmax/dose/BSA (m-5) 0.38 (0.19-1.22) 0.27 (0.22-0.51) 0.33 (0.15-2.00)  0.95 0.94 0.46 
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           N: Number or subjects. Values expressed in median (range). * P < 0.05 considered statistically significant 
Pharmacokinetic 
parameters   ABCC5 genotypes   Pairwise P values* 
c.1782T>C  TT (N=4) TC (N=15) CC (N=30)  TT vs CC  TT vs TC TC vs CC
Doxorubicin         
AUC0-∞/dose/BSA (hm-5) 19.8 (15.8-26.42) 17.59 (9.82-67.17) 17.62 (6.18-30.16)  0.41 0.81 0.33 
Cmax/dose/BSA (m-5) 49.7 (34.79-68.97) 41.59 (12.80-97.70) 31.40 (4.55-81.22)  0.12 0.52 0.29 
CL/BSA (Lh-1m-2) 20.0 (18.22-21.04) 23.66 (8.68-40.86) 23.67 (13.80-55.66)  0.08 0.15 0.57 
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5) 10.51 (9.6-12.63) 9.47 (5.79-24.34) 9.63 (3.68-21.71)  0.53 0.61 0.43 
Cmax/dose/BSA (m-5) 0.45 (0.30-2.00) 0.38 (0.18-1.09) 0.33 (0.15-1.49)  0.17 0.39 0.45 
i.1834C>T  CC (N=29) CT (N=19) TT (N=4)  CC vs CT CT vs TT CC vs TT
Doxorubicin         
AUC0-∞/dose/BSA (hm-5) 20.57 (6.18-67.17) 15.89 (9.04-31.63) 13.79 (7.12-18.46)  0.38 0.21 0.10 
Cmax/dose/BSA (m-5) 40.96 (4.55-97.70) 34.79 (13.57-73.53) 19.03 (7.00-38.67)  0.54 0.13 0.10 
CL/BSA (Lh-1m-2) 22.30 (8.68-49.0) 24.07 (15.04-55.66) 27.28 (19.19-36.94)  0.75 0.72 0.60 
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5) 9.92 (5.41-24.34) 9.31 (5.79 -21.71) 8.62 (3.68-10.63)  0.74 0.37 0.21 
Cmax/dose/BSA (m-5) 0.36 (0.15-1.49) 0.32 (0.18-2.0) 0.36 (0.19-0.48)  0.26 0.84 0.53 
i.7980C>T  CC (N=24) CT (N=27) TT (N=1)  CC vs CT   
Doxorubicin         
AUC0-∞/dose/BSA (hm-5) 15.97 (6.18-31.63) 19.0 (7.12-67.17) 8.2  0.19   
Cmax/dose/BSA (m-5) 30.50 (4.55-73.53) 40.96 (7.00-97.70) 23.25   0.12   
CL/BSA (Lh-1m-2) 24.52 (15.04-55.66) 22.20 (8.68-40.86) 40.75  0.28   
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5) 8.66 (5.41-21.71) 9.92 (3.68-24.34) 6.06  0.28   
Cmax/dose/BSA (m-5) 0.32 (0.16-0.73) 0.38 (0.15-2.00) 0.26  0.25   
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parameters   ABCC5 genotypes   Pairwise P values* 
c.3624C>T  CC (N=24) CT (N=22) TT (N=4)  CC vs TT  CC vs CT CT  vs TT
Doxorubicin         
AUC0-∞/dose/BSA (hm-5) 16.54 (7.12-38.03) 20.65 (9.04-67.17) 18.18 (6.18-21.96)  0.98 0.67 0.46 
Cmax/dose/BSA (m-5) 32.48 (7.00-77.67) 37.09 (10.90-97.70) 25.69 (4.55-52.29)  0.45 0.48 0.27 
CL/BSA (Lh-1m-2) 21.67 (15.04-40.86) 23.65 (8.68-55.66) 27.09 (19.71-49.40)  0.34 0.59 0.49 
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5) 10.40 (3.68-24.34) 9.31 (5.41-21.71) 9.98 (5.59-14.01)  0.86 0.50 0.91 
Cmax/dose/BSA (m-5) 0.38 (0.18-2.00) 0.31 (0.15-1.22) 0.40 (0.31-1.49)  0.58 0.37 0.17 
c.4896G>A  GG (N=19) GA (N=23) AA (N=7)  GG vs AA  GG vs GA GA vs AA
Doxorubicin         
AUC0-∞/dose/BSA (hm
-5) 15.85 (7.12-31.63) 19 (8.2-67.17) 16.79 (6.18-20.74)  0.76 0.14 0.13 
Cmax/dose/BSA (m-5) 32.93 (7.00-80.72) 37.98 (10.42-97.70) 28.21 (4.55-42.38)  0.53 0.39 0.16 
CL/BSA (Lh-1m-2) 23.03 (13.80-55.66) 22.20 (8.68-40.75) 24.07 (21.57-49.40)  0.54 0.59 0.59 
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5) 9.61 (3.68-18.71) 9.47 (5.79 -21.71) 11.28 (5.59-24.34)  0.33 0.49 1.00 
Cmax/dose/BSA (m-5) 0.31 (0.15-2.00) 0.39 (0.22-1.22) 0.31 (0.22-0.59)  0.64 0.04 0.24 
c.5557A>G  AA (N=19) AG (N=23) GG (N=10)  AA vs GG AG vs GG AA vs AG
Doxorubicin         
AUC0-∞/dose/BSA (hm-5) 20.57 (6.18-29.33) 16.79 (9.81-67.17) 16.54 (712-38.03)  0.69 0.98 0.54 
Cmax/dose/BSA (m-5) 37.98 (4.55-97.70) 27.76 (10.42-81.22) 36.33 (7.00-80.72)  0.80 0.52 0.22 
CL/BSA (Lh-1m-2) 22.20 (17.92-49.40) 24.77 (8.68-36.80) 23.90 (13.80-55.66)     
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5) 9.61 (6.06-15.20) 9.76 (3.68-24.34) 9.92 (5.59-20.63)  0.81 0.96 0.81 
Cmax/dose/BSA (m-5) 0.39 (0.15-2.00) 0.31 (0.16-0.76) 0.48 (0.28-0.79)  0.65 0.04 0.14 
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parameters   ABCC5 genotypes   Pairwise P values* 
g.6272A>G  AA (N=9) AG (N=23) GG (N=20)  AA vs GG AG vs GG AA vs AG
Doxorubicin         
AUC0-∞/dose/BSA (hm-5) 20.57 (6.18-38.03) 17.59 (7.12-67.17) 17.08 (8.2-30.16)  0.87 0.93 0.71 
Cmax/dose/BSA (m-5) 31.72 (4.55-77.67) 36.21 (7.00-73.53)   33.91 (12.57-97.70)  0.72 0.35 0.89 
CL/BSA (Lh-1m-2) 21.77 (17.38-55.66) 25.41 (8.68-36.94)   22.90 (13.80-40.86)  0.52 0.77 0.86 
Doxorubicinol         
AUC0-∞/dose/BSA (hm
-5) 10.40 (5.41-20.63) 9.02 (3.68-24.34) 9.61 (6.06-21.71)  0.72 0.86 0.83 
Cmax/dose/BSA (m-5) 0.44 (0.16-1.09) 0.33 (0.15-2.00) 0.33 (0.18-1.49)  0.23 0.64 0.43 
g.7161G>A  GG (N=28) GA (N=19) AA (N=5)  GG vs AA GG vs GA GA vs AA
Doxorubicin         
AUC0-∞/dose/BSA (hm
-5) 18.30 (6.18-38.03) 18.46 (7.12-67.17) 15.89 (9.82-18.76)  0.24 0.91 0.26 
Cmax/dose/BSA (m-5) 34.01 (4.55-97.70) 38.67 (7.00-80.72) 20.91 (10.42-41.59)  0.67 0.99 0.65 
CL/BSA (Lh-1m-2) 22.46 (15.04-49.4) 21.57 (8.68-55.66) 30.34 (25.41-33.60)  0.04 0.53 0.06 
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5) 9.61 (5.79-21.71) 9.84 (5.41-24.34) 8.43 (3.68-20.63)  0.33 0.39 0.66 
Cmax/dose/BSA (m-5) 0.39 (0.15-1.22) 0.33 (0.16-2.00) 0.31 (0.19-0.76)  0.32 0.91 0.53 
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3.5.3.3 ABCC5 Hepatic Expression 
 
Polymorphisms in gene encoding ABCC5 could also potentially alter its 
expression and activity, influencing disposition of its drug substrates such as 
doxorubicin. The genotype and allele frequencies of the ABCC5 polymorphisms 
in Chinese healthy liver tissues investigated in the present study were in 
accordance to their frequency in the local population. High degree of inter-
individual variability in the ABCC5 expression levels was observed (CV = 
156.7%, Figure 3.13). Analysis of relative ABCC5 expression levels with respect 
to ABCC5 genotypes showed no significant influence of ABCC5 polymorphisms 


















Fig 3.13 Inter-individual variability in ABCC5 expression in Chinese healthy 
















Table 3.16 ABCC5 genotype and allele frequencies in Chinese healthy liver tissues 




Polymorphisms Genotypes N (%) RQ; (mean ± SD) 
 
P value 
g.-1990G>A GG 25 (62.5) 19.67 ± 30.36 GG vs GA GG vs AA GA vs AA 
 GA    12 (30) 19.98 ± 27.8 0.81 0.05 0.13 
 AA 3 (7.5) 1.67 ± 0.86    
g.-1821T>C TT 25 (83.3) 19.67 ± 30.36 TT vs TC TT vs CC TC vs CC 
 TC  5 (16.7) 16.31 ± 25.79 0.56   
 CC     0     
g.-1679T>A TT 21 (52.5) 19.72 ± 30.75 TT vs TA TT vs AA TA vs AA 
 TA    18 (45) 17.38 ± 27.10 0.64   
 AA 1 (2.5) 9.5    
g.-1205C>T CC 1 (2.7) 36.28 CC vs CT CC vs TT CT vs TT 
 CT 20 (51.3) 14.78 ± 25.56   0.55 
 TT 18 (46.2) 22.32 ± 32.56    
g.-889T>C TT      0  TT vs TC TT vs CC TC vs CC 
 TC      0     
 CC 40 (100) 18.41 ± 28.44    
g.-793C>A CC 21 (51.3) 19.72 ± 30.75 CC vs CA CC vs AA CA vs AA 
 CA    18 (45) 17.38 ± 27.10 0.64   
 AA 1 (2.5) 9.5    
i.374C>T CC 14 (35.9) 23.11 ± 29.67 CC vs CT CC vs TT CT vs TT 
 CT 16 (41.0) 9.5 ± 14.96 0.39 0.51 0.89 
 TT   9 (23.1) 19.22 ± 35.92    
c.1145A>G AA    18 (50) 31.80 ± 43.53 AA vs AG AA vs GG AG vs GG
 AG 12 (33.3) 10.59 ± 15.08 0.59 0.88 0.69 
 GG 6 (16.7) 27.33 ± 36.86    
c.1185T>C TT 13 (32.5) 21.31 ± 35.30 TT vs TC TT vs CC TC vs CC 
 TC 17 (42.5) 11.42 ± 15.46 0.69 0.69 0.77 
 CC    10 (25) 31.80 ± 43.53    
c.1782T>C TT 11 (28.9) 31.80 ± 43.53 TT vs TC TT vs CC TC vs CC 
 TC 15 (39.5) 10.59 ± 15.08 0.59 0.88 0.69 
 CC 12 (31.6) 27.33 ± 36.86    
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Table 3.16 ABCC5 genotype and allele frequencies in Chinese healthy liver tissues 
and influence on ABCC5 mRNA levels. (Contd)  
 
N; no of subjects. Values expressed as mean ± SD. RQ : Relative Quotient. *P < 0.05 




Polymorphisms Genotypes N (%) RQ; (mean ± SD) Pairwise P values* 
i.1834C>T CC 30 (76.9) 17.87 ± 28.97 CC vs CT CC vs TT CT vs TT 
 CT 8 (20.5) 13.70 ± 16.68 0.84   
 TT 1 (2.6) 2.87    
i.7980C>T CC 18 (78.3) 19.99 ± 32.87 CC vs CT CC vs TT CT vs TT 
 CT 4 (17.4) 14.13 ± 29.50 0.31   
 TT 1 (4.3) 9.50    
c.3624C>T CC 14 (35.9) 23.11 ± 29.67 CC vs CT CC vs TT CT vs TT 
 CT 16 (41) 9.5 ± 14.96    
 TT  9 (23.1) 19.22 ± 35.92    
c.4896G>A GG  8 (21.6) 30.25 ± 44.49 GG vs GA GG vs AA GA vs AA 
 GA 21 (57.8) 7.62 ± 8.93 0.86 0.88 0.68 
 AA  8 (21.6) 27.33 ± 36.86    
c.5557A>G AA  8 (19.5) 31.80 ± 43.53 AA vs AG AA vs GG AG vs GG 
 AG 25 (60.9) 10.59 ± 15.08 0.59 0.88 0.69 
 GG  8 (19.5) 27.33 ± 36.86    
g.+6272A>G AA  7 (18.4) 21.31 ± 35.30 AA vs AG AA vs GG AG vs GG 
 AG 23 (60.5) 11.42 ± 15.46 0.69 0.69 0.77 
 GG 8 (21.1) 31.80 ± 43.53    
g.+7161G>A GG 27 (71.1) 20.40 ± 31.36 GG vs GA GG vs AA GA vs AA 
 GA 11 (28.9) 10.50 ± 15 0.38   




Polymorphisms within the ubiquitously expressed ABCC5 efflux transporter could 
influence the pharmacokinetics and pharmacodynamics of its identified drug 
substrates that include nucleotide analogues, thiopurines and doxorubicin.(255) 
There have been no functional studies to date that have examined the influence 
of coding or regulatory ABCC5 gene polymorphisms on the disposition of 
doxorubicin. Earlier studies to facilitate identification of causal genetic variations 
in association studies have identified haplotype tagged polymorphisms in the 
ABCC5 gene.(259) Among the 24 polymorphisms used to characterize the 
haplotype and linkage disequilibrium profile across approximately 100 kb of the 
ABCC5 gene in the Caucasian, Chinese, Malay, Indian and African-American 
populations, 17 high frequency polymorphisms were identified as tagged 
polymorphisms for the analyzing genotype–phenotype correlations in Asian 
breast cancer patients in the present study. The allele and genotype frequencies 
of ABCC5 polymorphisms in the Asian breast cancer patients corresponded to 
the frequency among the population they were recruited from.   
 
The ABCC5 3’-UTR g.+7161G>A polymorphism was found to significantly 
influence the clearance of doxorubicin in Asian breast cancer patients with 
approximately 35% higher clearance of doxorubicin observed in patients who 
were homozygous for the variant allele. It is not known if the higher clearance 
and lower exposure levels of doxorubicin observed in patients carrying the 3’-
UTR g.+7161G>A polymorphism are associated with altered pharmacodynamic 
outcome and requires further investigations in future studies. It is interesting to 
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note that the ABCC5 gene is highly expressed in the myocardial tissue, including 
endothelial and smooth muscle cells where it plays a crucial role in the efflux 
transport of the second messenger 3’,5’-cyclic GMP (cGMP).(249). The latter 
functions as a second messenger of nitric oxide and play a vital role in regulation 
of smooth muscle tone(388,389) cardiac contractility(390,391) and cardiomyocyte 
hypertrophy(392,393). Recent reports have indicated that the 3’-UTR regions have 
several cis-acting binding sites for various transcription factors and mutations in 
these region have been associated with alterations in protein expression and 
disease phenotypes.(394,395) Breast cancer patients homozygous for the g.-1679T 
allele had significantly higher exposure levels of doxorubicinol when compared to 
the patients who were heterozygous for the polymorphism. However, the reasons 
for the lack of influence of the g.-1679T>A polymorphism on doxorubicin 
pharmacokinetic parameters are unknown and could possibly be due to the 
smaller cohort of breast cancer patients studied.  
 
A lack of significant influence of the g.-1679T>A and g.+7161G>A 
polymorphisms were observed in relation to the hepatic ABCC5 expression 
levels. There was also no significant association of other ABCC5 polymorphisms 
on the hepatic ABCC5 mRNA   levels. The interindividual variability in ABCC5 
expression levels was high, with a subset of patients expressing significantly 
higher ABCC5 levels compared to the rest of the study subjects. Apart from other 
potential regulatory mechanisms, this could also be due to the presence of 
different ABCC5 isoforms. In a report by Moustafa et al(396) which examined 
hepatic ABC transporter gene expression levels, ABCC5 transcripts were not 
detected in cancerous and non-cancerous portions of liver from patients with 
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hepatocellular carcinoma.  However, studies by Suzuki et al(397) detected 
expression of ABCC5 isoforms in human tissues including kidney, lung and the 
liver, suggesting that specific isoforms of ABCC5 may have tissue specific 
expression. There have been relatively few studies to date that have examined 
ABCC5 mRNA expression in relation to polymorphisms in the ABCC5 gene. 
Dazert et al(249) analysed the expression and localization of ABCC5 in human 
heart, by real time PCR and immunohistochemistry techniques in relation to the 
polymorphisms identified across the ABCC5 gene and observed no significant 
genotype-phenotype correlations were observed. Apart from the possibiltity of 
detection of specific ABCC5 isoforms during RT-PCR, the possible existence of 
other potential regulatory mechanisms that influence ABCC5 expression may 
also help explain the observation of high inter-individual variability in hepatic 
mRNA expression of ABCC5 observed in the present study.  
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3.5.4 ATP binding cassette, subfamily B5 (ABCB5) 
 
3.5.4.1 ABCB5 Pharmacogenetics  
 
Three novel polymorphisms were identified by direct sequencing of the coding 
regions of ABCB5 gene (Table 3.17). All polymorphisms were non-synonymous 
transitions: c.2T>C (exon 1), c.343A>G (exon 2) and c.1573G>A (exon 12) 
polymorphisms resulting in the p.M1T, p.K115E and p.E525K amino acid 
changes, respectively. The locations of amino acid substitutions were assigned 
using Genbank sequence BC104920 as reference.   
 
The genotype and allele frequencies of the three novel ABCB5 polymorphisms 
identified in the Asian ethnic groups and the breast cancer patients are listed in 
Table 3.18. There were no significant deviations from Hardy-Weinberg 
equilibrium in the genotype frequencies in both healthy subjects and cancer 
patients.  The genotypic frequency of the heterozygous c.2T>C polymorphism 
was almost two-fold higher in the healthy Indian (23%) population compared 
with the Chinese (8%) and Malay (10%) populations. The frequency of the c.2C 
variant allele were also significantly higher among Indians (0.12) when 
compared to Chinese (0.05, P = 0.007) and Malays (0.04, P = 0.026). The allele 
frequency distribution of c.343A>G and c.1573G>A polymorphism did not differ 
significantly between healthy ethnic groups. Among cancer patients, the allele 
frequency of the c.343A>G variant allele was found to be significantly lower 
(0.05) when compared to the healthy Chinese subjects (0.14). The genotype 
and allele frequencies of the c.2T>C and c.1573G>A polymorphisms among 
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cancer patients conformed to the frequency found among the local population 
from which they were recruited.  
 
Table 3.17 ABCB5 exon polymorphisms. 
 
 
Polymorphisms Location Amino acid substitution Flanking seq (5’- 3’) 
c.2T>C    Exon 1    Methionine → Threonine (p.M1T) agatcat/cggtgga 
c.343A>G    Exon 2    Lysine → Glutamic acid (p.K115E) aaagca/gagtcag 





Table 3.18 Genotype and allele frequency of ABCB5 polymorphisms in healthy 




    
   N: number of subjects 
 
Populations N Genotype frequencies, N (%)  Allele frequencies 
c.2T>C  TT TC CC  T C 
Healthy subjects        
 Chinese 100     92 (92)       8 (8) 0 (0)  0.96 0.04 
 Malays 100     90 (90)     10 (10) 0 (0)  0.95 0.05 
 Indians 100     77 (77)     23 (23) 0 (0)  0.89 0.12 
Asian cancer patients 62  58 (93.5)       4 (6.5) 0 (0)  0.97 0.03 
c.343A>G  AA AG GG  A G 
Healthy Subjects        
 Chinese 100 77 (77.8) 17 (17.1)    5 (5.1)  0.86 0.14 
 Malays 100 67 (70.5) 22 (23.2)    5 (5.3)  0.83 0.17 
 Indians 100     80 (80)      17 (17) 3 (3)  0.89 0.11 
Asian cancer patients  62 57 (91.9) 4 (6.5)    1 (1.6)  0.95 0.05 
c.1573G>A  GG GA AA  G A 
Healthy Subjects        
 Chinese 100     20 (20)        2 (2) 78 (78)  0.21 0.79 
 Malays 100 17 (17.3) 16 (16.3)    65 (66.3)  0.26 0.74 
 Indians 100     22 (22)      12 (12) 66 (66)  0.28 0.72 
Asian cancer patients   62 2 (3.2) 12 (19.4)    48 (77.4)  0.13 0.87 
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3.5.4.2 Pharmacokinetic-Pharmacogenetic Associations 
 
The influence of ABCB5 c.2T>C, c.343A>G, and c.1573G>A polymorphisms 
on the pharmacokinetic parameters of doxorubicin and doxorubicinol are 
depicted in Table 3.19.  Pairwise comparisons failed to show any significant 
influences of the ABCB5 polymorphisms on the pharmacokinetic parameters 
of doxorubicin and doxorubicinol. 
 
Table 3.19 The influence of ABCB5 polymorphisms on pharmacokinetics of 
doxorubicin and doxorubicinol in Asian breast cancer patients.  
 
 
N: number of subjects. Values expressed in median (range). *P < 0.05 considered 
statistically significant 
Pharmacokinetic 
parameters  ABCB5 genotypes  
Pairwise P 
values* 
c.2T>C TT (N=50) TC (N=2) CC (N=0)  
Doxorubicin     
AUC0-∞/dose/BSA (hm-5) 17.48 (6.18-67.17) 11.17-20.84   
Cmax/dose/BSA (m-5) 34.01 (4.55-97.70) 23.35-68.97   
CL/BSA (Lh-1m-2) 22.90 (8.68-55.66) 21.04-36.80   
Doxorubicinol     
AUC0-∞/dose/BSA (hm-5) 9.63 (3.68-24.34) 9.01 (7.45-10.55)   
Cmax/dose/BSA (m-5) 0.33 (0.16-1.49) 0.15-2.00   
c.346A>G AA (N=42) AG (N=9) GG (N=1) AA vs AG 
Doxorubicin     
AUC0-∞/dose/BSA (hm-5) 18.02 (7.12-67.17) 17.36 (6.18-27.66) 17.03 0.32 
Cmax/dose/BSA (m-5) 35.50 (7.00-97.70) 23.35 (4.55-52.70) 41.59 0.10 
CL/BSA (Lh-1m-2) 22.34 (8.68-55.66) 24.07 (18.22-49.40) 25.41 0.44 
Doxorubicinol     
AUC0-∞/dose/BSA (hm-5) 9.78 (3.68-21.71) 8.32 (5.59-14.01) 24.34 0.34 
Cmax/dose/BSA (m-5) 0.35 (0.16-2.00) 0.28 (0.15-0.54) 0.49 0.11 
c.1573A>G AA (N=39) AG (N=11) GG (N=2) AA vs AG 
Doxorubicin     
AUC0-∞/dose/BSA (hm-5) 18.76 (7.12-67.17) 13.21 (8.20-23.64) 6.18-14.26 0.08 
Cmax/dose/BSA (m-5) 36.78 (7.00-97.70) 23.35 (10.90-68.97) 4.55-31.08 0.27 
CL/BSA (Lh-1m-2) 22.30 (8.68-55.66) 25.41 (19.57-40.75) 22.39-49.40 0.30 
Doxorubicinol     
AUC0-∞/dose/BSA (hm-5) 9.84 (3.68-20.63) 9.01 (5.41-24.34) 5.59-7.77 0.97 




The role of ABCB5 in mediating drug resistance and their precise role in drug 
transport are still under investigation. Relatively few studies have been 
carried out to date to elucidate the mechanistic basis of potential ABCB5 
mediated doxorubicin reistance in melanomal cells. In a study by Frank et 
al,(241) a distinct subpopulation (7.2%) of ABCB5 expressing human G3361 
malignant melanoma cells were found to exhibit high doxorubicin uptake on 
drug incubation. When ABCB5 expression and doxorubicin content were 
assayed concurrently, it was found that 80% of ABCB5 expressing tumor cells 
exhibited the phenotype associated with high intake of doxorubicin. In 
contrast, neither the doxorubicin high nor doxorubicin low G3361 melanoma 
cells expressed ABCB1. The ABCB5 positive cells accumulated significantly 
less doxorubicin (up to 52% reduced accumulation at 24 hours) during all 
exposure times tested compared with ABCB5  negative melanoma cells,(241) 
suggesting a significant ABCB5 mediated efflux transport activity.  
 
Screening the coding regions of ABCB5 gene in 300 healthy subjects of 
distinct ethnic groups identified three novel non-synonymous polymorphisms 
[c.2T>C (exon 1), c.343G>A (exon 2) and c.1573A>G (exon 12)]. Differences 
in allele and genotype frequencies of ABCB5 polymorphisms suggest that 
pharmacogenetic-based analysis of ABCB5 could provide additional insights 
into the mechanisms affecting inter-ethnic and inter-individual variations in the 
pharmacokinetics and pharmacodynamics of its drug substrates. The present 
study is the first to analyze the influence of ABCB5 genetic variants on the 
pharmacokinetics of doxorubicin and doxorubicinol in cancer patients on 
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adjuvant chemotherapy. Although differences in allele and genotype 
frequencies of ABCB5 polymorphisms among the Asian ethnic groups were 
observed, pharmacogenetic analysis of ABCB5 revealed lack of significant 
association between the identified ABCB5 polymorphisms and doxorubicin 
pharmacokinetics in Asian breast cancer patients. However, several studies 
have shown that both intronic and promoter region polymorphisms could 
potentially influence gene expression and activity(394,398) and identifying the 
presence of ABCB5 intronic and promoter variants in different population 
groups could therefore be important in elucidating their influence if any, on the 
pharmacokinetics and pharmacodynamics of doxorubicin.  
 
There is limited information on the pattern of ABCB5 expression in human 
tissues. Screening a melanoma cDNA library and investigating the expression 
pattern of ABCB5 identified two ABCB5a and ABCB5b mRNA isoforms, and 
were shown to be preferentially expressed in melanomas and in other 
pigmented cells.(240) However, examination of healthy liver tissues by RT-PCR 
failed to detect ABCB5 mRNA expression in the present study.  
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3.5.5 Ral-Binding Protein 1; RALBP1 (RLIP76) 
 
3.5.5.1 RLIP76 Pharmacogenetics  
 
The present study screened for polymorphisms in the exonic regions of the 
RLIP76 gene in the three healthy Asian ethnic groups (Chinese, Malays and 
Indians). No polymorphisms were identified in the coding regions suggesting 
a lack of genetic variability in the RLIP76 gene in the Asian ethnic groups.  
 
3.5.5.2 RLIP76 Hepatic Expression 
 
Studies have shown that RLIP76 is ubiquitously expressed in human tissues 
including erythrocytes, lung, muscle, kidney, and liver(275,399)where the protein 
has been localized to the plasma membrane and cytoplasm.(270) Hepatic 
expression levels of RLIP76 was observed to have a high degree of inter-














Fig 3.14 Inter-individual variability in RLIP76 expression in Chinese healthy 























Increased efflux of doxorubicin from multidrug resistant cells that do not 
overexpress ABCB1 has been demonstrated,(400,401,402,403) suggesting that 
efflux mechanism(s) distinct from ABCB1 may be involved in the cellular 
exclusion of doxorubicin. Awasthi et al(268) demonstrated that an ATP-
dependent uptake of doxorubicin by erythrocyte inside out vehicles (IOVs) 
that did not express ABCB1 was completely inhibited by antibodies to DNP-
SG ATPase, later identified as RLIP76. Since then, implications of 
mechanisms of doxorubicin transport and resistance mediated by RLIP76 has 
been investigated in several studies. Examination of the kinetic 
characterization of the doxorubicin transport indicated that the Km of the 
transporter for doxorubicin was found to be 1.7 uM, which is within the range 
of peak doxorubicin serum concentrations after conventional intravenous 
dosing of doxorubicin in humans during cancer chemotherapy.(404) 
 
The exceptionally broad substrate specificity [structurally unrelated anionic 
compounds, weakly cationic compounds (doxorubicin, dihydrodoxorubicin, 
daunomycin, and vinblastine) and uncharged compounds (doxorubicinone, 
deoxydoxorubicinone, and dihydrodoxorubicinone)] and its wide tissue 
distribution(270) indicate that RLIP76 mediated transport mechanisms may 
function as an important efflux mechanism for xenobiotics and 
endobiotics.(405) The RLIP76 mediated transport mechanism appears to be 
similar to that of ABCB1 and its related transporters not only because of its 
ability to transport doxorubicin with a relatively low Km and its wide substrate 
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specificity, but also because, similar to ABCB1, it is present in the canalicular 
membrane of hepatocytes.(271) Screening the exon and exon-intron spanning 
regions of the RLIP76 gene in health Asian ethnic groups failed to identify any 
polymorphic variations in the present study.  The present study does not 
suggest a significant contributory role for RLIP76 in mediating drug resistance 
in cancer chemotherapy in Asian breast cancer patients. It is conceivable that 
contributions from RLIP76 to variations in doxorubicin pharmacokinetics and 
pharmacodynamics may arise from rare variants in untranslated or intronic 
regions that were not detected in the present study. These genetic variations 
could also be responsible or contribute to the inter-individual variations in the 
hepatic mRNA expression levels of RLIP76 observed in the present study.  
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3.5.6 Solute carrier family, member 16 (SLC22A16) 
 
3.5.6.1 SLC22A16 Pharmacogenetics  
 
Four novel polymorphisms were identified by direct sequencing of the coding 
regions of SLC22A16 gene (Table 3.20). Three polymorphisms were non-
synonymous transitions: c.146A>G (exon 2), c.755T>C (exon 4) and 
c.1226T>C (exon 5) polymorphisms resulting in the p.H49R, p.V252A and 
p.M409T amino acid changes, respectively. The c.312T>C polymorphism was 
synonymous and was in complete linkage to the c.146A>G polymorphism. 
The locations of amino acid substitutions were assigned using Genbank 
sequence NM033125 as reference.    
 
  Table 3.20 SLC22A16 exon polymorphisms. 
 
The genotype and allele frequencies of the four novel SLC22A16 
polymorphisms identified in the Asian healthy ethnic groups and the breast 
cancer patients are listed in Table 3.21. There were no significant deviations 
from Hardy-Weinberg equilibrium in the genotype frequencies in both healthy 
subjects and cancer patients.  The genotypic frequency of the homozygous 
c.146GG polymorphism was almost two-fold higher in the healthy Chinese 
(13%) and Malay (18%) populations compared with the Indian (7%) and 
Polymorphism Amino acid substitution Flanking sequence  
(5’- 3’) 
c.146A>G      Histidine → Arginine (p.H49R) gtcacccctca/gtcatgtctg
c.312T>C      Synonymous gtagcaggaat/caagagg 
c.755T>C      Valine → Alanine (p.V252A) ttttttgcagt/ctggaaccctg
c.1226T>C      Methinonine →Threonine (p.M409T) tgcatcgccat/cggacaag 
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Caucasian (9%) populations. Genotypic frequencies were significantly 
different only between Malays and Indians (P = 0.019). The allele frequency 
distribution of c.146A>G polymorphism did not differ significantly between 
ethnic groups. The c.755T>C polymorphism in exon 4 was monomorphic in 
2% of Chinese and absent in the rest of the Asian ethnic groups and the 
Caucasian population. The genotypic frequency of the c.1226T>C 
polymorphism in exon 5 was observed to be similar in Caucasian (11%) and 
Indian (8%) study subjects and significantly higher compared to the Chinese 
(1%) and Malay (1%) ethnic groups (Chinese vs Caucasians; P < 0.001, 
Chinese vs Indians; P = 0.001, Malays vs Indians; P = 0.004, Malays vs 
Caucasians; P = 0.001). The allele frequency of all polymorphisms among 
cancer patients conformed to the frequency found among the local population 
from which they were recruited, suggesting lack of selection bias.  
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         Table 3.21 Genotype and allele frequency of SLC22A16 polymorphisms. 
 
 





3.5.6.2 Pharmacokinetic-Pharmacogenetic Associations 
 
The influence of SLCC22A16 c.146A>G, and c.755T>C polymorphisms on 
the pharmacokinetic parameters of doxorubicin and doxorubicinol are 
depicted in Table 3.22.  The c.312T>C polymorphism was in complete linkage 
Populations Location N Genotype frequencies, N (%) Allele frequencies 
c.146A>G [rs714368] Exon 2  AA AG GG A G 
Healthy subjects 
 
      
 Chinese  100 44 (44) 43 (43) 13 (13) 0.66 0.34
 Malays  100 39 (39) 43 (43) 18 (18) 0.61 0.39
 Indians  100 48 (50) 45 (45) 7 (7) 0.71 0.29
Asian cancer patients    62    24 (38.7)    33 (53.2)     5 (8.1) 0.65 0.35
c.312T>C [rs6907567] Exon 2  TT TC CC T C 
Healthy Subjects        
 Chinese  100 43 (43) 44 (44) 13 (13) 0.65 0.35
 Malays  100 39 (39) 43 (43) 18 (18) 0.61 0.39
 Indians  100 48 (48) 45 (45) 7 (7) 0.71 0.29
Asian cancer patients    62    24 (38.7)    33 (53.2)     5 (8.1) 0.65 0.35
c.755T>C [rs723685] Exon 4  TT TC CC T C 
Healthy Subjects        
 Chinese  100 88 (88) 10 (10) 2 (2) 0.93 0.07
 Malays  100 86 (86) 14 (14) 0 (0) 0.93 0.07
 Indians  100 85 (85) 15 (15) 0 (0) 0.93 0.07
Asian cancer patients    62    54 (87.1)      8 (12.9) 0 (0) 0.94 0.06
c.1226T>C [rs12210538] Exon 5  TT TC CC T C 
Healthy subjects        
 Chinese  100 99 (99) 0 (0) 1 (1) 0.99 0.01
 Malays  100 98 (98) 2 (2) 0 (0) 0.99 0.01
 Indians  100 85 (85) 14 (14) 1 (1) 0.92 0.08
Asian cancer patients    62    59 (95.2)     3 (4.8) 0 (0) 0.98 0.02
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(ID’I = 1) with the c.146A>G polymorphism and showed similar influence on 
the pharmacokinetics of doxorubicin and doxorubicinol. Breast cancer 
patients harboring the c.146GG genotype showed a trend towards higher 
exposure levels to doxorubicin compared to patients with either the reference 
genotype [GG vs. AA, AUC0-∞/dose/BSA(hm-5): 21.6; range: 18.8 to 27.7 vs 
17.4; range 8.2 to 26.3, P = 0.066] or heterozygotes [GG vs. AG, AUC0-
∞/dose/BSA(hm-5): 21.6; range: 18.8 to 27.7 vs 15.4; range 6.2 to 38.0, P = 
0.055]. The exposure levels of doxorubicinol was also higher in patients 
harboring the variant c.146GG genotype when compared to patients 
harboring the reference genotype [GG vs. AA, AUC0-∞/dose/BSA(hm-5): 13.3; 
range: 8.8 to 21.7 vs 9.8; range 6.1 to 24.3, P = 0.137]  or heterozygotes [GG 
vs. AG, AUC0-∞/dose/BSA(hm-5): 13.3; range: 8.8 to 21.7 vs 8.98; range 3.7 to 
20.6, P = 0.047]. No significant difference in exposure levels of doxorubicin 
and doxorubicinol were observed for the two patients who harbored the 
heterozygote genotype for the c.755T>C polymorphism when compared to 
the patients harboring the reference genotype. The c.1226T>C polymorphism 
was not detected in any of the cancer patients.   
 181



















* c.312T>C influence on doxorubicin and doxorubicinol pharmacokinetic parameters was similar to c.146A>G polymorphism.  









parameters Genotypes Pairwise P values 
c.146A>G*      AA  (N =17)       AG (N=21)      GG (N=5) AA vs AG AA vs GG AG vs GG 
Doxorubicin       
AUC0-∞/dose/BSA (hm-5) 17.36 (8.20 – 26.30) 15.4 (6.2 –38.0) 21.60 (18.80 – 27.70) 0.649 0.066 0.055 
t1/2 (h) 16.88 (11.80 – 24.60) 14.77 (11.3 – 20.60) 15.12 (13.20 – 19.00) 0.146 0.411 0.922 
Cmax/dose/BSA (m-5) 36.78 (13.60 – 65.4) 28.21(4.5 – 97.70) 40.96(10.40 – 49.70) 0.355 0.906 0.626 
CL/BSA (Lh-1m-2) 23.66 (16.40 – 55.7) 26.55 (15.0 – 49.40) 20.43 (19.60 – 29.20) 0.355 0.906 0.283 
Vss/BSA (Lm-2) 276.7 (122.00 – 703.7) 238.00 (130.4 – 487.60) 227.30(162.40 – 410.10) 0.692 0.557 0.626 
Doxorubicinol       
AUC0-∞/dose/BSA (hm-5) 9.84 (6.10 – 24.30) 8.98 (3.68 – 20.60) 13.31 (8.80 – 21.70) 0.118 0.137 0.047 
t1/2 (h) 26.38 (13.80 – 68.90) 28.57 (14.10 –112.40) 29.82 (20.30– 49.90) 0.783 1.000 0.922 
Cmax/dose/BSA (m-5) 0.29 (0.18 –0.73) 0.33 (0.15 – 1.09) 0.42 (0.29 – 1.49) 0.803 0.196 0.182 
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3.5.6.3 SLC22A16 Hepatic Expression 
 
The genotype and allele frequency of SLC22A16 polymorphisms in the 
hepatic tissues are shown in Table 3.23 and were in accordance to the 
frequencies reported in the local population from which the patients were 
recruited. No significant differences in SLC22A16 hepatic mRNA levels were 
observed with respect to different genotype groups.   
 
Table 3.23 SLC22A16 genotype frequencies in Chinese healthy liver tissues 
and influence on SLC22A16 mRNA levels. 
 
N; number of subjects. Values expressed as mean ± SD. *P < 0.05 considered 





Polymorphisms Genotypes N (%) RQ; (mean ± SD) 
Pairwise P 
values* 
c.146A>G AA 6 1.49 ± 1.67  AA vs AG  
 AG 33 0.72 ± 0.46  0.19  
 GG 0     
c.312T>C TT 6 1.49 ± 1.67  TT vs TC  
 TC 33 0.72 ± 0.46  0.19  
 CC 0     
c.755T>C TT 27 0.74 ± 0.43  TT vs TC  
 TC 7 1.09 ± 1.66  0.46  
 TT 0     
c.1226T>C TT 31 0.75 ± 0.87  TT vs TC  
 TC 5 1.17 ± 0.32  0.20  
 CC 1 0.93    
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Initial reports suggested that SLC22A16 is normally expressed in adult testis, 
bone marrow and fetal liver,(138) but was later detected in cancer cell lines 
derived from the liver and colon.(138,406) The present study showed that 
SLC22A16 mRNA is expressed in healthy liver tissues, with a high degree of 
variability observed in the hepatic SLC22A16 mRNA expression levels (CV = 
96.8%). Genotypic-phenotypic association analyses showed a non-significant 
trend towards low hepatic expression of SLC22A16 in liver tissues with 
respect to the c.146G>A polymorphism. The median expression level of 
SLC22A16 mRNA was approximately 1.5 fold higher in liver tissues harboring 
SLC22A16 AA (reference) genotype [mean ± SD; 1.49 ± 1.67] compared to 
the heterozygous variant AG genotype [mean ± SD; 0.72 ± 0.46] suggesting 
that polymorphisms in the SLC22A16 gene could contribute to interpatient 










Fig 3.15 Inter-individual variability in SLC22A16 expression in Chinese 




















In the present study, screening the coding regions of SLC22A16 gene in 300 
healthy subjects of distinct ethnic groups identified four novel polymorphisms, 
of which three were transitions that resulted in amino acid changes 
[c.146A>G (exon 2), c.755T>C (exon 4) and c.1226T>C (exon 5)]. The 
frequencies of the c.146A>G and c.1226C>T polymorphisms were observed 
to vary among the Asian ethnic groups. The Chinese and Malay ethnic groups 
had a higher percentage of subjects who were homozygous for the variant 
c.146A>G polymorphism compared to the Indians. A significantly higher 
proportion of subjects heterozygous for the c.1226C>T polymorphism was 
present among the Indian ethnic group compared to the Chinese and Malays. 
The differences in allele and genotype frequencies observed between the 
Asian ethnic groups suggest that pharmacogenetic-based analysis of 
SLC22A16 could provide additional insights into the mechanisms affecting 
inter-ethnic and inter-individual variations in the disposition of doxorubicin as 
well as other candidate drug substrates.  
   
SLC22A16 has 12 predicted alpha-helical transmembrane domains and one 
large extracellular loop between domains 1 and 2.(286)  In-vitro mutagenesis 
studies in transporters of the SLC22A family have shown that domains 4, 8, 
10 and 11 and possibly other additional domains are important in determining 
the structure of substrate binding pockets.(289,290) Among the three non-
synonymous polymorphisms identified in this study, the c.146A>G 
polymorphism is located in the first transmembrane domain and the c.755T>C 
and c.1226T>C polymorphisms are located in the 5th and 8th transmembrane 
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domains respectively. These are highly conserved regions among the organic 
ion transporter family and the occurrence of polymorphic variants in these 
conserved regions of the transmembrane domain may be associated with 
altered SLC22A16 transporting activity that warrants further 
investigations.(291,406) 
 
In-vitro studies by Okabe et al(138) on SLC22A16 mediated uptake of 
[14C]doxorubicin in Xenopus oocytes showed a sodium independent, 
saturable and dose-dependent kinetics with an apparent Km value of 5.2 ± 0.4 
μM. The investigators also showed an increase in apoptotic potential of 
doxorubicin in SLC22A16 overexpressing Jurkat cells that probably resulted 
from increased influx of doxorubicin. In the present study, the mean maximum 
concentration of doxorubicin attained at the dose of 60 mg/m2 in the breast 
cancer patients was 5.1 ± 2.5 μM and is within the range of intracellular 
concentrations responsible for the pharmacodynamic activity of 
doxorubicin.(138) This is probably suggestive of the role of SLC22A16 in 
influencing the intracellular accumulation of doxorubicin. 
   
In the present study, patients harboring the variant allele for the c.146A>G 
polymorphism had 24% and 35% higher exposure levels of doxorubicin and 
its major metabolite, doxorubicinol respectively, in comparison to patients 
belonging to the reference genotype. The exposure levels of doxorubicin and 
doxorubicinol were also 40% and 48% higher respectively, when compared to 
the patients who were heterozygous for the c.146A>G polymorphism. The 
modest impact of SLC22A16 c.146A>G polymorphism on doxorubicin 
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pharmacokinetics may be due to its effect being blunted by the polygenic 
influence of the various efflux transporters that are also involved in mediating 
the transport of doxorubicin. The pharmacodynamic influence of this novel 
polymorphism is not known and warrants further investigation in a larger 
sample size. In concordance with the low frequency of the c.755T>C and the 
c.1226T>C polymorphisms in the healthy Asian subjects, only 2 patients 
carried the c.755T>C polymorphism whereas the c.1226T>C polymorphism 
was absent in the Asian cancer patients. These results seem to suggest that 
the c.755T>C and c.1226T>C polymorphic variants may have limited impact 
on doxorubicin pharmacokinetics in Asian cancer patients.  
 
Correlation between SLC22A16 expression and the clinical response of 
patients to standard treatment containing doxorubicin was analyzed in the 
study by Okabe et al(138)  Although there was no significant difference 
between SLC22A16 expression levels of responders and non-responders, 
individual differences were clearly observed with some patients exhibiting 
high levels of SLC22A16 expression.The functional impact of the novel 
polymorphisms on expression levels of SLC22A16 in organs involved with the 
detoxification of doxorubicin or in different tumor types are not known and 
may further influence the pharmacokinetics and pharmacodynamics of 
doxorubicin. Further correlative studies aimed at characterizing the functional 
influence of these novel polymorphisms in different tumors as well as pre- and 
post-treatment tumor expression of SLC22A16 transporter proteins to 
correlate with efficacy and toxicity is warranted.  
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In conclusion, this study identified four novel polymorphisms in the SLC22A16 
gene in distinct healthy populations of Asian origin. Exploratory investigations 
in Asian breast cancer patients showed that the SLC22A16 c.146A>G variant 
may influence the pharmacokinetics of doxorubicin and doxorubicinol. In-vitro 
functional characterization of these novel polymorphisms with regards to 
SLC22A16 mediated transport of doxorubicin would be useful in 
understanding the role of this influx transporter in influencing the 
pharmacokinetics and pharmacodynamics of doxorubicin and its metabolites 
as well as other potential drug substrates.  
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3.6 PHARMACOKINEITC-PHARMACOGENETIC CORRELATES OF 
DOXORUBICIN METABOLIZING ENZYMES  
 
3.6.1 Carbonyl Reductase 1 (CBR1) 
 
 
3.6.1.1 CBR1 Pharmacogenetics  
 
 
Five polymorphisms were identified by direct sequencing of the exonic 
regions of CBR1 gene (Table 3.24). Two identified polymorphisms were in the 
5’-UTR (-48G>A) and 3’- UTR (+967G>A) regions. Among the coding region 
polymorphisms, one synonymous transversion (c.219G>C) in exon 1, and two 
synonymous transitions (c.627C>T and c.693G>A) in exon 3 were identified. 
 
The genotype and allele frequencies of the five CBR1 polymorphisms 
identified in the Asian ethnic groups and breast cancer patients are listed in 
Table 3.20.  The -48G>A polymorphism was monomorphic in the Indian 
population but was present at low frequencies among the Chinese (0.02) and 
Malays (0.01). No significant differences in the allele and genotype 
frequencies of the c.219G>C polymorphism were observed between different 
Asian ethnic groups. The allele frequency of the c.627C>T polymorphism was 
significantly higher among the Chinese (0.26) when compared to the Indians 
(0.18, P = 0.05). The c.693G>A polymorphism was monomorphic in the 
Chinese population but was present at low frequencies among Malays and 
Indians (0.01 in each case).  The +967G>A polymorphism was present at a 
significantly higher frequency among Chinese and Malays (0.23 in each case) 
when compared to the Indians (0.17, P = 0.01 in each case). The allele 
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frequency of CBR1 polymorphisms among breast cancer patients conformed 
to the frequency found among the local population. 
 
Table 3.24 Genotype and allele frequency of CBR1 polymorphisms in Asian ethnic 
groups and breast cancer patients. 
 
 
N: number of subjects 
 
Polymorphisms Location N Genotype frequencies N (%)  Allele frequency
- 48G>A 5’ UTR  GG GA AA  G A 
Healthy subjects         
   Chinese   100 95 (95)  5 (5) 0  0.98 0.02 
   Malays  100 99 (99)  1 (1) 0  0.99 0.01 
   Indians  100 100 (100)        0  0  1 0 
Asian cancer patients  62 58 (93.5)     4 (6.5) 0  0.97 0.03 
c.219G>C Exon 1  GG GC CC  G C 
Healthy subjects         
   Chinese   100 70 (70)  27 (27) 3 (3)      0.84     0.16 
   Malays  100 77 (77) 16 (16) 7 (7)  0.85 0.15 
   Indians   99  69 (69.7)  21(21.2)  9 (9.1)  0.80 0.20
Asian cancer patients  60 36 (60) 18 (30) 6 (10)  0.75 0.25 
c.627C>T Exon 3  CC CT TT  C T 
Healthy subjects         
   Chinese   100 62 (62) 25 (25) 13 (13)  0.74 0.26 
   Malays  100 66 (66) 17 (17) 17 (17)  0.75 0.25 
   Indians  100 68 (68) 27 (27) 5 (5)  0.82 0.18 
Asian cancer patients  60   38 (63.4)   10 (16.6) 12 (20)  0.72 0.28 
c.693G>A Exon 3  GG GA AA  G A 
Healthy subjects         
   Chinese   100 100 (100) 0 0  1 0 
   Malays  100 99 (99) 1 (1) 0  0.99 0.01 
   Indians  100 99 (99) 1 (1) 0  0.99 0.01 
Asian cancer patients  62  62 (100) 0 0  1 0 
+967G>A  3’ UTR  GG GA AA  G A 
Healthy subjects         
   Chinese   100 63 (63) 28 (28) 9 (9)  0.77 0.23 
   Malays  100 66 (66) 21 (21) 13 (13)  0.77 0.23 
   Indians  100 72 (72) 23 (23) 5 (5)  0.84 0.17 
Asian cancer patients  60   37 (61.7)   14 (23.3)   9 (15)  0.73 0.27 
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3.6.1.1.1 Linkage Disequilibrium, Haplotypes and Diplotypes  
 
Pairwise analysis showed moderate linkage of the c.219G>C with c.627C>T 
and +967G>A polymorphisms among Chinese and Malays (|D’| ≥ 0.7 in all 
groups), whereas the degree of linkage was weak among Indians [c.219G>C 
and c.627C>T; (|D’| ~ 0.57) and c.219G>C and +967G>A (|D’| ~ 0.41)]. The 
degree of linkage between the c.627C>T and +967G>A polymorphisms were 
high in all ethnic groups (|D’| > 0.8 in all cases). 
 
Table 3.25 shows the CBR1 haplotypes and diplotypes identified in the 
healthy Asian ethnic groups and breast cancer patients. A total of 8 CBR1 
haplotypes were determined in the Chinese population and four high 
frequency haplotypes (H1, H2, H3 and H4) accounted for a cumulative 
frequency of 95%. Among the 7 haplotypes inferred in Malay population, 
three were identified as high frequency haplotypes (H1, H2, and H3) and had 
a cumulative frequency of 90%. There were 7 haplotypes identified in Indian 
population and four high frequency haplotypes (H1, H2, H3 and H5) 
constituted 93% of the total haplotype frequencies. Major diplotypes (>5%) 
among the Chinese (H1-H1, H1-H2), Malays (H1-H1, H1-H2, H1-H3, H1-H6, 
H3-H3) and Indians (H1-H1, H1-H2, H1-H4) comprised 71%, 74% and 77% of 
the total diplotypes, respectively, in each ethnic group.  
 
The linkage pattern between the c.219G>C, c.627C>T and +967G>A 
polymorphisms [(ID’I ~ 0.7) in all groups] in the breast cancer patients was 
similar to those of healthy populations from which they were recruited. (Figure 
3.16). A total of 7 haplotype groups were identified and the major haplotypes 
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(>5%) were H1b (G-C-G), H2b (C-T-A) and H4b (C-T-G) with a cumulative 
frequency of 83% (Table 3.25). Among the 12 diplotypes inferred, the major 
diplotypes were H1b -H1b (56%), H1b -H2b (8%), H2b -H3b (7%), H2b -H2b (5%) 
and H3b -H4b (5%) which represented a cumulative frequency of 81%. 
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NB: Minor CBR1 diplotypes (frequency < 5%) are not shown. $; Haplotype represents the single sequence of genotype information derived from expectation maximization 
algorithm in the population based studies 
 Chinese (n=100)  Malays (n=100) 
 
Indians (n=100) 
Haplotypes$  Frequency  Haplotypes  Frequency  Haplotypes  Frequency 
H1 G C G 0.70  H1 G C G 0.69  H1 G C G 0.71 
H2 C T A 0.13  H2 C T A 0.11  H2 C T A 0.09 
H3 G T A 0.07  H3 G T A 0.10  H3 C C G 0.08 
H4 G T G 0.05  H4 G T G 0.03  H4 G T A 0.05 
H5 C C G 0.02  H5 C C G 0.03  H5 C T G 0.03 
H6 G C A 0.02  H6 G C A 0.03  H6 G C A 0.03 
H7 C C A 0.01  H7 C T G 0.01  H7 G T G 0.01 
H8 C T G <0.01             
Diplotypes                 
H1-H1 GG CC GG 0.56  H1-H1 GG CC GG 0.57  H1-H1 GG CC GG 0.59 
H1-H2 GC CT GA 0.15  H1-H2 GC CT GA 0.7  H1-H2 GC CT GA 0.13 
      H2-H2 CC TT AA 0.6  H1-H4 GG CT GA 0.5 
      H1-H3 GG CT GA 0.5       
      H1-H6 GG CC GA 0.5       





Asian breast cancer Patients (n=62) 
 
 
     
Haplotypes  Frequency  Diplotypes Frequency       
H1b G C G 0.65  H1b -H1b GG CC GG 0.56        
H2b C T A 0.13  H1 b -H2b GC CT GA 0.08        
H3b G T A 0.1  H2 b -H3b GC TT AA 0.07       
H4b C T G 0.05  H2 b -H2b CC TT AA 0.05        
H5b C C G 0.04  H3 b -H4b GG TT GA 0.05       
H6b C C A 0.03             























Fig 3.16 Pairwise linkage disequilibrium among CBR1 polymorphisms in Asian 
breast cancer patients.  
 
 
3.6.1.2 Pharmacokinetic-Pharmacogenetic Associations 
 
 
The influence of major CBR1 polymorphisms (c.219G>C, c.627C>T and 
+967G>A) on the pharmacokinetics of doxorubicin in Asian breast cancer 
patients are summarized in Table 3.26. There was no significant influence of 
the c.219G>C polymorphism on doxorubicin pharmacokinetics. The genotypic 
effect of c.627C>T and +967G>A polymorphisms on the pharmacokinetics of 
doxorubicin and doxorubicinol were similar. (Table 3.26)  Patients carrying the 
reference c.627CC genotype had significantly higher clearance [CL/BSA(Lh-
1m-2), median: 24.07; range: 16.44-49.40] of doxorubicin when compared to 
patients who were heterozygous [CL/BSA(Lh-1m-2), median: 20.13; range: 
8.68-31.79, P = 0.028]. Breast cancer patients carrying the reference c.627CC 
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genotype showed a trend of lower exposure levels [AUC0-∞/dose/BSA (hm-5): 
median: 15.44; range: 6.18-38.03] of doxorubicin compared with patients who 
were heterozygous [AUC0-∞/dose/BSA (hm-5): median: 20.36; range: 9.82-
67.17, P = 0.066] or homozygous for the variant allele [AUC0-∞/dose/BSA (hm-
5): median: 20.74; range: 15.15-30.16, P = 0.60]. Significantly lower peak 
plasma concentrations of doxorubicinol [Cmax/dose/BSA(hm-5), median: 0.32; 
range: 0.16-2.0] were observed in patients with the reference c.627CC 
genotypes compared to heterozygotes [Cmax/dose/BSA(hm-5), median: 0.49; 
range: 0.18-1.49, P = 0.030]. 
 
With regards to the +967G>A polymorphism, breast cancer patients carrying 
the reference +967GG genotype had significantly lower exposure levels 
[AUC0-∞/dose/BSA (hm-5): median: 15.62; range: 6.18-29.33] of doxorubicin 
when compared to patients who were heterozygous [AUC0-∞/dose/BSA (hm-
5): median: 22.43; range: 9.82-67.17] genotypes (P = 0.024). Patients carrying 
the reference +967GG genotype also had significantly higher clearance 
[CL/BSA(Lh-1m-2), median: 24.42; range: 16.44-49.40] of doxorubicin when 
compared to patients who were heterozygous [CL/BSA(Lh-1m-2), median: 
20.43; range: 8.68-31.79] for the polymorphism (P = 0.009). The +967GG 
genotypes were also associated with a significantly lower peak plasma 
concentrations of doxorubicinol [Cmax/dose/BSA(hm-5), median: 0.32; range: 
0.16-2.0] when compared to the patients harboring the heterozygote 
































N: number of subjects. *P < 0.05 considered statistically significant 
Pharmacokinetic 
parameters   CBR1 genotypes   * Pairwise P values  
c.219G>C  GG (n=30) GC (n=15) CC (n=5)  GG vs GC GC vs CC GG vs CC
Doxorubicin         
AUC0-∞/dose/BSA (hm-5)  15.85 (6.18 - 67.17) 18.76 (9.82 - 38.03)  15.15 (12.96 - 20.74)  0.139 0.191 0.944 
Cmax/dose/BSA (m-5)  33.12 (4.55 - 97.70) 41.59(12.80 - 81.22)  29.92 (17.59 - 42.38)  0.126 0.191 0.689 
CL/BSA (Lh-1m-2)  23.30 (8.68 - 55.66) 21.57(13.80 - 31.79)  26.09 (19.57 - 28.53)  0.094 0.163 0.906 
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5)  9.473(3.679 - 21.71) 11.64 (6.48 - 24.34)       7.77 (6.3 - 16.8)  0.064 0.278 0.923 
Cmax/dose/BSA (m-5)  0.31 (0.1483 -2.004) 0.39 (0.18 - 1.49)       0.38 (0.28 - 0.49)  0.152 0.541 0.556 
c.627C>T  CC (n =31) CT (n =10) TT (n =9)  CC vs CT CT vs TT CC vs TT
Doxorubicin         
AUC0-∞/dose/BSA (hm-5)  15.44 (6.18 - 38.03) 20.36 (9.82 - 67.17) 20.74 (15.15 - 30.16)  0.066 0.968 0.060 
Cmax/dose/BSA (m-5)  31.08 (4.55 - 97.70)   41.81 (12.80 - 81.22) 37.98 (27.76 - 80.72)  0.187 1.000 0.164 
CL/BSA (Lh-1m-2)     24.07 (16.44 - 49.40) 20.13 (8.68 - 31.79) 23.66 (13.80 - 28.53)  0.028 0.315 0.348 
Doxorubicinol         
AUC0-∞/dose/BSA (hm-5)  9.47(3.68 - 21.71) 12.87(6.59 - 24.34)    10.52 (6.3 - 16.8)  0.054 0.328 0.357 
Cmax/dose/BSA (m-5)  0.32(0.16 - 2.0) 0.49 (0.18 - 1.49)      0.38 (0.18 - 0.57)  0.030 0.182 0.650 
+967G>A  GG (n=30) GA (n=13) AA (n=7)  GG vs GA GA vs AA GG vs AA
Doxorubicin         
AUC0-∞/dose/BSA (hm-5)  15.62 (6.18 - 29.33) 22.43 (9.816 - 67.17) 18.76 (15.15 - 31.63)  0.024 0.526 0.126 
Cmax/dose/BSA (m-5)  32.03 (4.55 - 97.70) 40.96 (12.80 - 81.22) 42.04 (29.92 - 73.53)  0.239 0.751 0.126 
CL/BSA (Lh-1m-2)  24.42 (16.44 - 49.40) 20.43 (8.675 - 31.79) 24.93 (15.04 - 28.53)  0.009 0.178 0.473 
Doxorubicinol         
AUC0-∞/dose/BSA (hm
-5)  9.50 (3.68 - 24.34) 10.40 (6.48 - 16.79) 10.87 (6.25 - 18.71)  0.402 0.880 0.484 
Cmax/dose/BSA (m-5)      0.32 (0.16 - 2.0)      0.48 (0.22 - 1.49) 0.39 (0.18 - 0.57)  0.026 0.178 0.862 
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No major influences of CBR1 haplotypes on doxorubicin pharmacokinetics 
were observed in the present study. Phenotypic associations of linked high 
frequency CBR1 polymorphisms with pharmacokinetics of doxorubicin was 
examined by considering diplotypes which included composite genetic 
information from all the loci of interest. Sequence clustering using the 
complete linkage algorithm identified 2 major groups (D1 and D2) among the 
12 CBR1 diplotypes in Asian breast cancer patients. (Figure 3.17) The D2 
diplotype group was characterized by the presence of at least one variant 



























Significant differences were observed in the doxorubicin pharmacokinetic 
parameters between the two diplotype groups (Table 3.27).  Patients 
belonging to the D1 diplotype group had significantly higher clearance of 
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doxorubicin [CL/BSA(Lh-1m-2), median: 25.09; range: 16.44-55.66] compared 
to patients belonging to the D2 diplotype group [CL/BSA(Lh-1m-2), median: 
20.88; range: 8.68-31.79] (P = 0.014) (Figure 3.18). 
 
 
Table 3.27 The influence of CBR1 diplotypes on pharmacokinetics of 
doxorubicin and doxorubicinol in Asian breast cancer patients. 
 
 
      N: number of subjects 
 
Patients belonging to the D1 diplotype group also had significantly lower 
exposure levels of doxorubicin [AUC0-∞/dose/BSA (hm-5): median: 15.08; 
range: 6.18-38.03] compared to patients belonging to the D2 diplotype group 
[AUC0-∞/dose/BSA (hm-5): median: 21.35; range: 9.82-67.17] (P = 0.007) 
(Figure 3.10). With regards to doxorubicinol, patients harboring the D1 
diplotype family had lower exposure levels of doxorubicinol [AUC0-∞/dose/BSA 
(hm-5): median: 8.99; range: 3.68-20.63] when compared to the patients 
belonging to the D2 [AUC0-∞/dose/BSA (hm-5): median: 11.28; range: 6.25-
18.71, P = 0.057] diplotype family. 
Pharmacokinetic parameters CBR1  diplotype groups  Pairwise P value
 D1 (n=38) D2 (n=14)   
Doxorubicin     
AUC0-∞/dose/BSA (hm-5) 15.08 (6.18-38.03) 21.35 (9.82-67.17)  0.008 
Cmax/dose/BSA (m-5) 25.49 (4.55-77.67)  41.50 (12.80-81.22)  0.038 
CL/BSA (Lh-1m-2)   25.09 (16.44-55.66) 20.88 (8.68-31.79)  0.014 
t1/2(h)  15.38 (11.25-24.63)  15.76 (12.54-20.59)  0.404 
Doxorubicinol     
AUC0-∞/dose/BSA (hm-5) 8.99 (3.68-20.63) 11.28 (6.25-18.71)  0.057 
Cmax/dose/BSA (m-5) 0.31 (0.148-1.09) 0.42 (0.18-1.49)  0.059 




































Fig 3.18 Influence of CBR1 diplotypes on A) clearance [CL/BSA(Lh-1m-2)],  
and B) exposure levels [AUC0-∞/dose/BSA (hm-5)] of doxorubicin in Asian 
breast cancer patients. N; number of subjects. P < 0.05 statistically signficant. 
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3.6.1.3 CBR1 Hepatic Expression 
 
The genotype and allele frequency of CBR1 polymorphisms in the hepatic 
tissues (Table 3.28) were in accordance to the frequency reported in the local 
population from which the patients were recruited. High degree of variability in 
the hepatic mRNA levels of CBR1 in healthy liver tissues were observed in 
the present study (CV = 60.1%) (Figure 3.19). The relative hepatic expression 
levels with respect to CBR1 genotypes are also shown. No significant 
differences in CBR1 expression levels were observed with respect to different 
genotype groups.   
 
Table 3.28 CBR1 genotype frequencies in Chinese healthy liver tissues and 





N: number of subjects. *P < 0.05 considered statistically significant. 
 
Polymorphisms N  (%) Genotypes 
RQ; 
(mean ± SD) Pairwise P values* 
c.219G>C 24 GG 1.29 ± 0.76 CC vs CT CC vs TT CT vs TT 
 7 GC 1.79 ± 0.79 0.22 0.16 0.07 
 3 CC 0.62 ± 0.57    
c.627C>T 30 CC 1.19 ± 0.74 CC vs CT   
 6 CT  0.23   
 0 TT 1.79 ± 0.95    
+967C>T 27 CC 1.21 ± 0.73 CC vs CT   
 6 CT  0.23   
















      Fig 3.19 Inter-individual variability in CBR1 expression in Chinese healthy liver   
      tissues. (N = 41) RQ: Relative Quotient 
 
The ubiquitously expressed carbonyl reducatses have been isolated from a 
variety of tissues including brain, breast, ovary, and placenta and 
liver,(407,408,409) Earlier reports have indicated an absence or minimal hepatic 
expression of the CBR3 isoform.(300) Consistent with these observations, 
CBR3 expession analysis by RT-PCR expression analysis failed to detect the 
CBR3 mRNA in the healthy liver tissues in the present study.  
 
Human liver exhibits considerable carbonyl reductase activity and hence the 
alterations in the expression and activity of carbonyl reductases can have 
significant consequences on the metabolism of doxorubicin.(409) Higher 
expression of carbonyl reductases have been associated with increased 
protection from doxorubicin cardiotoxicity while also conferring doxorubicin 
resistance by increasing its intra-cellular conversion to doxorubicinol.(410)  
Studies in patients with non small cell lung cancer showed that reduced CBR 
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Liver tissue samples
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progression and that CBR mRNA levels was an independent and significant 
prognostic factor.(411) The role of CBR1 genetic polymorphisms (c.219G>C, 
c.627C>T and +967G>A) in modulating CBR1 activity and their contribution to 
interindividual variability in CBR1 expression may require further 
characterization and would also help better understand their role in altering 
the pharmacokinetics and pharmacodynamics of doxorubicin in cancer 
patients.  
 
3.6.2 Carbonyl Reductase 3 (CBR3) 
 
3.6.2.1 CBR3 Pharmacogenetics 
 
A total of five polymorphisms were identified by direct sequencing of the 5’-
UTR, 3’-UTR and coding regions of the CBR3 gene. One non-synonymous 
transition (c.11G>A; C4Y) and two synonymous transitions (c.255T>C and 
c.279C>T) were identified in exon 1. A synonymous (c.606G>A) and a non-
synonymous (c.730G>A; V244M) polymorphism were identified in exon 3 of 
the CBR3 gene.  
 
The genotype and allele frequencies of the five CBR3 polymorphisms 
identified in the Asian healthy ethnic groups and the breast cancer patients 
are listed in Table 3.29. The allele frequency of the c.11G>A polymorphism 
was significantly higher among the Chinese (0.38) and Malays (0.41) when 
compared to Indians (0.28) (Chinese vs Indians; P = 0.03, Malays vs Indians; 
P = 0.01). The c.255T>C polymorphism was observed to be monomorphic in 
the Chinese healthy subjects. The allele frequency of the c.279C>T 
polymorphism was significantly higher among the Chinese (0.39) when 
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compared to Indians (0.29, P = 0.03).  The c.606G>A polymorphism was 
monomorphic in the Chinese and Malay healthy subjects but was present at 
an allele frequency of 0.03 among the Indians. The allele frequency of the 
c.730G>A polymorphism was also significantly higher among the Indians 
when compared to the Chinese and Malays (Indians vs Chinese, P < 0.0001; 
Indians vs Malays, P = 0.003). The genotype and allele frequencies of CBR3 
polymorphisms among cancer patients conformed to the frequency in healthy 
study subjects. 
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Table 3.29 Genotype and allele frequency of CBR3 polymorphisms in Asian   
ethnic groups and breast cancer patients. 
 
 
N: number of subjects 
 
Polymorphisms Location N Genotype frequencies  Allele frequency 
c.11G>A  Exon 1  GG GA AA  G A 
Healthy subjects         
   Chinese   100 40 (40) 44 (44) 16 (16)  0.62 0.38 
   Malays  100 33 (33) 52 (52) 15 (15)  0.59 0.41 
   Indians  100 51(51) 42 (42) 7 (7)  0.72 0.28 
Asian cancer patients  62    32 (51.6) 18 (29) 12 (19.4)  0.66 0.33 
c.255T>C Exon 1  TT TC CC  T C 
Healthy subjects         
   Chinese   97    63 (64.9)    34 (35.1) 0  0.82 0.18 
   Malays  100 72 (72) 25 (25) 3 (3)  0.84 0.16 
   Indians  100 75 (75) 24 (24) 1 (1)  0.87 0.13 
Asian cancer patients  61    41 (67.2) 17 (27.9)    3 (4.9)  0.81 0.19 
c.279C>T Exon 1  CC CT TT  C T 
Healthy subjects         
   Chinese   98    38 (38.8)    44 (44.9)   16 (16.3)  0.61 0.39 
   Malays  100 39 (39) 46 (46) 15 (15)  0.62 0.38 
   Indians  100 50 (50) 42 (42) 8 (8)  0.71 0.29 
Asian cancer patients  61    33 (54.1) 16 (26.2) 12 (19.7)  0.67 0.33 
c.606G>A Exon 3  GG GA AA  G A 
Healthy subjects         
   Chinese   100 100 (100) 0 0  1 0 
   Malays  99 99 (100) 0 0  1 0 
   Indians  97 92 (94.8) 5 (5.2) 0  0.97 0.03 
Asian cancer patients  61 59 (96.7) 2 (3.3) 0  0.98 0.02 
c.730G>A Exon 3  GG GA AA  G A 
Healthy subjects         
   Chinese   99 37 (37.4) 47 (47.5) 15 (15.1)  0.61 0.38 
   Malays  98 31 (31.6) 51 (52.0) 16 (16.4)  0.58 0.42 
   Indians  98 22 (22.4) 40 (40.8) 36 (36.8)  0.43 0.57 
Asian cancer patients  62 24 (38.7) 23 (37.1) 15 (24.2)  0.57 0.43 
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3.6.2.1.1 Linkage Disequilibrium, Haplotypes and Diplotypes  
 
Strong linkage of the c.11G>A polymorphism with the c.255T>C, c.279C>T 
and c.730G>A polymorphisms were observed in all the ethnic groups (|D’| > 
0.9 in all cases). The c.11G>A and c.606G>A polymorphisms were strongly 
linked in the Indian healthy population (|D’| > 0.9).  The linkage between the 
c.255T>C and c.730G>A polymorphisms were strong among Chinese and 
Malays (|D’| > 0.9) but weak among Indians (|D’| ~ 0.3). Strong linkage was 
also observed between the c.279C>T and c.730G>A polymorphisms among 
all the ethnic groups. (|D’| > 0.9 in all groups). A total of 6 CBR3 haplotypes 
were determined in the Chinese population and three high frequency 
haplotypes (H1, H2 and H3) accounted for a cumulative frequency of 92% 
(Table 3.30). Among the 9 haplotypes inferred in Malay population, four were 
identified as high frequency haplotypes (H1, H2, H3 and H4) and had a 
cumulative frequency of 94%. There were 9 haplotypes identified in Indian 
population of which the H1, H2 and H3 haplotypes constituted 90% of the 
total haplotype frequencies. The H1 haplotype was tagged by the c.730G>A 
polymorphism, H2 haplotype by the linked c.11G>A and c.279C>T 
polymorphisms, and the H3 haplotype by the c.255T>C polymorphism in all 
ethnic groups studied. 
 
Pairwise analysis of CBR3 polymorphisms in cancer patients showed high 
degree of linkage between the c.11G>A, c.255T>C, c.279C>T, c.606G>A and 










NB: Minor CBR3 diplotypes (frequency < 5%) are not shown. $; Haplotype represents the single sequence of genotype information derived from expectation 
maximization algorithm in the population based studies 
  Chinese (n=100)  
 
 Malays (n=100)  
 
 Indians (n=100)  
Haplotypes$      Frequency  Haplotypes      Frequency  Haplotypes      Frequency 
H1 G T C G A 0.39  H1 G T C G A 0.40  H1 G T C G A 0.53 
H2 A T T G G 0.36  H2 A T T G G 0.34  H2 A T T G G 0.26 
H3 G C C G G 0.17  H3 G C C G G 0.15  H3 G C C G G 0.11 
H4 G T C G G 0.04  H4 A T C G G 0.05  H4 G T C A G 0.03 
H5 G T T G G 0.02  H5 G T T G G 0.02  H5 G C C G A 0.02 
H6 A T C G G 0.01  H6 A T T G A 0.01  H6 G T T G G 0.02 
        H7 G T C G G 0.01  H7 G T C G G 0.01 
        H8 G C T G A <0.01  H8 G T T G A 0.01 
        H9 A C T G G <0.01  H9 A T C G G 0.01 
Diplotypes                       
H1-H2 GA TT CT GG GA 0.24  H1-H2 GA TT CT GG GA 0.29  H1-H1 GG TT CC GG AA 0.31 
H1-H3 GG TC CC GG GA 0.18  H1-H1 GG TT CC GG AA 0.16  H1-H2 GA TT CT GG GA 0.28 
H1-H1 GG TT CC GG AA 0.15  H1-H3 GG TC CC GG GA 0.11  H2-H3 GA TC CT GG GG 0.10 
H2-H2 AA TT TT GG GG 0.15  H2-H2 AA TT TT GG GG 0.11  H1-H3 GG TC CC GG GA 0.09 
H2-H3 GA TC CT GG GG 0.15  H2-H3 GA TT CT GG GG 0.11  H2-H2 AA TT TT GG GG 0.06 
        H1-H4 GA TT CT GG GA 0.07         
 Asian breast cancer patients (n=62) 
 
       
Haplotypes      Frequency  Diplotypes      Frequency         
H1b G T C G A 0.41  H1b -H1b GG TT CC GG AA 0.23         
H2b A T T G G 0.31  H2b -H2b AA TT TT GG GG 0.18         
H3b G C C G G 0.19  H1b -H3b GG TC CC GG GA 0.16         
H4b G T C G G 0.03  H2b -H3b GA TC CT GG GG 0.11         
H5b A T C G G 0.03  H1b -H2b GA TT CT GG GA 0.11         
H6b G T T G A 0.01  H3b -H3b GG CC CC GG GG 0.05         
H7b G T C A G 0.01                 
H8b G T C A A 0.01                 
H9b G T T G G <0.01                 
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Haplotype analysis revealed a total of 9 haplotype groups of which the H1b (G-T-
C-G-A), H2b (A-T-T-G-G) and H3b (G-C-C-G-G) haplotypes had a cumulative 
frequency of 91% (Table 3.30). Similar to the healthy subjects, the H1b, H2b and 
H3b haplotypes in breast cancer patients were tagged by the c.730G>A, c.11G>A 
and c.279C>T, and the c.255T>C polymorphisms, respectively. A total of 14 
diplotypes were inferred by the expectation-maximization (EM) algorithm and the 
major diplotypes [H1b -H1b (23%), H2b -H2b (18%), H1b -H3b (16%), H2b -H3b 



















Fig 3.20 Pairwise linkage disequilibrium among CBR3 polymorphisms in Asian 
breast cancer patients. 
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3.6.2.2 Pharmacokinetic-Pharmacogenetic Associations 
 
 
No significant influences of the CBR3 polymorphisms (c.11G>A, c.255T>C, 
c.279C>T, c.606G>A and c.730G>A) on doxorubicin and doxorubicinol 
pharmacokinetics were observed in the present study (data not shown). 
Examination of the influence of the major CBR3 haplotype and diplotype 
structures also failed to reveal any significant association with doxorubicin 




Polymorphisms in the coding or regulatory regions of genes encoding carbonyl 
reductase drug metabolizing enzymes may have significant phenotypic influences 
due to their critical roles in the phase I metabolism of both endogenous and 
xenobiotic compounds.(310) The alterations in tissue specific expression and 
activity of carbonyl reductase drug metabolizing enzymes could also contribute to 
inter-individual variations in pharmacokinetics and pharmacodynamics of their 
putative drug substrates including doxorubicin.  
 
Screening the exon and exon-intron boundaries of the CBR1 gene in 300 healthy 
Asian subjects identified five polymorphisms (-48G>A, c.219G>C, c.627C>T, 
c.693G>A and +967G>A) that exhibited significant inter-ethnic variations in 
genotype and allele frequencies. The allele frequency of the c.219G>C 
polymorphism among the Chinese (0.16), Malay (0.15) and Indian (0.20) ethnic 
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groups were similar to the frequency reported in the Caucasian population 
(0.15).(142)  The non-synonymous c.262G>A (V88I) polymorphism was absent in 
the Asian health subjects and patients. This polymorphism is present at a low 
frequency among African Americans (< 0.2%) and has been postulated to be 
associated with higher intracellular prostaglandin E2 (PGE2) levels.(142) The allele 
frequency of the c.627C>T polymorphism in the Indian population (0.18) was 
similar to the Caucasians (0.15) but lower compared to the Chinese subjects 
(0.26, P = 0.05). The c.693G>A polymorphism reported in Caucasians (0.02)(142) 
was monomorphic among the Chinese and occurred at a low frequency in both 
Malays and Indians (0.01 in each ethnic group). 
 
Earlier reports by Lakhman et al(311) showed wide inter ethnic variations in allele 
frequency of the CBR3 c.730G>A (V244M) polymorphism (0.07 among Pacific 
origin and 0.67 among Indo-Pakistanis) that was proposed to cause structural 
variation and alterations in dinucleotide binding interactions leading to higher 
catalytic efficiency of the enzyme. In the present study, the c.730G>A 
polymorphism occurred at a significantly higher allele frequency among the 
Indians (0.57) compared to the Chinese (0.38) and Malays (0.42) (P < 0.0001 and 
P = 0.003, respectively). The significantly lower allele frequency of the c.11G>A 
and c.279C>T polymorphism among Indians when compared to the rest of the 
ethnic groups and the absence of c.255T>C and c.606G>A polymorphisms in the 
Chinese subjects suggested the existence of wide interethnic differences in 
frequency of CBR3 polymorphisms.  
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Association studies with polymorphic data from linked loci suggest that diplotype 
constitution, which characterize the subset of every single locus genotype in a 
gene and is representative of the type of chromosome pairs in an individual,(412,413) 
could be major determinants of phenotypes.(414) In the present study, 
homozygosity for the reference allele at the CBR1 c.627C>T and +967G>A loci 
was observed to be associated with increased clearance and reduced exposure 
levels of doxorubicin in Asian breast cancer patients. The reasons for the lack of 
influence of the homozygous variant alleles at the CBR1 c.627C>T and +967G>A 
loci on doxorubicin pharmacokinetic parameters are unknown and could possibly 
be due to smaller cohort of breast cancer patients studied. Since the CBR1 
c.219G>C, c.627C>T and +967G>A polymorphisms were observed to be in 
linkage disequilibrium, further analysis was done to delineate influences of the 
inferred CBR1 diplotypes on doxorubicin pharmacokinetics. Pairwise comparisons 
revealed that patients belonging to CBR1 D1 diplotype group had 20% higher 
clearance (P = 0.007) and 29% lower exposure (AUC0-∞) of doxorubicin (P = 0.014) 
compared to patients belonging to the CBR1 D2 diplotype group. The peak 
plasma concentration of doxorubicin was also 38% lower among patients 
belonging to the CBR1 D1 diplotype group (P = 0.038). This suggests that the 
increased clearance of doxorubicin in patients harboring the CBR1 D1 diplotype 
cohort may probably be due to the increased carbonyl reductase activity resulting 
in increased metabolic conversion of doxorubicin to doxorubicinol among these 
patients. The CBR1 D2 diplotypes were characterized by the presence of at least 
one variant allele at the c.627 and 3’-UTR +967 loci. There have been no studies 
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to date that examined the functional roles of the synonymous c.627C>T 
polymorphism. Recent reports investigating polymorphic variations in drug 
transporters have indicated that synonymous polymorphisms can alter mRNA 
stability and translation efficiency, contributing to alterations in drug 
disposition.(398)The 3’-UTR regions have several cis-acting binding sites for 
several transcription factors and mutations in these regions have been associated 
with alterations in protein expression and disease phenotypes.(394,395) Future 
studies are required to delineate the functional roles of the synonymous c.627C>T 
polymorphism and the 3’-UTR +967G>A polymorphism in affecting the 
pharmacokinetics of doxorubicin and doxorubicinol.  
 
The increased clearance of doxorubicin in breast cancer patients belonging to the 
CBR1 D1 diplotype group was however, not associated with increased exposure 
levels of doxorubicinol. Possible reasons that may have accounted for this 
observation may include further metabolism of doxorubicinol to its aglycone, 
doxorubicinolaglycone(102) thereby rendering it more favorable for excretion. In 
addition, the activities of other carbonyl group reducing enzymes such as 
aldehyde reductases (ALR1; AKR1A1) and dihydrodiol dehydrogenase 2 (DD2; 
AKR1C2) have been identified to be important in contributing to the intracellular 
formation of doxorubicinol,(302,415)and may also influence its clearance. 
Doxorubicinol is also an ABCB1 substrate and its clearance may be affected by its 
affinity towards ABCB1 and the variable ABCB1 expression levels in the biliary 
canalicular membrane of hepatocytes.(416) As previously shown, the homozygosity 
for the reference allele at the ABCB1 c.1236C>T, c.2677G>T/A and c.3435C>T 
 211
loci were associated with significantly lower peak plasma concentrations of 
doxorubicin and doxorubicinol. With regards to CBR3 pharmacogenetics, the 
CBR3 c.730G>A polymorphism was previously reported to alter the catalytic 
efficiency of the enzyme.(311) However, no influence of the c.730G>A 
polymorphism on doxorubicin pharmacokinetics was observed in the present 
study. The lack of association of CBR3 polymorphic variants with doxorubicin 
disposition could be due to the relatively low level of hepatic CBR3 expression.(300) 
 
Similar to roles played by ABC transporters, carbonyl reductase polymorphisms 
could also contribute to the mechanisms of drug resistance, treatment efficacy and 
toxicity during cancer chemotherapy. CBR expression in K562 cells resulted in 
protection against cytotoxicity when treated with doxorubicin(297) while cells 
selected for doxorubicin resistance showed 60% increase in CBR mRNA 
levels.(417) Taxanes such as paclitaxel has been shown to increase the intracellular 
conversion of doxorubicin to doxorubicinol by binding to the regulatory allosteric 
and catalytic sites of carbonyl reductase enzyme, thereby influencing the efficacy 
and toxicity of combination chemotherapy regimens.(418) Carbonyl reductase 
mediated intracellular conversion of doxorubicin to doxorubicinol has also been 
proposed to be important in the development of anthracycline cardiotoxicity.(419)  
In-vitro studies have shown higher potency of doxorubicinol than doxorubicin in 
depressing myocardial contractility and inhibiting ion channel pumps(420) while 
studies on transgenic mice over-expressing CBR1 in the heart showed higher 
intracardiac levels of doxorubicinol and increased signs of myocardial damage 
after doxorubicin administration.(419) Recent studies also suggest that CBR3 
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variants might also have important contributory roles in determining doxorubicin 
cardiotoxicity.(421,422)  Although the precise molecular mechanisms that mediate 
anthracycline cardiotoxicity remains to be identified, alterations in intracellular 
concentrations of doxorubicin and doxorubicinol by polymorphic carbonyl 
reductases could be assumed to play significant roles in the incidence of 
cardiotoxicity observed in a subset of patients on chemotherapy. 
 
The present study identified novel CBR1 and CBR3 polymorphisms and 
characterized their haplotype and diplotype structures in the three distinct Asian 
ethnic groups and breast cancer patients. Study results showed that CBR1 D2 
diplotypes tagged by at least one variant allele at CBR1 c.627 and +967 loci 
correlate with significantly higher exposure levels of doxorubicin, suggesting the 
possibility of lowered intracellular conversion to doxorubicinol in these patients. 
Larger studies with a higher sample size must be carried out to arrive at definitive 
conclusions and to further evaluate the role of carbonyl reductase polymorphisms 





CHAPTER 4: CONCLUSION AND FUTURE RESEARCH DIRECTIONS 
 
In conclusion, the overall pharmacokinetics of doxorubicin and doxorubicinol in 
Asian breast cancer patients were in confirmation with earlier reports in the 
present study. A high degree of inter-individual variability in the pharmacokinetic 
parameters of doxorubicin and doxorubicinol was observed in Asian breast cancer 
patients. Among the efflux doxorubicin transporters investigated in the present 
study, pharmacogenetic analysis suggested that ABCB1 and ABCC5 gene 
polymorphisms may be functionally important in influencing doxorubicin 
pharmacokinetics in the Asian breast cancer patients. The moderately linked 
ABCB1 1236CC-2677GG-3435CC genotypes influenced the disposition of 
doxorubicin resulting in significantly increased exposure levels, peak plasma 
concentrations and reduced clearance in patients who were homozygous for the 
variant allele at the three loci. Among the haplotype tagged polymorphisms in the 
ABCC5 gene, breast cancer patients homozygous for the ABCC5 c.-1679T allele 
had significantly higher exposure levels of doxorubicin when compared to the 
patients who were heterozygous for the polymorphism. No significant influences of 
the ABCG2 c.421C>A polymorphism on doxorubicin disposition was observed. 
Three novel ABCB5 exonic polymorphisms [c.2T>C (exon 1), c.343A>G (exon 2) 
and c.1573G>A (exon 12)] identified in the present study did not influence 
doxorubicin disposition in Asian breast cancer patients.  Screening the coding 
regions of the RLIP76 gene among the three distinct Asian ethnic groups failed to 
identify any polymorphic variations. Four novel polymorphisms were identified by 
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direct sequencing of the coding regions of SLC22A16 gene [c.146A>G (exon 2), 
c.312T>C (exon 2), c.755T>C (exon 4) and c.1226T>C (exon 5)]. Breast cancer 
patients harboring the c.146GG genotype showed a trend towards higher 
exposure levels to doxorubicin and doxorubicinol compared to patients with either 
the reference genotype or heterozygotes. With regards to the genes encoding 
doxorubicin metabolizing enzymes, screening the exon and exon-intron 
boundaries of CBR1 gene identified five polymorphisms (-48G>A, c.219G>C, 
c.627C>T, c.693G>A and +967G>A) which exhibited significant inter-ethnic 
variations The CBR1 D2 diplotype cohort characterized by at least one variant 
allele at c.627 and +967 loci correlate with significantly higher exposure levels of 
doxorubicin suggesting the possibility of lowered intracellular conversion to 
doxorubicinol in these patients.  
 
Investigating the pharmacogenetics of the nuclear receptor PXR showed 
significant differences in the genotype and allele frequencies of PXR 
polymorphisms and their linkage patterns among the distinct Asian ethnic groups.  
The PXR*1B haplotypes which occurred at a higher frequency in Chinese and 
Malays compared to Indians, was found to be associated with significantly 
decreased hepatic mRNA expression of PXR and also its downstream target 
gene, ABCB1. The PXR*1B haplotype was found to be significantly associated 
with reduced clearance of doxorubicin in Asian breast cancer patients suggesting 
that genetic polymorphisms and specific haplotype clusters in the PXR nuclear 
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receptor could have significant contributory roles in affecting interethnic variations 
in the disposition of doxorubicin in the Asian populations. 
 
It is conceivable that apart from the pharmacogenetic factors, variations in 
doxorubicin pharmacokinetics could involve factors such as varying schedules of 
administration, and influences of other study subject covariates such as age, 
ethnicity and body surface area (BSA) that are likely to play significant roles. The 
present exploratory study showed that functional polymorphisms in genes 
encoding the PXR nuclear receptor, ABCB1, ABCC5 and SLC22A16 doxorubicin 
transporters and doxorubicin reducing carbonyl reductase 1 (CBR1) significantly 
influence the pharmacokinetics of doxorubicin in Asians and may contribute to the 
inter-individual and inter-ethnic variability in doxorubicin disposition among 
different patient groups. The relationship between doxorubicin pharmacokinetics 
and pharmacodynamics is complex and may be influenced by the polygenic 
effects of nuclear receptors (PXR), transporters (ABCB1, ABCC5 and SLC22A16) 
and drug metabolizing enzyme (CBR1) genes. Further studies in a larger patient 
cohort are required to delineate the polygenic influence of these genes on 
doxorubicin pharmacokinetic-pharmacodynamics in Asian breast cancer patients 








Aphasia, receptive and/or expressive, is graded under Speech impairment in the NEUROLOGY category. 
Arachnoiditis/meningismus/ 
radiculitis 
absent mild pain not interfering 
with function 
moderate pain interfering 
with function, but not 
interfering with activities of 
daily living 
severe pain interfering 
with activities of daily 
living 
unable to function or 
perform activities of 
daily living; bedridden; 
paraplegia 
Also consider Headache, Vomiting, Fever. 
Ataxia (incoordination) normal asymptomatic but abnormal 
on physical exam, and not 
interfering with function 
mild symptoms interfering 
with function, but not 
interfering with activities of 
daily living 
moderate symptoms 
interfering with activities 
of daily living 
bedridden or disabling 
CNS cerebrovascular ischemia none - - transient ischemic event 
or attack (TIA) 
permanent event (e.g., 
cerebral vascular 
accident) 
CNS hemorrhage/bleeding is graded in the HEMORRHAGE category. 
Cognitive disturbance/ 
learning problems 
none cognitive disability; not 




interfering with work/school 
performance; decline of 1 
SD (Standard Deviation) or 
loss of developmental 
milestones 
cognitive disability; 
resulting in significant 
impairment of 
work/school performance; 
cognitive decline > 2 SD 
inability to work/frank 
mental retardation 
Confusion normal confusion or disorientation 
or attention deficit of brief 
duration; resolves 
spontaneously with no 
sequelae 
confusion or disorientation 
or attention deficit 
interfering with function, but 
not interfering with 
activities of daily living 
confusion or delirium 
interfering with activities 
of daily living 
harmful to others or 
self; requiring 
hospitalization 
Cranial neuropathy is graded in the NEUROLOGY category as Neuropathy-cranial. 
Delusions normal - - present toxic psychosis 
Depressed level of 
consciousness 
normal somnolence or sedation not 
interfering with function 
somnolence or sedation 
interfering with function, but 
not interfering with 
activities of daily living 
obtundation or stupor; 
difficult to arouse; 
interfering with activities 
of daily living 
coma 
Note: Syncope (fainting) is graded in the NEUROLOGY category. 
Dizziness/lightheadedness none not interfering with function interfering with function, but 
not interfering with 
activities of daily living 
interfering with activities 
of daily living 
bedridden or disabling 




none mild involuntary movements 
not interfering with function 
moderate involuntary 
movements interfering with 
function, but not interfering 
with activities of daily living 
severe involuntary 
movements or torticollis 
interfering with activities 
of daily living 
bedridden or disabling 
Hallucinations normal - - present toxic psychosis 
Headache is graded in the PAIN category. 
Insomnia normal occasional difficulty 
sleeping not interfering with 
function 
difficulty sleeping 
interfering with function, but 
not interfering with 
activities of daily living 
frequent difficulty 
sleeping, interfering with 
activities of daily living 
- 
Note: This toxicity is graded when insomnia is related to treatment. If pain or other symptoms interfere with sleep do NOT grade as insomnia. 
Irritability 
(children <3 years of age) 
normal mild; easily consolable moderate; requiring 
increased attention 




none mild increase in SAS 
(subarachnoid space) and/or 
mild ventriculomegaly; 
and/or small (+/- multiple) 
focal T2 hyperintensities, 
involving periventricular 
white matter or < 1/3 of 
susceptible areas of 
cerebrum 
moderate increase in SAS; 
and/or moderate 
ventriculomegaly; and/or 
focal T2 hyperintensities 
extending into centrum 
ovale; or involving 1/3 to 
2/3 of susceptible areas of 
cerebrum 
severe increase in SAS; 
severe ventriculomegaly; 
near total white matter T2 
hyperintensities or diffuse 
low attenuation (CT); 
focal white matter 
necrosis (cystic) 
severe increase in SAS; 
severe 
ventriculomegaly; 
diffuse low attenuation 
with calcification (CT); 
diffuse white matter 
necrosis (MRI) 
Memory loss normal memory loss not interfering 
with function 
memory loss interfering 
with function, but not 
interfering with activities of 
daily living 
memory loss interfering 
with activities of daily 
living 
amnesia 
Mood alteration- anxiety 
agitation 
normal mild mood alteration not 
interfering with function 
moderate mood alteration 
interfering with function, but 
not interfering with 
activities of daily living 
severe mood alteration 
interfering with activities 
of daily living 
suicidal ideation or 
danger to self 
Mood alteration- depression normal mild mood alteration not 
interfering with function 
moderate mood alteration 
interfering with function, but 
not interfering with 
activities of daily living 
severe mood alteration 
interfering with activities 
of daily living 
suicidal ideation or 
danger to self 
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Mood alteration- euphoria normal mild mood alteration not 
interfering with function 
moderate mood alteration 
interfering with function, but 
not interfering with 
activities of daily living 
severe mood alteration 
interfering with activities 
of daily living 
danger to self 
Neuropathic pain is graded in the PAIN category. 
Neuropathy- cranial absent - present, not interfering with 
activities of daily living 
present, interfering with 
activities of daily living 
life-threatening, 
disabling 
Neuropathy- motor normal subjective weakness but no 
objective findings 
mild objective weakness 
interfering with function, but 
not interfering with 
activities of daily living 
objective weakness 
interfering with activities 
of daily living 
paralysis 
Neuropathy-sensory normal loss of deep tendon reflexes 
or paresthesia (including 
tingling) but not interfering 
with function 
objective sensory loss or 
paresthesia (including 
tingling), interfering with 
function, but not interfering 
with activities of daily living 
sensory loss or 
paresthesia interfering 
with activities of daily 
living 
permanent sensory loss 
that interferes with 
function 
Nystagmus absent present - - - 
Also consider Vision-double vision. 
Personality/behavioral normal change, but not disruptive to 
patient or family 
disruptive to patient or 
family 
disruptive to patient and 
family; requiring mental 
health intervention 
harmful to others or 
self; requiring 
hospitalization 
Pyramidal tract dysfunction 
(e.g., ↑ tone, hyperreflexia, 
positive Babinski, ↓ fine motor 
coordination) 
normal asymptomatic with 
abnormality on physical 
examination 
symptomatic or interfering 
with function but not 
interfering with activities of 
daily living 
interfering with activities 
of daily living 
bedridden or disabling; 
paralysis 
Seizure(s) none - seizure(s) self-limited and 
consciousness is preserved 
seizure(s) in which 
consciousness is altered 
seizures of any type 
which are prolonged, 
repetitive, or difficult 
to control (e.g., status 
epilepticus, intractable 
epilepsy) 
Speech impairment  
(e.g., dysphasia or aphasia) 
normal - awareness of receptive or 
expressive dysphasia, not 
impairing ability to 
communicate 
receptive or expressive 
dysphasia, impairing 
ability to communicate 
inability to 
communicate 
Syncope (fainting) absent - - present - 
Also consider CARDIOVASCULAR (ARRHYTHMIA), Vasovagal episode, CNS cerebrovascular ischemia. 
Tremor none mild and brief or 
intermittent but not 
interfering with function 
moderate tremor interfering 
with function, but not 
interfering with activities of 
daily living 
severe tremor interfering 
with activities of daily 
living 
- 
Vertigo none not interfering with function interfering with function, but 
not interfering with 
activities of daily living 
interfering with activities 
of daily living 
bedridden or disabling 
Neurology-Other 
(Specify, __________) 
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